Phage compositions for treating staphylococcus infections

Abstract

The present disclosure relates to bacteriophages and compositions capable of infecting and killing Staphylococci and uses thereof for treating Staphylococci, e.g., Staphylococcus aureus bacterial infections.

Description

[0001] Cross-reference to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 978,006, filed February 18, 2020, the entire contents of which are incorporated herein by reference and used for all purposes.

[0003] sequence list

[0004] This application contains a sequence list, which has been electronically submitted in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on February 18, 2020, and is named 054249-519P01US_SEQUENCE_LISTING_ST25.txt, with a size of 377,606 bytes. Background Technology

[0005] As the number of bacterial strains resistant to traditional small-molecule antibiotics increases, the demand for alternative antibiotics continues to grow. Phage therapy uses bacterial viruses or phages to target and destroy bacteria at different sites of infection. Recent advances in biotechnology allow for the rapid expansion of naturally occurring phage libraries to generate effective and specific phages that can target and destroy bacteria of interest. Antibiotic-resistant Staphylococcus aureus (SA) is common in hospitals and in areas inhabited by immunocompromised patients. Secondary SA infection is a potentially fatal infection (>20%) and a common threat to these patients. In fact, approximately 50 cases of SA bacteremia are diagnosed annually in the United States alone. Phage therapy is particularly attractive because it can circumvent traditional antibiotic resistance mechanisms, avoid the toxic side effects of traditional small-molecule therapies, effectively combat biofilms, and avoid disrupting the natural gut microbiota.

[0006] Therefore, there is a significant unmet need for more effective, potent, and specific anti-SA therapies to replace or enhance the traditional small-molecule antibiotics currently used to treat SA infections. Summary of the Invention

[0007] This article describes bacteriophages, bacteriophage compositions, and their uses in medical and non-medical applications.

[0008] In one aspect, this article provides an isolated, purified phage comprising the polynucleotide sequence of SEQ ID NO: 1.

[0009] In one aspect, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1. In another aspect, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1.

[0010] In one aspect, this article provides an isolated, purified phage comprising the polynucleotide sequence of SEQ ID NO: 2.

[0011] In one aspect, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0012] In one aspect, this document provides a phage composition comprising one or more phages, said phage being selected from the following phages: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, this document provides a phage composition comprising one or more phages, said phage being selected from the following phages: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0013] In one aspect, this document provides the use of a composition comprising one or more unique phages targeting Staphylococcus aureus in the treatment of a subject suffering from a Staphylococcus aureus infection. The use includes administering the composition to the subject; wherein at least one of the one or more phages is selected from phages comprising: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, at least one of the one or more phages is selected from phages comprising: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0014] In one aspect, this document provides a bacterial host-producing strain comprising a bacteriophage, wherein the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0015] In one aspect, this article provides a method for treating subjects with bacterial infections, which includes selecting a phage based on resistance to blood complement inactivation and administering the phage to the subject.

[0016] In one aspect, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject one or more unique bacteriophages selected from the following: polynucleotide sequences selected from SEQ ID NO: 1 and SEQ ID NO: 2, polynucleotide sequences having at least 93% identity with SEQ ID NO: 1, and polynucleotide sequences having at least 93% identity with SEQ ID NO: 2. In another aspect, the treatment method comprises administering to the subject one or more unique bacteriophages selected from the following: polynucleotide sequences selected from SEQ ID NO: 1 and SEQ ID NO: 2, polynucleotide sequences having at least 90% identity with SEQ ID NO: 1, and polynucleotide sequences having at least 90% identity with SEQ ID NO: 2.

[0017] In one aspect, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus spp., wherein the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2. Attached Figure Description

[0018] The embodiments will now be described by way of example only with reference to the accompanying drawings, wherein:

[0019] Figure 1 Plating efficiency and plaque morphology were demonstrated. Serially diluted isotiters of phage were inoculated at 2 μL onto Staphylococcus aureus bacterial colonies. Phage potency was assessed by plaque clarity and plating efficiency.

[0020] Figure 2 The effect of campstatin on Sa87 activity after plasma exposure was demonstrated. Sa87 was exposed to fresh plasma isolated from three donors for 60 minutes, with or without the complement inhibitor campstatin; phage titration was performed using a double-layer agar method. D represents the donor.

[0021] Figure 3 The activity of the leader phage after exposure to plasma was demonstrated. The leader phage candidates were diluted in fresh plasma from six donors, and infectivity was monitored for 90 minutes.

[0022] Figure 4 AP-SA02 significantly reduced SA biofilm quality. Using AP-SA02 (10 μL in a 96-well plate) showed that... 7 (1 phage / well) was used to treat the biofilm for 5 hours, and the percentage of biofilm that disappeared was reported as a percentage relative to the same strain treated with the vector. NRS100 was a negative control.

[0023] Figures 5A-5B AP-SA02 activity was demonstrated in the presence of vancomycin. Figure 5A The image shows bacterial growth as measured by turbidity (absorbance at 600 nm) in the checkerboard assay in the presence of AP-SA02 and vancomycin. The gray box indicates... Figure 5B The lines on the graph depicted in the image. AP-SA02 is active against VRSA strains. Vancomycin, 16 μg / mL; AP-SA02, 0.1 pg / mL.

[0024] Figures 6A-6B The study demonstrated synergistic activity between vancomycin and AP-SA02. Figure 6A This displays bacterial growth data measured by turbidity (absorbance at 600 nm) in the presence of AP-SA02 and vancomycin during a checkerboard assay. The gray box shows... Figure 6B The lines on the graph depicted in the image. AP-SA02 and vancomycin showed synergistic activity against VRSA strains. Vancomycin, 2 μg / mL. Detailed Implementation

[0025] It should be understood that this disclosure is not limited to the specific embodiments described, as variations are naturally possible. It should also be understood that the terminology used herein is for descriptive purposes only and is not intended to be limiting, as the scope of this disclosure will be limited only by the appended claims.

[0026] The detailed description of this disclosure is divided into several sections only for the convenience of the reader, and any disclosure found in any section may be combined with disclosure in another section. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0027] definition

[0028] It must be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural indicators unless the context clearly specifies otherwise. Thus, for example, reference to “bacteriophage composition” includes a variety of such candidate reagents, and reference to “bacteriophage” includes reference to one or more bacteriophages and their equivalents known to those skilled in the art, and so on.

[0029] As used herein, the term "consists essentially of" means that only the explicitly stated bacteriophage (one or more) is present in the bacteriophage composition, and does not mean that the composition may also contain other non-phage components, such as pharmaceutically suitable carriers, diluents, excipients, antibiotics (e.g., chemical antibiotics), or combinations thereof.

[0030] As used herein, the term “about” when used before numerical names such as temperature, time, quantity, concentration, etc., including their range, indicates an approximate value that may vary (+) or (-) by 10%, 5%, or 1%.

[0031] When a range (e.g., a dose range) is listed in this document, it should be understood that the value may include any single value or range within the range(s), including endpoints.

[0032] As used herein, the term "mutant" refers to a bacteriophage that is genetically different from ARSA0001 or ARSA0002 but still retains the ability to infect and kill Staphylococcus aureus target bacteria. Mutants typically include bacteriophages with, for example, silent mutations, conserved mutations, small deletions, and / or small replications of genetic material, and retain the phenotypic characteristics of a reference bacteriophage. In embodiments, the mutant retains any observable characteristics or properties that depend on the phage genome as described herein, i.e., the phenotypic characteristics of the phage and / or lytic activity against Staphylococcus species. Preferred mutants retain the ability to infect and kill Staphylococcus aureus target bacteria and have less than 10%, even more preferably less than 7%, more preferably less than 1% of nucleic acid variation compared to the genome of a reference bacteriophage. Optionally, or in combination, the mutant preferably has less than 7% amino acid variation in the encoded polypeptide sequence compared to the polypeptide of the reference bacteriophage.

[0033] As used herein, the terms “% identity,” “% sequence identity,” and “percent identity” relating to nucleic acid or amino acid sequences indicate the level of identity or homology between the sequences and can be determined by techniques known in the art. The percentage of identity can be determined using any of a variety of sequence alignment methods, including, but not limited to, global, local, and hybrid methods such as fragmentation methods. Schemes for determining the percentage of identity are conventional procedures within the scope of those skilled in the art. Global methods align sequences from the beginning to the end of the molecule and determine the optimal alignment by summing the fractions of individual nucleotide pairs and by applying a vacancy penalty. Non-limiting methods include, for example, CLUSTAL W, see, e.g., Julie D. Thompson et al., CLUSTAL W: Improve the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-specific Gap Penalties and Weight Matrix Choice, 22(22) Nucleic Acids Research 4673-4680 (1994); and iterative refinement. Non-limiting methods include, for example, BLAST, Match-box, see, for example, Align-M, see, for example, Ivo Van Walle et al., Align-MA New Algorithm for Multiple Alignment of Highly Divergent Sequences, Bioinformatics 20(9):1428-1435 (2004). This definition also relates to or can be applied to the supplementation of the test sequence. This definition also includes sequences with deletions and / or additions, as well as sequences with substitutions. As described below, preferred algorithms may take into account gaps, etc. Preferably, identity exists in regions of at least about 100 nucleotides in length, or more preferably in regions of 100-1000 or more nucleotides in length.

[0034] As used herein, the term "bacterial complementation" refers to the ability of a bacteriophage with a specific genome to compensate for different, unique bacteriophages with different genomes. More specifically, phage-resistant mutant colonies (of target bacteria) may originate from a specific phage but may still be susceptible to different phages. In other words, phage-resistant mutant bacteria produced by one phage may still be susceptible to another phage.

[0035] As used in this article, the term "generalized transduction" refers to the process by which any bacterial DNA can be transferred to another bacterium via a bacteriophage. This is a rare event; a very small percentage of bacteriophage particles happen to carry the DNA of the donor bacterium, approximately 10,000 bacteriophages. Essentially, this is the packaging of bacterial DNA into a viral envelope.

[0036] As used herein, the terms “treat” or “treating” are intended to encompass both preventative and corrective treatment (treatment of a subject already suffering from a disease). This can include medical administration of a subject aimed at curing, improving, stabilizing, or preventing a disease, pathology, or disorder. The term includes active treatment, i.e., treatment specifically aimed at improving a disease, pathology, or disorder; and also includes causal treatment, i.e., treatment aimed at eliminating the cause of the associated disease, pathology, or disorder. Furthermore, the term includes palliative treatment, i.e., treatment aimed at relieving symptoms rather than curing a disease, pathology, or disorder; preventative treatment, i.e., treatment aimed at minimizing or partially or completely suppressing the development of the associated disease, pathology, or disorder; and supportive treatment, i.e., treatment used to supplement another specific therapy aimed at improving the associated disease, pathology, or disorder. It should be understood that while treatment aims to cure, improve, stabilize, or prevent a disease, pathology, or disorder, it is not actually necessary to result in a cure, improvement, stabilization, or prevention. The effects of treatment can be measured or assessed in the manner described herein and known in the art as applicable to the disease, pathology, or disorder involved. Such measurement and assessment can be performed in a qualitative and / or quantitative manner. Therefore, for example, the manifestations or characteristics of a disease, pathological condition or disorder and / or symptoms of a disease, pathological condition or disorder can be reduced to any effect or to any amount.

[0037] As used herein, the terms "lytic" or "lytic activity" refer to the property of a bacteriophage to cause lysis of bacterial cells. The lytic activity of a bacteriophage can be tested on bacteria (e.g., Staphylococcus aureus strains) according to techniques known in the art. The lytic cycle is named after the process that occurs when a bacteriophage infects a cell, replicates new bacteriophage particles, and breaks through the host cell membrane. Some bacteriophages exhibit a lysogenic cycle, during which the bacteriophage DNA remains virtually dormant due to the active inhibition of the bacteriophage process. Whenever the bacteria divide, the bacteriophage DNA is also replicated. In this way, the virus can continue to replicate within its host without lysing the host. At some point, conditions may change, and the bacteriophage enters a lytic cycle. "Obligately lytic" refers to a bacteriophage that does not undergo a lysogenic cycle.

[0038] As used herein, the term "complement system" or "blood complement system" refers to the part of the innate immune system that triggers phagocytosis, inflammation, and membrane disruption of foreign substances, including bacteriophages. The complement system consists of the classical pathway, the alternative pathway, and the lectin pathway. The classical pathway begins when IgG or IgM recognizes an antigen and forms a multiprotein complex called C1. The C1 multiprotein complex consists of one molecule of C1q, two molecules of C1r, and two molecules of C1s. After several internal proteolytic steps, subunits C4 and C2 are generated and further processed to form C2a, C2b, C4a, and C4b. C2b and C4b combine to form the classical form of C3 convertase. C3 is further processed to form C3a and C3b. C3b can then link with C3 to form C5 convertase. Low levels of C3 can be converted to C3b in the absence of antigen and can combine with other proteases to form the alternative complex in the alternative complement pathway. The lectin pathway replaces the C1q protein from C1 with lectin-binding proteins, including mannose-binding lectin (MBL).

[0039] As used herein, the term "C3" or "complement component C3" refers to any protein involved in the complement pathway: classical, alternative, or lectin-based. One form of activated C3 is the heterodimer C4b2a, also known as C3-convertase, which activates the C2 and C4 proteins. Another form of activated C3 is the heterodimer of activated C3b and activating factors B and Bb, forming C3bBb.

[0040] As used herein, the term "bacteriophage target" refers to any species of bacteria that can be infected by a specific bacteriophage. A bacteriophage recognizes the surface of a target bacterial cell, binds to it, and injects its genetic material into the bacterial host. Genetic material from an infected bacteriophage can be integrated into the bacterial genome. Bacteriophages can become lysogenic, in which the viral genome remains dormant within the bacterial host genome until a triggering event occurs. Bacteriophages can also become lytic, in which numerous copies of the infected bacteriophage are produced by mechanisms of the infected bacteria, and these copies are subsequently released through bacterial lysis, extrusion, or budding.

[0041] As used herein, the terms "bacterial host manufacturing strain" or "manufacturing strain" refer to the bacteria used to grow bacteriophages. A bacteriophage production method may require at least two operational units: the growth of the host bacteria and the production process of phage reproduction (or infection). It is important to consider fundamental parameters of bacterial growth and phage infection, such as the selection of the bacterial substrate and the optimal temperature for bacterial growth and phage infection, as these factors can affect the infectivity of the phage.

[0042] As used herein, the term "bacteremia" refers to the presence of bacteria in the bloodstream. Bacteria can be introduced into the bloodstream through everyday activities, including brushing teeth, or through surgical procedures, the implantation of temporary medical devices, urinary tract infections, sites of severe injury, or sites of long-term implantation of devices.

[0043] As used in this article, the term "septicemia" refers to a bacterial infection that enters the bloodstream from other parts of the body; it is also known as bacterial blood poisoning.

[0044] As used herein, the term "Silviavirus" refers to viruses belonging to Regim: Virus, Group 1: dsDNA, Order: Caudovirales, Family: Herelleviridae, Subfamily: Twortvirinae, Genus: Silviavirus. Species in the genus Silviavirus include, but are not limited to, Staphylococcus virus Remus, Staphylococcus virus SA11, Staphylococcus virus Romulus, Staphylococcus virus Qdsa001, Staphylococcus virus MR003, Staphylococcus virus StAP1, and Staphylococcus virus Stsau2.

[0045] Uses or methods typically involve administering the phage or phage composition described herein to a subject. As used herein, “subject” is a mammal, such as a human or other animal. Preferably, the subject is a human.

[0046] As used herein, the term "in need of treatment" means a judgment made by a caregiver (e.g., a physician, nurse, registered nurse, or individual in the case of a human; a veterinarian in the case of an animal including a non-human mammal) that a subject needs treatment or will benefit from treatment. This judgment is based on a variety of factors within the caregiver's scope of expertise, but includes the knowledge that the subject is ill or will become ill due to a condition treatable by the compositions of the present invention.

[0047] As used herein, the term "isolated" means that the bacteriophage has been removed from its native environment. Specifically, isolated bacteriophages are cultured or grown separately from their natural environment.

[0048] As used herein, the term "purified" means that the bacteriophage has been removed from the host bacteria from which it was manufactured. Specifically, purified bacteriophages have production impurities, such as bacterial components, removed from their manufacturing or production environment. Bacterial components include, but are not limited to, bacterial host proteins, lipids, and / or bacterial endotoxins. The term "purified" can also refer to genetic purification, where the bacteriophage strain is genetically homogeneous.

[0049] As used herein, the term "substantially purified" means a composition containing less than 1%, less than 0.1%, less than 0.001%, or undetectable amounts of contaminants such as host bacterial proteins or endotoxins. Furthermore, as used herein, when the term "substantially pure" is used to describe a bacteriophage strain, it means that the composition has a genetic purity such that the strain represents more than 99%, more than 99.9%, more than 99.999%, or 100% of a specific genome sequence.

[0050] Typically, a composition is substantially pure when at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% (by volume, by wet or dry weight, or by molar percentage or mole fraction) of the total material in the sample is free from impurities or genetic variants.

[0051] As used herein, the terms "subject" or "patient" refer to a human or non-human animal. Preferably, the subject or patient is in need of treatment with the composition described herein, for example, suffering from a bacterial infection susceptible to treatment with the composition.

[0052] As used herein, “synergistic amount” refers to the sum of a first amount (e.g., bacteriophage) and a second amount (e.g., different bacteriophages) that result in a synergistic effect (i.e., greater than an additive effect). Therefore, the terms “synergy,” “synergism,” “synergistic,” “combined synergistic amount,” and “synergistic therapeutic effect” used interchangeably herein refer to the measured effect of a combination of compounds administered, where the measured effect is greater than the sum of the individual effects of each of the compounds described herein when administered as a single agent.

[0053] As used herein, the term "substantially free" means having less than 10% of a substance that will be free of. For example, 0.01% to 10% (free of) a substance, including any sub-values ​​and sub-ranges thereof, including endpoints. For example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%.

[0054] As used herein, the term "obtainable" also includes the term "obtained." In one implementation, the term "obtainable" means "obtained."

[0055] Other terms and phrases are defined below.

[0056] bacteriophage composition

[0057] In one aspect, this article provides an isolated, purified phage comprising the polynucleotide sequence of SEQ ID NO: 1.

[0058] In one aspect, this article provides an isolated, purified phage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1.

[0059] In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 99.9%, 99.8%, 99.7%, 99.6%, 99.5%, 99.4%, 99.3%, 99.2%, 99.1%, 99.0%, or 99% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 98.9%, 98.8%, 98.7%, 98.6%, 98.5%, 98.4%, 98.3%, 98.2%, 98.1%, 98.0%, or 98% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 97.9%, 97.8%, 97.7%, 97.6%, 97.5%, 97.4%, 97.3%, 97.2%, 97.1%, 97.0%, or 97% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 96.9%, 96.8%, 96.7%, 96.6%, 96.5%, 96.4%, 96.3%, 96.2%, 96.1%, 96.0%, or 96% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 95.9%, 95.8%, 95.7%, 95.6%, 95.5%, 95.4%, 95.3%, 95.2%, 95.1%, 95.0%, or 95% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 94.9%, 94.8%, 94.7%, 94.6%, 94.5%, 94.4%, 94.3%, 94.2%, 94.1%, 94.0%, or 94% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 93.9%, 93.8%, 93.7%, 93.6%, 93.5%, 93.4%, 93.3%, 93.2%, 93.1%, 93.0%, or 93% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 92.9%, 92.8%, 92.7%, 92.6%, 92.5%, 92.4%, 92.3%, 92.2%, 92.1%, 92.0%, or 92% identity with SEQ ID NO: 1.In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 91.9%, 91.8%, 91.7%, 91.6%, 91.5%, 91.4%, 91.3%, 91.2%, 91.1%, 91.0%, or 91% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 90.9%, 90.8%, 90.7%, 90.6%, 90.5%, 90.4%, 90.3%, 90.2%, 90.1%, 90.0%, or 90% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 89.9%, 89.8%, 89.7%, 89.6%, 89.5%, 89.4%, 89.3%, 89.2%, 89.1%, 89.0%, or 89% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 88.9%, 88.8%, 88.7%, 88.6%, 88.5%, 88.4%, 88.3%, 88.2%, 88.1%, 88.0%, or 88% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 87.9%, 87.8%, 87.7%, 87.6%, 87.5%, 87.4%, 87.3%, 87.2%, 87.1%, 87.0%, or 87% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 86.9%, 86.8%, 86.7%, 86.6%, 86.5%, 86.4%, 86.3%, 86.2%, 86.1%, 86.0%, or 86% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 85.9%, 85.8%, 85.7%, 85.6%, 85.5%, 85.4%, 85.3%, 85.2%, 85.1%, 85.0%, or 85% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 84.9%, 84.8%, 84.7%, 84.6%, 84.5%, 84.4%, 84.3%, 84.2%, 84.1%, 84.0%, or 84% identity with SEQ ID NO: 1.In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 83.9%, 83.8%, 83.7%, 83.6%, 83.5%, 83.4%, 83.3%, 83.2%, 83.1%, 83.0%, or 83% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 82.9%, 82.8%, 82.7%, 82.6%, 82.5%, 82.4%, 82.3%, 82.2%, 82.1%, 82.0%, or 82% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 81.9%, 81.8%, 81.7%, 81.6%, 81.5%, 81.4%, 81.3%, 81.2%, 81.1%, 81.0%, or 81% identity with SEQ ID NO: 1. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 80.9%, 80.8%, 80.7%, 80.6%, 80.5%, 80.4%, 80.3%, 80.2%, 80.1%, 80.0%, or 80% identity with SEQ ID NO: 1. In embodiments, the phage genome comprises polynucleotides.

[0060] In one aspect, this article provides an isolated, purified phage comprising a polynucleotide sequence identified as SEQ ID NO: 2.

[0061] In one aspect, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, the purified phage comprises a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0062] In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 99.9%, 99.8%, 99.7%, 99.6%, 99.5%, 99.4%, 99.3%, 99.2%, 99.1%, 99.0%, or 99% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a phage containing a polynucleotide sequence having at least 98.9%, 98.8%, 98.7%, 98.6%, 98.5%, 98.4%, 98.3%, 98.2%, 98.1%, 98.0%, or 98% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 97.9%, 97.8%, 97.7%, 97.6%, 97.5%, 97.4%, 97.3%, 97.2%, 97.1%, 97.0%, or 97% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a phage containing a polynucleotide sequence having at least 96.9%, 96.8%, 96.7%, 96.6%, 96.5%, 96.4%, 96.3%, 96.2%, 96.1%, 96.0%, or 96% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 95.9%, 95.8%, 95.7%, 95.6%, 95.5%, 95.4%, 95.3%, 95.2%, 95.1%, 95.0%, or 95% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a phage containing a polynucleotide sequence having at least 94.9%, 94.8%, 94.7%, 94.6%, 94.5%, 94.4%, 94.3%, 94.2%, 94.1%, 94.0%, or 94% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 93.9%, 93.8%, 93.7%, 93.6%, 93.5%, 93.4%, 93.3%, 93.2%, 93.1%, 93.0%, or 93% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 92.9%, 92.8%, 92.7%, 92.6%, 92.5%, 92.4%, 92.3%, 92.2%, 92.1%, 92.0%, or 92% identity with SEQ ID NO: 2.In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 91.9%, 91.8%, 91.7%, 91.6%, 91.5%, 91.4%, 91.3%, 91.2%, 91.1%, 91.0%, or 91% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 90.9%, 90.8%, 90.7%, 90.6%, 90.5%, 90.4%, 90.3%, 90.2%, 90.1%, 90.0%, or 90% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 89.9%, 89.8%, 89.7%, 89.6%, 89.5%, 89.4%, 89.3%, 89.2%, 89.1%, 89.0%, or 89% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 88.9%, 88.8%, 88.7%, 88.6%, 88.5%, 88.4%, 88.3%, 88.2%, 88.1%, 88.0%, or 88% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 87.9%, 87.8%, 87.7%, 87.6%, 87.5%, 87.4%, 87.3%, 87.2%, 87.1%, 87.0%, or 87% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 86.9%, 86.8%, 86.7%, 86.6%, 86.5%, 86.4%, 86.3%, 86.2%, 86.1%, 86.0%, or 86% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 85.9%, 85.8%, 85.7%, 85.6%, 85.5%, 85.4%, 85.3%, 85.2%, 85.1%, 85.0%, or 85% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 84.9%, 84.8%, 84.7%, 84.6%, 84.5%, 84.4%, 84.3%, 84.2%, 84.1%, 84.0%, or 84% identity with SEQ ID NO: 2.In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 83.9%, 83.8%, 83.7%, 83.6%, 83.5%, 83.4%, 83.3%, 83.2%, 83.1%, 83.0%, or 83% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 82.9%, 82.8%, 82.7%, 82.6%, 82.5%, 82.4%, 82.3%, 82.2%, 82.1%, 82.0%, or 82% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 81.9%, 81.8%, 81.7%, 81.6%, 81.5%, 81.4%, 81.3%, 81.2%, 81.1%, 81.0%, or 81% identity with SEQ ID NO: 2. In embodiments, this document provides an isolated, purified phage comprising a polynucleotide sequence having at least 80.9%, 80.8%, 80.7%, 80.6%, 80.5%, 80.4%, 80.3%, 80.2%, 80.1%, 80.0%, or 80% identity with SEQ ID NO: 2. In embodiments, the phage genome comprises polynucleotides.

[0063] In one aspect, this document provides a phage composition comprising one or more phages.

[0064] In some embodiments, this document provides phage compositions comprising two phages according to any of the embodiments described herein. In some embodiments, this document provides phage compositions comprising two or more phages according to any of the embodiments described herein. In some embodiments, this document provides phage compositions comprising three or more phages according to any of the embodiments described herein. In some embodiments, this document provides phage compositions comprising four or more phages according to any of the embodiments described herein. In some embodiments, this document provides phage compositions comprising five or more phages according to any of the embodiments described herein.

[0065] In one embodiment, the composition comprises one or more phages resistant to inactivation in blood. In another embodiment, the composition comprises two or more phages resistant to inactivation in blood. In another embodiment, the composition comprises three or more phages resistant to inactivation of blood complement in blood. In another embodiment, the composition comprises one or more phages resistant to inactivation mediated by blood complement C3 protein. In another embodiment, the composition comprises two or more phages resistant to inactivation mediated by blood complement C3 protein. In another embodiment, the composition comprises three or more phages resistant to inactivation mediated by blood complement C3 protein.

[0066] In one embodiment, the composition includes a bacteriophage targeting Staphylococcus spp. In another embodiment, the composition includes a bacteriophage targeting Staphylococcus aureus. In another embodiment, the composition includes a bacteriophage targeting one or more of vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and / or methicillin-resistant Staphylococcus aureus (MRSA). In another embodiment, the composition includes a bacteriophage targeting vancomycin intermediate Staphylococcus aureus (VISA). In another embodiment, the composition includes a bacteriophage targeting vancomycin-resistant Staphylococcus aureus (VRSA). In another embodiment, the composition includes a bacteriophage targeting methicillin-resistant Staphylococcus aureus (MRSA).

[0067] In one embodiment, the composition includes a bacteriophage that infects and kills Staphylococcus spp. In another embodiment, the composition includes a bacteriophage that infects and kills Staphylococcus aureus. In another embodiment, the composition includes a bacteriophage that infects and kills one or more of VISA, VRSA, and / or MRSA. In another embodiment, the composition includes a bacteriophage that infects and kills VISA. In another embodiment, the composition includes a bacteriophage that infects and kills VRSA. In another embodiment, the composition includes a bacteriophage that infects and kills MRSA.

[0068] In embodiments, this document provides phage compositions comprising one or more phages belonging to the genus *Sylviavirus*. In embodiments, the phage composition comprises strains from the genus *Sylviavirus*. In embodiments, the phage composition comprises phages selected from MR003 (accession number AP019522.1), Qdsa001 (accession number KY779848.1), Remus (accession number NC_022090.1), Romulus (accession number NC_020877.1), SA11 (accession number NC_019511.12), StAP1 (accession number KC532239.1), and Stsau2 (accession number NC_030933.1). In some embodiments of the phage composition, the phage is *Sylviavirus Staphylococcus aureus* Remus. In some embodiments of the phage composition, the phage is *Sylviavirus Staphylococcus aureus* SA11. In some embodiments of the phage composition, the phage is Silvia virus Staphylococcus aureus Romulus. In some embodiments of the phage composition, the phage is Silvia virus Staphylococcus aureus Qdsa001. In some embodiments of the phage composition, the phage is Silvia virus Staphylococcus aureus MR003. In some embodiments of the phage composition, the phage is Silvia virus Staphylococcus aureus StAP1. In some embodiments of the phage composition, the phage is Silvia virus Staphylococcus aureus Stsau2.

[0069] In one aspect, this document provides a phage composition comprising one or more phages selected from the following: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, the composition comprises one or more phages selected from the following: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 9% identity with SEQ ID NO: 2.

[0070] In one embodiment, the phage composition comprises a phage containing the polynucleotide sequence of SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage containing the polynucleotide sequence of SEQ ID NO: 2. In yet another embodiment, the phage composition comprises a phage containing a polynucleotide sequence having at least 99.9%, 99.8%, 99.7%, 99.6%, 99.5%, 99.4%, 99.3%, 99.2%, 99.1%, 99.0%, or 99% identity with SEQ ID NO: 1. In yet another embodiment, the phage composition comprises a phage containing a polynucleotide sequence having at least 98.9%, 98.8%, 98.7%, 98.6%, 98.5%, 98.4%, 98.3%, 98.2%, 98.1%, 98.0%, or 98% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 97.9%, 97.8%, 97.7%, 97.6%, 97.5%, 97.4%, 97.3%, 97.2%, 97.1%, 97.0%, or 97% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 96.9%, 96.8%, 96.7%, 96.6%, 96.5%, 96.4%, 96.3%, 96.2%, 96.1%, 96.0%, or 96% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 95.9%, 95.8%, 95.7%, 95.6%, 95.5%, 95.4%, 95.3%, 95.2%, 95.1%, 95.0%, or 95% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 94.9%, 94.8%, 94.7%, 94.6%, 94.5%, 94.4%, 94.3%, 94.2%, 94.1%, 94.0%, or 94% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 93.9%, 93.8%, 93.7%, 93.6%, 93.5%, 93.4%, 93.3%, 93.2%, 93.1%, 93.0%, or 93% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 92.9%, 92.8%, 92.7%, 92.6%, 92.5%, 92.4%, 92.3%, 92.2%, 92.1%, 92.0%, or 92% identity with SEQ ID NO: 1.In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 91.9%, 91.8%, 91.7%, 91.6%, 91.5%, 91.4%, 91.3%, 91.2%, 91.1%, 91.0%, or 91% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 90.9%, 90.8%, 90.7%, 90.6%, 90.5%, 90.4%, 90.3%, 90.2%, 90.1%, 90.0%, or 90% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 89.9%, 89.8%, 89.7%, 89.6%, 89.5%, 89.4%, 89.3%, 89.2%, 89.1%, 89.0%, or 89% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 88.9%, 88.8%, 88.7%, 88.6%, 88.5%, 88.4%, 88.3%, 88.2%, 88.1%, 88.0%, or 88% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 87.9%, 87.8%, 87.7%, 87.6%, 87.5%, 87.4%, 87.3%, 87.2%, 87.1%, 87.0%, or 87% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 86.9%, 86.8%, 86.7%, 86.6%, 86.5%, 86.4%, 86.3%, 86.2%, 86.1%, 86.0%, or 86% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 85.9%, 85.8%, 85.7%, 85.6%, 85.5%, 85.4%, 85.3%, 85.2%, 85.1%, 85.0%, or 85% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 84.9%, 84.8%, 84.7%, 84.6%, 84.5%, 84.4%, 84.3%, 84.2%, 84.1%, 84.0%, or 84% identity with SEQ ID NO: 1. In an embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 83.9%, 83.8%, 83.7%, 83.6%, 83.5%, 83.4%, 83.3%, 83.2%, 83.1%, 83.0%, or 83% identity with SEQ ID NO: 1.In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 82.9%, 82.8%, 82.7%, 82.6%, 82.5%, 82.4%, 82.3%, 82.2%, 82.1%, 82.0%, or 82% identity with SEQ ID NO: 1. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 81.9%, 81.8%, 81.7%, 81.6%, 81.5%, 81.4%, 81.3%, 81.2%, 81.1%, 81.0%, or 81% identity with SEQ ID NO: 1. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 80.9%, 80.8%, 80.7%, 80.6%, 80.5%, 80.4%, 80.3%, 80.2%, 80.1%, 80.0%, or 80% identity with SEQ ID NO: 1. In another embodiment, the phage genome comprises polynucleotides.

[0071] In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 99.9%, 99.8%, 99.7%, 99.6%, 99.5%, 99.4%, 99.3%, 99.2%, 99.1%, 99.0%, or 99% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 98.9%, 98.8%, 98.7%, 98.6%, 98.5%, 98.4%, 98.3%, 98.2%, 98.1%, 98.0%, or 98% identity with SEQ ID NO: 2. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 97.9%, 97.8%, 97.7%, 97.6%, 97.5%, 97.4%, 97.3%, 97.2%, 97.1%, 97.0%, or 97% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 96.9%, 96.8%, 96.7%, 96.6%, 96.5%, 96.4%, 96.3%, 96.2%, 96.1%, 96.0%, or 96% identity with SEQ ID NO: 2. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 95.9%, 95.8%, 95.7%, 95.6%, 95.5%, 95.4%, 95.3%, 95.2%, 95.1%, 95.0%, or 95% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 94.9%, 94.8%, 94.7%, 94.6%, 94.5%, 94.4%, 94.3%, 94.2%, 94.1%, 94.0%, or 94% identity with SEQ ID NO: 2. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 93.9%, 93.8%, 93.7%, 93.6%, 93.5%, 93.4%, 93.3%, 93.2%, 93.1%, 93.0%, or 93% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 92.9%, 92.8%, 92.7%, 92.6%, 92.5%, 92.4%, 92.3%, 92.2%, 92.1%, 92.0%, or 92% identity with SEQ ID NO: 2. In an embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 91.9%, 91.8%, 91.7%, 91.6%, 91.5%, 91.4%, 91.3%, 91.2%, 91.1%, 91.0%, or 91% identity with SEQ ID NO: 2.In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 90.9%, 90.8%, 90.7%, 90.6%, 90.5%, 90.4%, 90.3%, 90.2%, 90.1%, 90.0%, or 90% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 89.9%, 89.8%, 89.7%, 89.6%, 89.5%, 89.4%, 89.3%, 89.2%, 89.1%, 89.0%, or 89% identity with SEQ ID NO: 2. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 88.9%, 88.8%, 88.7%, 88.6%, 88.5%, 88.4%, 88.3%, 88.2%, 88.1%, 88.0%, or 88% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 87.9%, 87.8%, 87.7%, 87.6%, 87.5%, 87.4%, 87.3%, 87.2%, 87.1%, 87.0%, or 87% identity with SEQ ID NO: 2. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 86.9%, 86.8%, 86.7%, 86.6%, 86.5%, 86.4%, 86.3%, 86.2%, 86.1%, 86.0%, or 86% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 85.9%, 85.8%, 85.7%, 85.6%, 85.5%, 85.4%, 85.3%, 85.2%, 85.1%, 85.0%, or 85% identity with SEQ ID NO: 2. In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 84.9%, 84.8%, 84.7%, 84.6%, 84.5%, 84.4%, 84.3%, 84.2%, 84.1%, 84.0%, or 84% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 83.9%, 83.8%, 83.7%, 83.6%, 83.5%, 83.4%, 83.3%, 83.2%, 83.1%, 83.0%, or 83% identity with SEQ ID NO: 2. In an embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 82.9%, 82.8%, 82.7%, 82.6%, 82.5%, 82.4%, 82.3%, 82.2%, 82.1%, 82.0%, or 82% identity with SEQ ID NO: 2.In one embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 81.9%, 81.8%, 81.7%, 81.6%, 81.5%, 81.4%, 81.3%, 81.2%, 81.1%, 81.0%, or 81% identity with SEQ ID NO: 2. In another embodiment, the phage composition comprises a phage having a polynucleotide sequence having at least 80.9%, 80.8%, 80.7%, 80.6%, 80.5%, 80.4%, 80.3%, 80.2%, 80.1%, 80.0%, or 80% identity with SEQ ID NO: 2. In yet another embodiment, the phage genome comprises polynucleotides.

[0072] In one embodiment, this document provides a phage composition comprising two or more phages selected from the following: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2; and wherein the target bacterial range of the composition is wider than the cumulative range of a single phage in the composition. In another aspect, the phage composition may comprise two or more phages selected from the following: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2; and wherein the target bacterial range of the composition is wider than the cumulative range of a single phage in the composition.

[0073] In embodiments, the phage composition includes one or more additional phages. In some embodiments, the one or more additional phages are suitable for treating bacterial infections, particularly staphylococcal infections. In embodiments, the additional one or more phages may be naturally occurring or non-naturally occurring. In embodiments, the one or more additional phages may be phages having at least 80% nucleic acid sequence identity with any phage described herein. In embodiments, the one or more additional phages may be phages having at least 80% nucleic acid sequence identity with SEQ ID NO: 1. In embodiments, the one or more additional phages may be phages having at least 80% nucleic acid sequence identity with SEQ ID NO: 2. In embodiments, the phage includes a polynucleotide sequence having at least 80% but not 100% identity with either SEQ ID NO: 1 or SEQ ID NO: 2.

[0074] In embodiments, the target bacterial range of the phage composition is broader than that of any single phage included in the composition. This activity can be considered synergistic because the effect of the composition (target killing range) is greater than the sum of the individual effects (target killing range) of each phage component. In embodiments, phage compositions are provided herein in which the target bacterial range of the composition can have a potency greater than the sum of the effectiveness of a single phage.

[0075] In embodiments, this document provides phage compositions comprising two or more phages, wherein the composition comprises a phage having the polynucleotide sequence of SEQ ID NO: 1, and the composition targets more Staphylococcus aureus strains compared to a phage having the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides phage compositions comprising two or more phages, wherein the composition comprises a phage having at least 93% identity with the polynucleotide sequence of SEQ ID NO: 1, and the composition targets more Staphylococcus aureus strains compared to a phage having at least 93% identity with the polynucleotide sequence of SEQ ID NO: 1. In embodiments, the composition comprises a phage having at least 90% identity with the polynucleotide sequence of SEQ ID NO: 1, and the composition targets more Staphylococcus aureus strains compared to a phage having at least 90% identity with the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides phage compositions comprising two or more phages, wherein the composition comprises a phage having the polynucleotide sequence of SEQ ID NO: 2, and the composition targets more Staphylococcus aureus strains compared to a phage having the polynucleotide sequence of SEQ ID NO: 2. In embodiments, this document provides phage compositions comprising two or more phages, wherein the composition comprises a phage having at least 93% identity with the polynucleotide sequence of SEQ ID NO: 2, and the composition targets more Staphylococcus aureus strains compared to a phage having at least 93% identity with the polynucleotide sequence of SEQ ID NO: 2. In embodiments, this document provides phage compositions comprising two or more phages, wherein the composition comprises a phage having at least 90% identity with the polynucleotide sequence of SEQ ID NO: 2, and the composition targets more Staphylococcus aureus strains compared to a phage having at least 90% identity with the polynucleotide sequence of SEQ ID NO: 2. In embodiments, the composition may have any combination of the polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2.

[0076] This document provides phage compositions comprising two or more phages, wherein the composition includes at least one genetically modified phage. This document provides phage compositions comprising two or more phages, wherein the composition includes at least one naturally occurring phage. This document provides phage compositions comprising two or more phages, wherein the composition does not include a naturally occurring phage. This document provides phage compositions comprising two or more phages, wherein the composition includes one or more phages resistant to inactivation of the blood complement system.

[0077] In some embodiments, the phage composition includes additional components selected from pharmaceutically acceptable carriers, diluents, excipients, and combinations thereof. In some embodiments, the phage composition includes a pharmaceutically acceptable carrier. In some embodiments, the phage composition includes a diluent. In some embodiments, the phage composition includes an excipient. In some embodiments, the phage composition includes a combination of a pharmaceutically acceptable carrier, diluent, and excipient. In some embodiments, the phage composition includes a combination of a pharmaceutically acceptable carrier and a diluent. In some embodiments, the phage composition includes a combination of a pharmaceutically acceptable carrier and an excipient. In some embodiments, the phage composition includes a combination of a diluent and an excipient.

[0078] In some embodiments, the phage composition includes a storage medium stored at 8°C or lower. In some embodiments, the phage composition includes a storage medium stored at 7°C or lower. In some embodiments, the phage composition includes a storage medium stored at 6°C or lower. In some embodiments, the phage composition includes a storage medium stored at 5°C or lower. In some embodiments, the phage composition includes a storage medium stored at 4°C or lower. In some embodiments, the phage composition includes a storage medium stored at 3°C ​​or lower. In some embodiments, the phage composition includes a storage medium stored at 2°C or lower. In some embodiments, the phage composition includes a storage medium stored at 1°C or lower. In some embodiments, the phage composition includes a storage medium stored at 0°C or lower.

[0079] In some embodiments, the phage composition is a liquid, semi-liquid, solid, frozen, or lyophilized formulation. In some embodiments, the phage composition is a liquid formulation. In some embodiments, the phage composition is a semi-liquid formulation. In some embodiments, the phage composition is a solid formulation. In some embodiments, the phage composition is a frozen formulation. In some embodiments, the phage composition is a lyophilized formulation.

[0080] In some embodiments, the phage composition is stored in a container containing about 1 ml to about 5 ml of injectable solution. In some embodiments, this includes a single-use, single-dose container. In other embodiments, this may include a multi-dose container containing an injectable solution providing multiple doses of the phage composition described herein. The composition may also be stored in a variety of suitable containers, including, but not limited to, vials, cuvettes, cartridges, pre-filled syringes, plastic bags, ampoules, bottles, pouches, pumps, nebulizers, stoppers, needles, plungers, caps, supports, catheters, implants, or blister packs. In some embodiments, the aforementioned containers may be made of glass or plastic, or they may be plastic-coated, or they may be made of a variety of other suitable materials. The containers may be transparent, or may be provided with light protection by being amber or various other colors, or may be wrapped in aluminum foil.

[0081] In some embodiments (alternatively or additionally), the "mutant" phage is capable of lysing some or all of the target bacterial strains identical to one or more of ARSA0001 and / or ARSA0002, and / or further capable of lysing one or more additional bacterial strains. In one embodiment, the mutant may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with one or more of the nucleic acid sequences of ARSA0001 and ARSA0002. In some embodiments, the mutant or variant may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity throughout its entire genome sequence when compared to one or more of the genomic sequences of ARSA0001 and ARSA0002. In one embodiment, when compared with SEQ ID NO.: 1, the mutant may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity throughout its entire genome sequence. In one embodiment, when compared with SEQ ID NO.: 2, the mutant may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity throughout its entire genome sequence.

[0082] In this implementation, a “mutant” can be a phage progeny. A phage progeny can be a phage that can be obtained by lysing a staphylococcal (e.g., Staphylococcus aureus) target bacterium using a phage as described herein (i.e., a “parent bacteriophage”). In other words, a phage progeny can be a second-generation (or more distant) phage.

[0083] In this implementation, "genetically modified" can refer to a bacteriophage whose polynucleotide sequence has been altered through genetic engineering techniques. The genetic engineering of the polynucleotide sequence can be achieved using any modern molecular biology techniques well known in the art, including but not limited to homologous recombination, bacteriophage engineering, CRISPR-Cas-based manipulation, conversion of full-length naked bacteriophages into host bacteria, and any combination thereof.

[0084] In an implementation, phage progeny can be obtained by contacting one or more phages described herein, including, for example, those selected from ARSA0001 or ARSA0002, with a Staphylococcus target bacterium, thereby causing the one or more phages to infect and lyse the target bacterium; and obtaining phages released after the target bacterium has lysed. Phage progeny typically include one or more nucleotide mutations compared to their parent phages.

[0085] In embodiments, the phage may be provided as a single therapeutic composition or as a plurality of separate compositions, each of which includes one or more phage components in the composition. In embodiments where the phage is provided in a plurality of separate compositions, the phage may be administered to the subject sequentially or simultaneously (appropriately simultaneously).

[0086] In one embodiment, the phage composition comprises 1 × 10⁻⁶ ppm per milliliter. 5 and 1×10 11 The phage concentration for each phage type is between PFUs. In an embodiment, the phage composition comprises 1 × 10⁻⁶ PFUs per milliliter. 6 and 1×10 11 The phage concentration for each phage type is between PFUs. In an embodiment, the phage composition comprises 1 × 10⁻⁶ PFUs per milliliter. 7 and 1×10 11 The phage concentration for each phage type is between PFUs. In some embodiments, the phage composition comprises 1 × 10⁻⁶ PFU per milliliter. 8 and 1×10 11 The phage concentration for each phage type between PFUs. In some embodiments, the composition comprises 1 × 10⁻⁶ PFU per milliliter of composition. 8 Up to 1×10 9 PFU, 1×10 8 Up to 1×10 10 PFU, 1×10 8 Up to 1×10 11 PFU, 1×10 9 Up to 1×10 10 PFU, 1×10 9 Up to 1×10 11 PFU or 1×1010 Up to 1×10 11 Each phage of PFU. In some embodiments, the phage composition is at least about 1 × 10⁻⁶ per milliliter of composition. 8 Each phage of PFU, at least approximately 1 × 10 9 Each phage of PFU, at least approximately 1 × 10 10 Each phage of PFU or at least about 1 × 10 11 Each phage of the PFU is administered to the subject in dose. In one embodiment, one or more phages may be combined to form a composition comprising 1 × 10⁻¹¹ per milliliter of the composition. 8 1×10 9 Or 1×10 10 Or 1×10 11 Compositions for each phage of PFU. Concentration includes any value or range within the stated range, including endpoints. In a specific embodiment, the composition may be at a concentration of at least 1 × 10⁻⁶ per milliliter. 8 The total phage dose of PFU may be administered. In a specific embodiment, the composition may be administered at a dose of at least 1 × 10⁻⁶ PFU per milliliter. 9 The dosage of total phages from PFU was administered.

[0087] In some embodiments, the total dose may vary depending on the formulation and storage container. In some embodiments, the total dose may be lower or higher when administered to a patient, depending on whether it is delivered from a single-dose prefilled syringe or a multi-dose container. In some embodiments, the phage composition may be administered at a basal dose rate or a bolus rate. In some embodiments, the phage composition may be administered via IV fluid infusion.

[0088] In some embodiments, the phage composition is stored in the range of 2-8°C. In some embodiments, the phage composition is stored between 2 and 3°C. In some embodiments, the phage composition is stored between 2 and 4°C. In some embodiments, the phage composition is stored between 2 and 5°C. In some embodiments, the phage composition is stored between 2 and 6°C. In some embodiments, the phage composition is stored between 2 and 7°C. In some embodiments, the phage composition is stored between 3 and 4°C. In some embodiments, the phage composition is stored between 3 and 5°C. In some embodiments, the phage composition is stored between 3 and 6°C. In some embodiments, the phage composition is stored between 3 and 7°C. In some embodiments, the phage composition is stored between 3 and 8°C. In some embodiments, the phage composition is stored between 4 and 5°C. In some embodiments, the phage composition is stored between 4 and 6°C. In some embodiments, the phage composition is stored between 4 and 7°C. In some embodiments, the phage composition is stored between 4 and 8°C. In some embodiments, the phage composition is stored between 5 and 8°C. In some embodiments, the phage composition is stored between 5 and 6°C. In some embodiments, the phage composition is stored between 5 and 7°C. In some embodiments, the phage composition is stored between 6 and 8°C. In some embodiments, the phage composition is stored between 6 and 7°C. In some embodiments, the phage composition is stored between 7 and 8°C. In some embodiments, the phage composition is stored at 2, 3, 4, 5, 6, 7, or 8°C. The temperature can be any value or subrange within the range, including endpoints.

[0089] In one embodiment, the phage composition is stored at room temperature. In another embodiment, the phage composition is stored at approximately 20-30°C. In another embodiment, the phage composition is stored at approximately 20-25°C. In another embodiment, the phage composition is stored at approximately 20-22°C. In another embodiment, the phage composition is stored at approximately 20°C. In another embodiment, the phage composition is stored at approximately 21°C. In another embodiment, the phage composition is stored at approximately 22°C. In another embodiment, the phage composition is stored at 23°C. In another embodiment, the phage composition is stored at 24°C. In another embodiment, the phage composition is stored at 25°C. The temperature can be any value or subrange within the stated range, including endpoints.

[0090] In some embodiments, the phage composition is resistant to inactivation of the subject's immune system. In some embodiments, the phage is resistant to inactivation of the subject's mononuclear phagocytic system. In some embodiments, the phage is resistant to inactivation of the subject's complement system. In some embodiments, the phage is resistant to inactivation of the subject's blood complement system. In some embodiments, the phage is resistant to inactivation of the subject's blood complement C3-complex of proteins.

[0091] In some embodiments, the phage composition includes at least one lytic phage. In some embodiments, the phage includes at least one lytic phage capable of killing bacteria and releasing phage progeny through cell lysis.

[0092] In one aspect, this document provides a bacterial host-producing strain comprising a bacteriophage, wherein the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, this document provides a bacterial host-producing strain comprising a bacteriophage, wherein the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0093] In embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 2. In embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1. In embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In other embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1. In embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2. In embodiments, this document provides a bacterial host-manufacturing strain comprising a bacteriophage according to any of the various embodiments described herein.

[0094] In embodiments, this document provides for the use of a composition according to any of the various embodiments described herein in treating a subject with a Staphylococcus aureus infection. In embodiments, this use includes administering a composition according to any of the embodiments described herein to a subject suffering from a Staphylococcus aureus infection.

[0095] In embodiments, this document provides the use of compositions comprising one or more unique phages targeting Staphylococcus aureus in the treatment of subjects suffering from Staphylococcus aureus bacterial infections. Use includes administering the composition to the subject; wherein at least one phage is selected from phages comprising: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. Use may include administering the composition to the subject; wherein at least one phage is selected from phages comprising: polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0096] How to use

[0097] In one aspect, this article provides a method for treating subjects with bacterial infections, which includes selecting a phage based on resistance to blood complement inactivation and administering the phage to the subject.

[0098] In one implementation, phage selection includes performing a blood / serum resistance assay and selecting phages based on a predetermined amount of time they survive in blood / serum.

[0099] In one aspect, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject one or more unique bacteriophages selected from the following: polynucleotide sequences selected from SEQ ID NO: 1 and SEQ ID NO: 2, polynucleotide sequences having at least 93% identity with SEQ ID NO: 1, and polynucleotide sequences having at least 93% identity with SEQ ID NO: 2. In another aspect, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject one or more unique bacteriophages selected from the following: polynucleotide sequences selected from SEQ ID NO: 1 and SEQ ID NO: 2, polynucleotide sequences having at least 90% identity with SEQ ID NO: 1, and polynucleotide sequences having at least 90% identity with SEQ ID NO: 2. In one aspect, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject one or more unique bacteriophages described in any embodiment herein.

[0100] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection. In some embodiments, the bacterial infection comprises at least a portion of Staphylococcus. In some embodiments, the bacterial infection comprises at least a portion of Staphylococcus aureus. In some embodiments, the bacterial infection comprises a Staphylococcus aureus strain resistant to a chemical antibiotic. In some embodiments, the bacterial strain comprises a drug-resistant and / or multidrug-resistant Staphylococcus aureus strain. In some embodiments, the bacterial strain is a drug-resistant strain, vancomycin intermediate Staphylococcus aureus (VISA). In some embodiments, the bacterial strain is a drug-resistant strain, vancomycin-resistant Staphylococcus aureus (VRSA). In some embodiments, the bacterial strain is a drug-resistant strain, methicillin-resistant Staphylococcus aureus (MRSA).

[0101] In one embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant to inactivation in the blood. In another embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant to inactivation of the blood complement system. In another embodiment, the bacteriophage may be any bacteriophage described herein.

[0102] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage comprising a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage comprising a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0103] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage that infects and kills one or more of vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and methicillin-resistant Staphylococcus aureus (MRSA). In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage that infects and kills vancomycin intermediate Staphylococcus aureus (VISA). In embodiments, the bacteriophage composition comprises a bacteriophage that infects and kills vancomycin-resistant Staphylococcus aureus (VRSA). In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage that infects and kills methicillin-resistant Staphylococcus aureus (MRSA).

[0104] In embodiments, this document provides a method of treating a subject suffering from a bacterial infection, comprising administering one or more phages to the subject. In embodiments, the one or more phages are suitable for treating bacterial infections, particularly staphylococcal infections. In embodiments, the phage includes one or more additional phages and may be a phage having 93%-100% nucleic acid sequence identity with any phage described herein. The phage may have a polynucleotide sequence comprising a polynucleotide sequence having at least 93% but not 100% identity with either SEQ ID NO: 1 or SEQ ID NO: 2. In embodiments, the phage includes one or more additional phages and may be a phage having 90%-100% nucleic acid sequence identity with any phage described herein. The phage may have a polynucleotide sequence comprising a polynucleotide sequence having at least 90% but not 100% identity with either SEQ ID NO: 1 or SEQ ID NO: 2. The percentage of identity may be any value or subrange of the range, including endpoints.

[0105] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising one or more phages, wherein the target bacterial range of the composition may be broader than the range of any single phage or phages coexisting in the composition, or have an efficacy greater than the sum of the efficacies of any single phage. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 90% identity with the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 91% identity with the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 92% identity with the polynucleotide sequence of SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 93% identity with a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 94% identity with a polynucleotide sequence having at least 94% identity with SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 95% identity with a polynucleotide sequence having at least 95% identity with SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 96% identity with a polynucleotide sequence having at least 96% identity with SEQ ID NO: 1. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 97% identity with a polynucleotide sequence having at least 97% identity with SEQ ID NO: 1. In one embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having at least 98% identity with SEQ ID NO: 1. In another embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having at least 99% identity with SEQ ID NO: 1.

[0106] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having at least 91% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having at least 92% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 94% identity with a polynucleotide sequence having at least 94% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 95% identity with a polynucleotide sequence having at least 95% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 96% identity with a polynucleotide sequence having at least 96% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 97% identity with a polynucleotide sequence having at least 97% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 98% identity with a polynucleotide sequence having at least 98% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising a phage having at least 99% identity with a polynucleotide sequence having at least 99% identity with SEQ ID NO: 2. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition having any combination of the polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2.

[0107] In some embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising at least one genetically modified phage. In some embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising at least one naturally occurring phage, or which may not include a naturally occurring phage. In some embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising at least one lytic phage. In some embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a phage composition comprising at least one phage resistant to inactivation of the blood complement system.

[0108] In one aspect, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus spp., wherein the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In another aspect, the bacteriophage may comprise a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1, and a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0109] In some embodiments, modifying the microbial community includes killing most of the specific bacterial strains in the microbial community, limiting the growth of the specific bacterial strains in the microbial community, and / or slowing down the growth of the specific bacterial strains in the microbial community. In some embodiments, modifying the microbial community includes killing most of the specific bacterial strains in the microbial community. In some embodiments, modifying the microbial community includes limiting the growth of the specific bacterial strains in the microbial community. In some embodiments, modifying the microbial community includes slowing down the growth of the specific bacterial strains in the microbial community.

[0110] In one embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject a bacteriophage targeting Staphylococcus aureus, wherein the bacteriophage comprises the polynucleotide sequence of SEQ ID NO: 1. In another embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus aureus, wherein the bacteriophage comprises the polynucleotide sequence of SEQ ID NO: 2. In yet another embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus aureus, wherein the bacteriophage comprises a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1. In yet another embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus aureus, wherein the bacteriophage comprises a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus aureus, wherein the bacteriophage comprises a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1. In embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage targeting Staphylococcus aureus, wherein the bacteriophage comprises a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0111] In one embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject a bacteriophage that infects and kills Staphylococcus aureus bacteria, wherein the bacteriophage comprises the polynucleotide sequence of SEQ ID NO: 1. In another embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage that infects and kills Staphylococcus aureus bacteria, wherein the bacteriophage comprises the polynucleotide sequence of SEQ ID NO: 2. In yet another embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage that infects and kills Staphylococcus aureus bacteria, wherein the bacteriophage comprises a polynucleotide sequence having at least 93% identity with SEQ ID NO: 1. In yet another embodiment, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage that infects and kills Staphylococcus aureus bacteria, wherein the bacteriophage comprises a polynucleotide sequence having at least 93% identity with SEQ ID NO: 2. In embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage that infects and kills Staphylococcus aureus bacteria, wherein the bacteriophage comprises a polynucleotide sequence having at least 90% identity with SEQ ID NO: 1. In embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering to the subject at least one bacteriophage that infects and kills Staphylococcus aureus bacteria, wherein the bacteriophage comprises a polynucleotide sequence having at least 90% identity with SEQ ID NO: 2.

[0112] In some embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering a genetically modified bacteriophage to the subject. In other embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering at least one naturally occurring bacteriophage to the subject, or optionally excluding a naturally occurring bacteriophage. In other embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering at least one lytic bacteriophage to the subject. In other embodiments, this document provides a method for modifying the microbial flora of a subject, comprising administering at least one bacteriophage resistant to inactivation of the blood complement system to the subject.

[0113] In its implementation, this document provides a method for administering bacteriophages to a subject, wherein the bacteriophages are comprised of 1 × 10⁻⁶ phages per milliliter. 8 and 1×10 11 The phage concentration range for each phage type is between PFUs. In some embodiments, the phage concentration is 1 × 10⁻⁶ per milliliter of composition. 8 Up to 1×10 9 PFU, 1×108 Up to 1×10 10 PFU or 1×10 8 Up to 1×10 11 Each phage of the PFU. In some embodiments, the phage concentration is 1 × 10⁻⁶ per milliliter of composition. 9 Up to 1×10 10 PFU or 1×10 9 Up to 1×10 11 Each phage of the PFU. In some embodiments, the phage concentration is 1 × 10⁻⁶ per milliliter of composition. 10 Up to 1×10 11 Each phage of PFU. In some embodiments, the phage is at least about 1 × 10⁻⁶ per milliliter of composition. 8 Each phage of PFU, at least approximately 1 × 10 9 Each phage of PFU, at least approximately 1 × 10 10 Each phage of PFU or at least about 1 × 10 11 Each phage of the PFU is administered to the subject at a dose. In an embodiment, one or more phages may be combined to form a total concentration of 1 × 10⁻⁶ per milliliter of composition. 8 1×10 9 1×10 10 Or 1×10 11 Each phage of PFU. Concentration includes any value or range within the stated range, including endpoints.

[0114] In one embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 81% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 82% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 83% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 84% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In one embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 85% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 86% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 87% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 88% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 89% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In one embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 90% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 90% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 92% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 93% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes.In one embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 94% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 95% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 96% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 97% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In yet another embodiment, the method provided herein includes administering a bacteriophage, wherein at least about 98% of the bacteriophages retain lytic activity after exposure to human plasma for a period of about 10 minutes to about 120 minutes. In one embodiment, the method provided herein includes administering a bacteriophage, wherein at least approximately 99% of the bacteriophage retains lytic activity after exposure to human plasma for a period between approximately 10 minutes and approximately 120 minutes. In a specific embodiment, the time period is between approximately 10 minutes and approximately 90 minutes.

[0115] In some embodiments, the methods provided herein include administering bacteriophages, wherein at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 20 minutes. In some embodiments, at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 30 minutes. In some embodiments, at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 40 minutes. In some embodiments, at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 50 minutes. In some embodiments, at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 60 minutes. In some embodiments, at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 70 minutes. In some embodiments, at least about 80% of the bacteriophages retain lytic activity after exposure to human plasma for a period of 10 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 10 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 10 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 10 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 10 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 30 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 40 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 50 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 60 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 70 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 20 to 110 minutes.In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 20 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 30 to 40 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 30 to 50 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 30 to 60 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 30 to 70 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 30 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 30 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 30 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 30 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 30 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 50 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 60 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 70 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 90 minutes. In some embodiments, the phages are administered to the subject at times of 40 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 40 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 50 to 60 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 50 to 70 minutes.In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 50 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 50 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 50 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 50 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 50 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 60 to 70 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 60 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 60 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 60 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 60 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 60 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 70 to 80 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 70 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 70 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 70 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 70 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 80 to 90 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 80 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 80 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for a period of 80 to 120 minutes.In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 90 to 100 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 90 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 90 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 100 to 110 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 100 to 120 minutes. In some embodiments, at least about 80% of the phages retain lytic activity after exposure to human plasma for 110 to 120 minutes. The time period can be any value or subrange within the range, including endpoints. At the end of the time point, the phage composition retains at least greater than 80% lytic activity in human plasma.

[0116] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant at least partially to the inactivation of the subject's immune system. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant to the inactivation of the subject's mononuclear phagocytic system. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant to the inactivation of the subject's complement system. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant to the inactivation of the subject's blood complement system. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage resistant to the inactivation of the subject's blood complement C3-complex protein.

[0117] In one embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject one or more bacteriophages belonging to the genus *Sylviavirus*. In another embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject a bacteriophage strain from the genus *Sylviavirus*. In another embodiment, the bacteriophage includes bacteriophages selected from MR003 (accession number AP019522.1), Qdsa001 (accession number KY779848.1), Remus (accession number NC_022090.1), Romulus (accession number NC_020877.1), SA11 (accession number NC_019511.12), StAP1 (accession number KC532239.1), and Stsau2 (accession number NC_030933.1). In another embodiment, the bacteriophage is *Sylviavirus Staphylococcus aureus* Remus. In another embodiment, the bacteriophage is *Sylviavirus Staphylococcus aureus* SA11. In one embodiment, the bacteriophage is Silvia virus staphylococcal virus Romulus. In another embodiment, the bacteriophage is Silvia virus staphylococcal virus Qdsa001. In yet another embodiment, the bacteriophage is Silvia virus staphylococcal virus MR003. In yet another embodiment, the bacteriophage is Silvia virus staphylococcal virus StAP1. In yet another embodiment, the bacteriophage is Silvia virus staphylococcal virus Stsau2.

[0118] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more intravenously administered phages to the subject. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more phages administered via intra-articular injection to the subject. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more phages administered via inhalation to the subject. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more phages to the subject via nebulization to the subject. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more phages to the subject via intranasal, oral, inhalation, vaginal, rectal, or parenteral routes, such as intradermal, subcutaneous, intramuscular, intraperitoneal, rectal, intra-arterial, intra-lymphatic, intravenous, intra-articular, intrathecal, and tracheal routes. If parenteral administration is used, it is typically characterized by injection.

[0119] In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject. In embodiments, the bacterial infection is selected from bacteremia, sepsis, lung infection, sinusitis, urinary tract infection, intra-abdominal infection, skin infection, skin structure infection, endocarditis, and implant infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is bacteremia. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is sepsis. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a lung infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is sinusitis. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a urinary tract infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is an intraperitoneal infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a skin infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a skin structure infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is endocarditis. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is an implant infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a cardiac implant infection. In embodiments, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a cardiac implant infection caused by a ventricular assist device. In one embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a pacemaker-related cardiac implant infection. In another embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering one or more unique phages to the subject, wherein the bacterial infection is a prosthesis joint infection.In one embodiment, this document provides a method for treating a subject suffering from a bacterial infection, comprising administering to the subject one or more unique bacteriophages, wherein the bacterial infection is prosthesis valvular endocarditis. In another embodiment, the bacterial infection is resistant to one or more antibiotics.

[0120] In embodiments, this document provides a method for treating bacterial infections by administering any of the phage compositions described herein in combination with antibiotics. In embodiments, the antibiotics are selected from fluoroquinolones, carbapenems, aminoglycosides, anesarcomacin, cephalosporins, penicillins, β-lactams, β-lactamase inhibitors, folic acid pathway inhibitors, fusobionic acid, glycopeptides, glycylcycline, lincosamide, lipopeptides, macrolides, oxazolidinones, phenicol phosphonates, streptozotocin, and tetracyclines.

[0121] In embodiments, this document provides methods for administering any of the phages described herein to a subject, wherein the administration occurs over a period of about 6 to about 24 hours. In some embodiments, the phage is administered to the subject every 6 hours. In some embodiments, the phage is administered to the subject every 12 hours. In some embodiments, the phage is administered to the subject every 18 hours. In some embodiments, the phage is administered to the subject every 24 hours.

[0122] In implementations, this document provides methods for administering any of the phages described herein to a subject for up to 7 days. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of one dose. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of two doses. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of three doses. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of four doses (1 day). In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of five doses. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of six doses. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of seven doses. In some implementations, the phage is administered to the subject every 6 hours, up to a maximum of eight doses (2 days).

[0123] In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of nine doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of ten doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of eleven doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twelve doses (3 days). In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of thirteen doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of fourteen doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of fifteen doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of sixteen doses (4 days). In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of seventeen doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of eighteen doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of nineteen doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty doses (5 days). In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-one doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-two doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-three doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-four doses (6 days). In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-five doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-six doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-seven doses. In some embodiments, the phage is administered to the subject every 6 hours, for a maximum of twenty-eight doses (7 days). In some embodiments, the phage is administered to the subject every 12 hours. In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of one dose. In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of two doses (1 day). In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of three doses. In some implementations, the phage is administered to the subject every 12 hours, for a maximum of four doses (2 days). In some implementations, the phage is administered to the subject every 12 hours, for a maximum of five doses. In some implementations, the phage is administered to the subject every 12 hours, for a maximum of six doses (3 days). In some implementations, the phage is administered to the subject every 12 hours, for a maximum of seven doses. In some implementations, the phage is administered to the subject every 12 hours, for a maximum of eight doses (4 days). In some implementations, the phage is administered to the subject every 12 hours, for a maximum of nine doses. In some implementations, the phage is administered to the subject every 12 hours, for a maximum of ten doses (5 days).In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of eleven doses. In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of twelve doses (6 days). In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of thirteen doses. In some embodiments, the phage is administered to the subject every 12 hours, for a maximum of fourteen doses (7 days). In some embodiments, the phage is administered to the subject every 18 hours. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of one dose. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of two doses. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of three doses. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of four doses (3 days). In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of five doses. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of six doses. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of seven doses. In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of eight doses (6 days). In some embodiments, the phage is administered to the subject every 18 hours, for a maximum of nine doses. In some embodiments, the phage is administered to the subject every 24 hours. In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of one dose (1 day). In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of two doses (2 days). In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of three doses (3 days). In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of four doses (4 days). In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of five doses (5 days). In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of six doses (6 days). In some embodiments, the phage is administered to the subject every 24 hours, for a maximum of seven doses (7 days). In some embodiments, the phage is administered for at least 7 days. In some embodiments, the phage is administered for at least 14 days. In some embodiments, the phage is administered for at least 21 days. In some embodiments, the phage is administered for at least 28 days. In some embodiments, the phage is administered for at least one month. In some embodiments, the phage is administered for at least two months.

[0124] In one embodiment, a method for administering a bacteriophage composition to a subject, wherein the subject is a human being, is disclosed.

[0125] Example

[0126] Example 1: AP-SA02 Product Optimization

[0127] Experiments were conducted to produce phage therapies that met the following criteria: 1) specific lysis to avoid specific transduction of bacterial genes; 2) the ease of broad transduction was not known to occur through empirical testing and / or genomic inference; and 3) complete sequencing to avoid phages with genes known to carry antibiotic resistance or bacterial virulence genes.

[0128] In general, phages used together to treat subjects should: 1) have broad activity against the target pathogen rather than other species to maximize potential utility and minimize off-target effects, and 2) be complementary, in which a resistant mutant produced by one phage is sensitive to another phage.

[0129] In addition to the characteristics of the phage itself, the manufacturing method of materials for clinical use should give people confidence that the final product retains these characteristics (i.e., it is still the same phage) and does not contain potentially harmful (or harmful amounts of) impurities, such as endotoxins or host cell proteins.

[0130] Each phage was identified by obtaining a set of different MRSA isolates and several VRSA strains, followed by screening against multiple phages to identify those exhibiting broad host range coverage and potent efficacy. Similar to antibiotics, if the minimum inhibitory concentration is less than or equal to 10... 3 A susceptibility breakpoint of 1 phage / mL (corresponding to 0.1 pg / mL protein) indicates that the bacteria are susceptible to phages.

[0131] Each phage candidate is then advanced through a series of selection criteria and different methods (including sequencing, bioinformatics, and comparative genomics) to identify potential receptors, phage identity, and confirm lytic activity. This process yields a small library of candidate phages with the properties required for candidate products: broad host range, complementarity, compatibility, and targeting of different bacterial receptors. These are fundamental intrinsic properties that contribute to the robustness and potency of the therapeutic cocktail. Compatibility aims to ensure that clinical isolates are targeted by more than one phage, thus limiting the emergence of resistance. Targeting different receptors on the bacterial surface also helps prevent resistance and has the potential to reduce bacterial virulence and adaptability. Compatibility between the different components of the multiphage product ensures that the activity of one phage does not interfere with the infectivity of another.

[0132] Then, the efficacy and potency of the phage candidates are validated. Specifically, this includes performing kill kinetics analyses to demonstrate synergy, activity in body fluids, and the presence of current in vitro antistaphylococcal therapies and biofilm inactivation.

[0133] Efforts were also made to select phages based on manufacturing feasibility and process optimization, with the aim of obtaining high-quality phage products free of host cell proteins and other contaminants, while maintaining adequate phage titers. Equally important, the ability to formulate phage components in the same diluent suitable for both inhalation and intravenous (IV) delivery to achieve long-term stability was a key consideration in the selection process.

[0134] Example 2: Selection of phage components for optimizing product AP-SA02

[0135] Host range and potency. SA phages typically have a host range exceeding 80% (Table 1), but their potency is variable. While phages belonging to the Kayvirus family, such as Sa87, have a wide host range, their potency is not ideal. In contrast, taking plaque turbidity as an example, Silvia viruses such as ARSA0001 are highly effective and can completely eliminate bacteria, resulting in clear plaques and very high plating efficiency. Figure 1 The efficacy of ARSA0001 was further demonstrated by the failure to obtain anti-phage bacteria.

[0136] Table 1

[0137]

[0138]

[0139] Compatibility with relevant biological fluids. The selection criterion for lead candidates was phage activity in body fluids to ensure infectivity was not inhibited locally or systemically. To ensure in vivo efficacy, the activity of individual phages was evaluated after exposure to human blood and plasma. Phages were diluted to concentrations equal to 10-1 ppm in plasma obtained from three healthy volunteers or phage buffer. 7 Phages / mL were incubated at 37°C. The activity of each phage fraction was assessed using a standard double agar plaque assay. Ten (10) Staphylococcus aureus phages were screened, and most were partially inactivated within 60 minutes of exposure to blood or plasma compared to the phage diluent (Table 2). Heat inactivation by serum and the complement inhibitor campstatin eliminated the inadequacy of recovery after exposure to blood, indicating that these phages were inhibited by complement (…). Figure 2 For the two lead candidates, ARSA0001 and ARSA0002, no significant loss of phage titer was observed.

[0140] Table 2

[0141] J-Sa36 0.06 Sa83 0.95 Sa87 6.33 ARSA0003 1.07 Sa474 0.03 ARSA0001 93.94 ARSA0004 1.76 Sa101 0.05 Sa68 0.71 ARSA0002 94.44

[0142] Next, the activities of Sa87, ARSA0001, and ARSA0002 were assessed 90 minutes after exposure to plasma obtained from 6 subjects to ensure that the inhibition was not donor-specific. Figure 3 Since all phages from AP-SA01 are highly correlated, Sa87 was chosen as an example of Kayvirus. Significant loss of activity was observed only in Sa87. Recently published data also suggest that Staphylococcus aureus phages may not retain full activity in human blood. The data in this paper indicate that the antimicrobial activity of ARSA0001 and ARSA0002 is not inhibited by blood components, and that these viruses are suitable therapeutic candidates.

[0143] Example 3: AP-SA02 Characterization: Biomembrane Activity

[0144] AP-SA02 characterization: Biofilm compatibility. Biofilms formed from several different clinical isolates of Staphylococcus aureus were treated with AP-SA02 for 5 hours. The remaining biofilm biomass was stained with crystal violet and quantified. Figure 4 NRS100 was not infected by any of the component phages of AP-SA02 and served as a negative control. Biofilm clearance achieved with one concentration of AP-SA02 ranged from 60% to 90%. These data indicate that AP-SA02 can penetrate pre-existing biofilms and reduce attached biomass.

[0145] Example 4: AP-SA02 characterization: compatibility with current anti-staphylococcal therapies

[0146] Standard treatment for subjects with Staphylococcus aureus infection includes vancomycin and daptomycin. Since subjects receiving AP-SA02 may be receiving these treatments, the effect of AP-SA02 on these antibiotics was assessed, and vice versa. Using standard checkerboard analysis, the minimum inhibitory concentration (MIC) of each antimicrobial agent, alone or in combination with each other, was used to calculate whether the two antimicrobial agents had a synergistic, antagonistic, or no-difference effect (Table 3). The combination of AP-SA02 and vancomycin showed additive, no-difference, or synergistic effects in killing all tested Staphylococcus aureus strains. It was noted that the combination of AP-SA02 and vancomycin did not have an antagonistic effect. Several vancomycin-resistant strains (MIC > 16 μg / mL) were also tested. Although vancomycin had no antimicrobial effect on these strains, phages at concentrations less than 1 pg / mL were able to inhibit growth (…). Figure 5A And B). It was observed that, in the presence of bacteriophages, the breakpoint for vancomycin changed from resistance or intermediate to the sensitive range (0.5-2 μg / mL). Figure 6A(and B). Furthermore, these data indicate a synergistic effect between vancomycin and AP-SA02, as adding a sub-inhibitory concentration (100 pg / mL) of AP-SA02 to a sub-inhibitory concentration (2 μg / mL) of vancomycin resulted in complete inhibition of SA growth. Higher concentrations (10 ng / mL) of AP-SA02 alone also inhibited VRSA. The AP-SA02 clinical candidate drug demonstrated potent activity against both MRSA and VRSA strains and maintained its activity in the presence of current standard antistaphylococcal therapies.

[0147] Table 3 Vancomycin and Daptomycin

[0148] HFH-29753 1.01 HFH-29753 1.00 F339777 1.01 F336222 1.00 NRS35 2.00 NRS35 1.00 NRS696 1.10 NRS696 1.00 HIP13170 0.07 HIP13170 1.00 NRS719 1.01 NRS719 1.00 NRS698 1.01 NRS698 1.01 NRS706 0.51 NRS706 1.10 NRS713 1.01 NRS713 1.01 HIP15178 1.00 HFH 30364 1.00

[0149] Example 5: Manufacturing of AP-SA02

[0150] The manufacture of AP-SA02 includes the selection of phages and host bacteria, as well as the increased robustness during purification. Further information and protocols for phage growth and manufacture can be found, for example, in PCT / US19 / 12113 (WO 2019 / 136108), PCT / US19 / 12114 (WO 2019 / 136109), PCT / GB17 / 50376 (WO 2019 / 136109) and US Patent No. 10,517,908, each of which is incorporated herein by reference in its entirety.

[0151] All processes are conducted under cGMP conditions, including manufacturing, product storage, quality control (QC) of raw materials, analysis and stability testing, and quality assurance (QA) of product release. Bacterial fermentation, filtration, and chromatography are performed in ISO 8 certified cleanrooms. Aseptic filling is performed in ISO 5 certified isolators within ISO 7 certified cleanrooms. QC analysis and stability testing are conducted in a controlled environment. Where possible, single-use components (filters, piping, containers, etc.) are used to reduce the risk of contamination during manufacturing.

[0152] All publications mentioned in the foregoing specification are incorporated herein by reference. Various modifications and variations of the methods and systems described herein will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in conjunction with specific preferred embodiments, it should be understood that the claimed invention should not be unduly limited to these specific embodiments. In fact, various modifications to the modes of carrying out the invention that will be apparent to those skilled in the art of biochemistry and biotechnology or related fields are intended to fall within the scope of the claims. sequence list <110> Armata Pharmaceuticals <120> Phage composition for treating staphylococcal infections <130> 054249-519001WO <140> Submit together <141> 2021-02-18 <150> US 62 / 978,006 <151> 2020-02-18 <160> 2 <170> PatentIn version 3.5 <210> 1 <211> 144299 <212> DNA <213> bacteriophage ARSA0001 <400> 1 ctwcatagtg tataaatagt taggtwtcta actgttagat acctaactat ttattttat 60 atagttttaa ctactgtgaa ctatgcttat gtagtattaa actatgctga ttatatgcta 120 aactattcta atgtatagtt aaactaagct gaagtagtat ttactgtgta taaaggtata 180 tttagtatta gatattgtgt atatggtata ctataattct gaacattact tatttaatat 240 atatatatag tttgtttcta tggtagtatt gacttaattt tccctagagt aaaagtttaa 300 tatatttagt aatttccgaa caataaagaa attttaacta ttttacacat atgtgttgac 360 agtatattac ttatggttta tactaagtat ataaagttaa aggagatgat ttatcatgaa 420 gattaaaaga gaagttcgt ttatagaatt aatgtatatg tattataaag gtgatgtagg 480 taaaggtcag tactattcta ctaatagtca gtttattgtt gttataactg ttgatgatat 540 atcgttttat aatgcattgt accctaataa atctattact attactatac ctaatgacac 600 taagtttatt gtagaagcgg ttatagatgc ttctactgag ttaagtagta tagtagttac 660 ttaaagcaa ggtaacagtg tattaaactc agtatggtat aggattagta ttaatgaagt 720 tattgactac tatgtcgaag gtaaaaatac atggttacta tctgttagta ctgttgtaga 780 taatgagtta gttactatat ggaaagatgg taacgtattg tgatttggta tatagtaata 840 ttcagtatac ttatatatgt acatcacttg tattattatg tgtagtacta gtatatagag 900 gggttaaata accgcttcaa taaagactta gtaacgagga gttgtattat gagtttatca 960 gatatttatg tacatttaaa tcagttagga tataaatag aagttttagg ggacatgagt 1020 acattaaaag ttaatgacta ctacatcgaa aatagatgta tagatagtgg ttttagggtt 1080 acaggggata atgtattttt atctgtatat tatggtgaag acgtagtaag attctttaaa 1140 aaggttat taaatagta tttgttag tttacttga gaatattat aagggggg 1200 ttagtttatg agtatattta tagtatagt ttctatatttt ttagtattgt 1260 actaagtata aggtttggta agagtatta taagcatgta cttgatatt atgatagtgt 1320 tagtgattta gatcagcta gtgtatttgg tttatttt atgagtattt gtattggtac 1380 tatttctatt gtttgagtt tattttacat agtaagtaga gtattttatt attaggagg 1440 gttgtagatg atgagttca ctttaatgta tattgcggtt agtattttag gtattagtat 1500 tatagttggt atgcttagtg ctttaattac tgatatagtt aaatctatta agcagaaaga 1560 agtgttttt agtatatatc ttattgtttc tttgttt actgttttg ttttgcttc 1620 tataatacta catatgttag gtatgtata gaaagaggggt attagtatag gttactttgt 1680 agtagttta tcattatgt atttagttat agatatagat atatgttata gatatatatag 1740 taaagaggt atagtaata gatttaagtt agcagtgtttt ttaactatac ttatattgat 1800 tatgtttata tattggagtag gtgttttatt aacacatag aaagaggctt tattggag 1860 aattagatat actagataga gtgttacata fathercagg fathergtgag tttacgtata caaattgtat aagaacaagt gatgataagt atatttatag gttctttctg gaagatactt attttggttg tgctattatg gtatatgatg atatgagtga gtatgaagta gtagtacaag gtacaggtaa ggtgtatgtt tccttattga aagatgtagt tagtaatatg tataagatac 2160. 2160. 2160. 2160. 2160. 2160. 2160. 2160. 2160. 2160 tatttgaga acaagtaga cagtataact aaagtttttc tctagggaa agcagtcaaa ggtaaaaata gggcttgaac ccgcattcta tggttgacat ttaggtaaaa ttagataggt tttccctaga agaaaagttt aaaaggtaaa aaaggagttg gttactatgt caaaattagc tagttttgt aggaagtatg gagaagttac tggcataatg gagagtatta cagattatga ggtgtactta ggtaggggtt ataaagtaag gtgtagta ggtaatagcc ttatttatat tcttgtatat aaagacaatc atatcattgc taggtttgag gaagcggata atatagtatt tcctttgagt gatacgcttg aggtgggac aattaagac ttagaggagc tagaaggttt gtatactaat atctatatat tactagggta tttataca gaatatgaaa ataaagttat 2640 gtatgaatat gggaggttag aataatggat attatggtaa gtgaattatt tgagtatata 2700 ttaggtcata acactcacat tcttgggaat tggcatactt attacttaga taaaggttac 2760 tgtattaaag ttaatgatga taaacattat aataacatga agtttatcaa aaatggtaga 2820 gtagtaaaag aggttattaa cagtgacacc ttactaccta aaggattcag tagtatctat 2880 agtcttattg attactatga ggaagcttta gatgaaaagt gcagaaaaga aaaagagcgt 2940 ctgaaagaaa ttcgtacgtt cctaggtaag taagtattat atataaccgc ttctatatga 3000 aactttatac ctatagctat tataactata ggtatttttt tatattctct acataaatgt 3060 gttgatttta tgtgtgttaa ggtttatact tatatataa ttaaaggagt gaatataata 3120 tggatatgaa caaggaagta ttagaatgat tagatagttt aggtggtaag ttagaacaag 3180 caggtacaca tagttatgaa tctttaatta aatacacaat tactcaaggt attatagatt 3240 tatgttcaat aagtatatta ttatctataa cagctatctt atgggtggct ttgtataagt 3300 cagataaaaa gtctaatgaa ggtcatagta ccctattatt tgagtttgtt tatagaatg 3360 aaaaagagct ttctgctgca ggatgcacag taattatat tgctgttact ctgtctatta 3420 tttcttttt agtgctatta ataggcttgc ctattgctat tcaagagatt tttaatccag 3480 Aaggatattt gattaagagt acgatagata atttaaata attgtaaaa taggaggaa 3540 atataatgt tagacaagc taaagcata actacagatt atattatgga atttattgat 3600 gaacatgagc atttattcta tgagactta cacaagttag caggggatt agtgttgaaa 3660 gatacacatg acacaaaccc tattgttatt aatgatggtg atggttactc aggtactatt 3720 atatctaaat ttaaatcaa ggtagagggt gttccagata tcactgttag tgatttttac 3780 ggttcatgtt ctttctgtga tactttagct atatctatg aaggtagtga tgaacttgag 3840 atattagag atttagctac tatggtacta catacaatc atatctatgga agagaaagta 3900 gataatgta tagggagtg attagtgtt tgtagaga aaagaatta aagagtata 3960 gaaacaggt tactctgttg attaatggg tggtttttta ggattattg gtcttggcga 4020 tgttttatac tagtagaaa ctaatagaa attacktaag tcattagcg taggtaag 4080 tgacaaccaa tatgtatatg actttaatgg ttatgaatac tttacagac ataagttaaa 4140 tatcaagaa gagaactaa tgtctaaagc tattgctcag tagttaca aaggtttaa 4200 gattttaat ggagttaagc atatttggga tgtaggttttc ttagagcaat cttttaatat 4260 acatcgtaaa gatttgata cggttaaact taactaagt ttgatgaag agggtaacct 4320 Attattatgaa ttagattag gttggattaa tattattaaa gagtatacag gtgtaaaga 4380 ctttcttaat acagtagata actatctcca cttctctat aaagatatag tcactagtgg 4440 tcttgagtta aaacaagtac tatataac ttttatggga ggagattatg agtttgtagt 4500 atctccatat aatgttgtag tatatagg agttgagtta attgatataa agaatttta 4560 ctctgatact tatggaattt attcctatgg ttatgcact atgtacata aacctttaca 4620 aaaattaag tattatctgg ataccctat gatgagta taaccactc aaatattata 4680 taaaaggagt gcttatatg agtaacggaa agtagcgtt aattggtagt aaggtattag 4740 aagattataa tattataca atcatgagtg agaaacatat attacktaga gatagtgttg 4800 atgtgacttt taatgatggg aaggtattac ctatatacat tgagtgta ttaaaacaat 4860 tagtaaga tgataaaat ctatattttt ctgaagaga taggatatt agtaaactta 4920 ctaatgacga gttattaca gttactaaaaaaagga gatagataa tgagtagta 4980 taaaaaaata gcagaaagag ttattgagaa atttttagat gagactaata aggtgtaga 5040 tttactaat acagagaat ttaccgctt cttagataat acagagact tgtactaat 5100 atctggtact caagata agattattaa gtgtttacaa aacattgtag ttactgtatt 5160 Tatggatag gggaataac aatgaaaaaaaaaaga aaatagtaca agaggtag 5220 aaaaagaag aaactatgat ggagacgat tctgttgtaa taaaaaaaat tcaaaaata 5280 acaggcggag ctattcttcc tttagccaat ggcaaggaat atgtagtagt gtttagtaaa 5340 gtagacccta ctaaattaat tgtatttat gtggaacgta atcaatcta tttaagtggt 5400 tctggtttcg atgtgaact gtcttatgta gagtaaaa gcaaccctat taccttagaa 5460 acagttaggt taatcactaa tttattataa aggttattag gcttttaaag attaagttat 5520 tttatagaat aaatactact agaaaatgat tactgtttaa tacagaattt taacgtacct 5580 agcttaaggg tattaaatat aaaggagggt attagaatga ctaaagttgt aagtagagga 5640 tatagttttg aagaacaaga agtaagtatg aactataatc aaggacaatg ggtgatttat 5700 gcaagtagaa aaccttatat tactgatatt atgaaaaagt accctgataa ggtggaagta 5760 ttagaacaat tagaaaatga aacaccagta ttggttaaag ttgtattgga tgaagattta 5820 attacattga gaaagccaat aagtaacgag cgtaaagaac aaatgaaaaa gattgctaaa 5880 gaaagatttg gtaaataata gagaggctga ctttaatgaa catcagtatg tacactaaca 5940 cctgtaggga ctagattaat attacaagat atcttatagg gttatagtgt cattgagaat 6000 gagtatgctt tattaaggtt agttaaagaa gataaacagt atttataata tcatattgaa 6060 gaagtagaag cggtattaaa ccgcttcttt tttatattat atttatattc tgagtaatta 6120 tgttgtattt aatcttggct aataattgta tatcaatttg agcatagtat gcccgtttca 6180 acatagttaa tctaataatt tgtatattta tctgttagtt atgtataaat atttgttatt 6240 acttatttat atatttgtat ttcgtactaa ccgtacgact tattcttta aaagataag 6300 aaaaaacag cgtatacctt gttgttttac gctacgctac aaaaggtaa cgcctgtaat 6360 aagttattcg tattaaata ctaacaacta attactgtt gtttagatta taacatatgt 6420 tttgagaat tagatgagaa tttagttaca acagcattat atatatta cagttatgtt 6480 acagttgct aagtagttt tgttactaca atatattgaa tatgaagct ttagacctttt 6540 tctgcagaca agtatattatt acaggtagt atgataaag ataagtaca gggattaat 6600 taaggttgga ttaatgaagc ggataagtta gatactggtt aaaaaaat actttacatt 6660 acctaaaact tatgatacac ttaggatagg aaaggagg atatcaatg atattcaag 6720 aagcaagga taaattatac gatgaattac ttatacagt aagtctttgt gagggaacag 6780 aagaagattt actagaactt attgagaattt tatttat ttacaatgac gagcctgcat 6840 ttttaagtaa agacggtatg caatacta ttaagattt tatggagaga agaaaaacat 6900 tagaacctat cttaactgaa ttaggtatag ggtacgcaat gatagaatat cacacacata 6960 cagaatacga gttagttact tattcagtac ttaaagttat acagtatgat gtagataact 7020 atactgtaat tattgatact aatagtgata agaatattaa gttatcagat ttaacattag 7080 aagctgttaa ggatattttg aatcaaatta agtagctagg gttgttttac tctagctttt 7140 tcatatgctt gtgttgccta tttaactacc ttatataagc aagtaagtat tataggataa 7200 atactaccta aaaagtatta ccgttgaata tagacctata agcttaatgc tctcttactg 7260 ttataaacat cataagtata aatctatgat tttcctaagt agcaggcgct gttttccctt 7320 tatattaacc gcttcaaaca acataaaaaa agattaggtt aatagcctaa tctataactc 7380 ttttatataa ttcttgtaat tctttttcta acttttttat tgtttctata tcattatttc 7440 ttttaataga ctgacatata aatgcaatac ctttaatcaa attaaatggt tagtttaca 7500 7560 7620 cattaaatct aggatagtgt aatgtaata gcgtagtaaaaccgaaa ggattgata 7680 agatatgac gtaaatcaa ttggatat actaatgaa ttattagata tagatggtta 7740 aaagcaat actactata gaatgactt aaatactca acacattac aagttaata 7800 tttagcttac attgatgta gttatgaac attagaacta ttgaagaaa cgaagctctt 7860 tagcgtatca help gattaccaat windows gttaggtag tgacaaca 7920 cttatttata gagctagata atacgttata cctagtgaat gagaatgcag aattattaa 7980 agaaaaaaag ttaaaat agttgacact attack taggtaata tatagatgt 8040 agtaaaaaaaaaagg attgattaattgaaaaca ctaattacta acagtaaacc 8100 atatagaac tacggctatg aaatggaac attcgagaga gaaacaacg taattatcac 8160 acgagcatac cacgaaccaa acgagcagg tttagtctt gtaatacact atacggaggt 8220 daadad gaatatta tattacatta no aggatta taacagatt aaagcacaag 8280 gtacaatatc aaatgactat agattatggt caggtattga tgaatgtgat gacttatact 8340 accatattaa taaagcttgt catagtcttt ataataatgg tgtaaggaa attacagtta 8400 cagacaatg cgttaaacta acacttaata ataaaac aaacttatt aaaaagtttt 8460 aagaaaagtg tgacactta ctaaaataca tgtatatata taaataataa gaaaacacaa 8520 taaacgaaaa ggattgatta attatgaaa accagtaaa agaatggca aacggaaaca 8580 ctaaacttga agattatta gttttagcaa ttgaggaagc ggttatgaca gagcttgttg 8640 attagatgc attagataa acaccact window gttattaac atgaccact 8700 taacacaagc agaacgtaaa ccacacaagc ttgattatag cacttacgag ggagctatat 8760 tagcahage aaaaaaaaaaaaaaaaaaaaaaaaaaccacta acgttatctt aatttgaaca aatgattg gatttgaa cacgaatt tatgcaga caatgctat 8880 tctaggaga cattacacat gaacttatct tattagagac tctagatat atggacac 8940 gttaatagct tcactgatat cgtgaagct attackaa gttaagcaaaacaatt 9000 aaaggcagtg aaagacag cggaacgatt aacagtaca atagtttaga tgagttaga 9060 agaactg acatacaac actagcacca gacgtaata aagaattact acatacat 9120 tagtgtaaa cttcccaaaa taattaacta aaactattgc aattaactgt atatttgata 9180 tatgtatt no aaaaaaga aaaggattg aaattacttag aaattactta 9240 accaaatgga aaacagca gaacttgaag gattgaatt tgacttatta ctaacagcta 9300 tctatgaaac atagaggta gatgttgctg aacacgattt actatgcaaa tacattcata 9360 ttgtaaacca attaaagag aaaagaca taacaccatt agaatatata ccgtctaacc 9420 tagactttac agacgataca acaatagac tagttgata taagtgttt gagttagcag 9480 attatatatt ggacatatg cgtgttgaag agttataa acacattaaa gactatgaac 9540 aaattaagc agaagctata gaatgatgt aaaaaaaatt gaagggat aactccctt 9600 tcttttttt tattattt taggattgta tacaataggt taattaat tattatacg 9660 ggggcagggg taaatgcca ctaaagtggg tgggtctgac agggctatgg gggctacctaa 9720 ggaacctaat tagtagta tattataa cttattatta aaagtcaa tcaccatta 9780 ctttattaaa ctaggtcaac attactaata actattgta ttcattttac ataaagtta 9840 gtaatatatc cccctcttcc cttacactta attagagtat tgtatatta cagcatataa 9900 gtagtttagt atataggagc ctttccttat atatagtttt cttaggtatt ctttagtata 9960 ccattttaat actagttat actagtact attagtagtg agtaatatta tataacttat 10020 tattaaaagt thunderstorm aagtatatta tattaaaag tchaaaagt tttattg 10080 ttattaaagt aaacatgta agatttcttt tactgttatt attgtcctgt ctatctctac 10140 tgcctttact attatagtag tagtgttact ctatttctta caataaaa aacacctaaa 10200 ttaataggta tttaatgtga catatcatat ctatattca atattctct atctacttgt 10260 tcgaaacctt tcttttatc ttttaata tagttaccat gtaaaacttt ttcaatacct 10320 gaaggtgcat taataacag gctattgttt ctttgttgt ctactgctct aaatgtctga 10380 ccttctgtcc actgattgat gtcattctta ttatagcctg tatattgaat atattctact 10440 acgtattcca tgtcattaa gactttagc atactctc ttactttagc ataatcatct 10500 gtaagggtat ctaagtctag aggttttact tttgctatat tgcttatact acgttctttt 10560 acaggtgttt ttgcatattc taccattaaa tcaaataact cactatctgt gcctaagctt 10620 cgaaaagaat atggttcatt tagaaatacc caagcaatag gttgttggtt ttctttttta 10680 ataagtattt tttcttttct cttggtagta tttttatttg cgaggctggt ttcatatcct 10740 aactgattta ccttcttaat aaattcattt gtatacattt tttaatacct ccttatttat 10800 tgtccacgat ttctatttca tgtattgtaa tcatgtcatc tctaaaatca tctatatgtt 10860 taaggtaaac aataccatca tgatttctag acatgccttg taattctttg tatccttcag 10920 atttaatgtc tttaataagc tgttcttgac tagtatatat tttatcttct ctataagagt 10980 agctgtcttc gtatagctca caattatcat gctctacttg gtaatatttc attctttttt 11040 actccttttt tcatagatat ttcctacaac ttcagtatta ccaatctctg aaatgcacat 11100 catagagaat ggtatgtaat ctcccccttc aacccatcca aaagaagctt ctttaaatat 11160 11220. 11220. 11220. 11220. 11220. 11220. 11220. 11220. 11220. 11220 cttatcttca agtcctgtag attgcataat tacaaggttt tctcctaagt aaccatcaca agcaaatagg tgtgaata ctgtatggtc tgcaaagtca aatctagcaa tattaaacat tctttgtgat tctttatccc atgctctaaa tttcggtatc attctattac ctccaataaa tgagatgatt caatacgtt gcctttaacc tcacagtcgt acataagga agattttttg tctgtatact caaagtaatc attttcagag attgcgctct caaacataaa gtcttttaag tgaatgccac ttacaacatc aatagatatc actgctctgt taattgtttc tactgcagat tcaaaatcac ctggtattgc taacacttca tcttcgaact caataatc accctcatat attttagtac cgtttttgtc tttaagtcct gtgtattgta gtaactgtat atccttagaa aaaataaaat taccaccttc tacattatt ttctcatctt ttttccatgc tctaaaccta agtgtcatac tgctaccttc actttttcga cccctatgct tgcagttttg aatgggagtt ttttacgagt cagttttaat gtcctatttt tggcttcttc ctcattcgta ctttgcacaa aataatgctt ttttatttta taatcacatt taaacgctaa gaacttaata caaagactca ctttataggt ttgcatcatt ctaccaactc cccatctttc cagattaacg tcatagttag gtcatcgttt aagatgtaga atgctttggt aggcacacat ctgccatata aacattcttt father ttctcatata gtgtagtt atagtctcct tcttgaatct cgaataattc aatcaaccta tcaaccttag cctcttctgt gattcctct tcagcttcga cttcaaaagt gtcgtcagct throw cactus acattttctt ccgtcttccg aagaaaata aacaaagttc tcattatctt gattttctgt gtaaattctc tttccttttg ttaatcagg atattcccaa gcccattcca tgagttcggc tagcgtcatt acttttttag tttttatttt catttctata tctcctaatt atttaatttt tctatcattt tcacaatctc ttttgatttt ctaatgtcag cattttcaca gttttttaat atgaagttaa ttttgttttt tacatcatta acgatactgt ctacttcttt ttctgttggc ttagtaggga aaagcaaccc tacaactacc tgaatttgat ttttatttag tgagtaaaca ctaatgttac atttctcatt aaagtcaata 12600 tgtggtttac ttgaattaaa tacctcatct acaattgtat ttaattcttg tataggttta 12660 aaatatgtt gttttctttg tattattacc tgtgacatta gtttatatag tttctgttct 12720 tttcaagaa cttctttgtgt aagcctttta acttctccta tccttatagt attaccccat 12780 gcatcataat tatttttaac atactcagct tcttctatgt tagtagtata tcctattact 12840 tttgaggtgg gttcctcatc ataataacag tcctcttcta catatatagc atatatctta 12900 ttcatatcta tcaaaccttt ctttaagtta aattaactat aacatataaa cattaggatg 12960 tcaactacta atatacactt ttttcagtaa gcaaaaaaaa agaacctttt tacaggttct 13020 ttactgggtt attaattttt taaatcttgg tttcctttta ttaattttt atcatcaata 13080 ggatgaccat tgtataaata ttttacttcc atatatacat gattatccgt agccgtaagg 13140 gcatctagga tatccggatt tgtgttaatt gcatttgtat caggaaacga aaatttctt 13200 ttatccgact ggattatatc tacatgaaat ttttcttgtt ttggtaaagc gtaattaagg 13260 tcttctaaat tttgtaagaa tttagtaaga gaaaagggtt taaactttcc ttgtaaatta 13320 ttatctatat agtcatttaa tagtcttgtc atttcctctt tatttaaagt cattgtttca 13380 taatcgttaa catcataaaa aacaacaaca ttaggttgct caatacttgt gtctccatct 13440 ttgtacttag caatgtaata gcctatttca cctttgtgag ctaaataatc ttctttcatg 13500 atattaaata cttctctagc aataggtttt gtatatagtt cttcccattt atttgtttct 13560 gtgttgtaaa aatgtggtaa taagtttgcc attctgagtt atcctttctt attctgattt 13620 aagccatatc tttagtat ttttaggcgg ttcattactt attgtgtatc catcagtacc 13680 catatctagt gtgtttacaa tgacaggctg agctacagct tctttttcac tctctaatgt 13740 tttgaaacta ggcacgtctg ttttattaga ttcttgtcca tcgactaacc aagagacttt 13800 aaagtcacct tttataag tagtattagg ttttaaatct gttaatgtta cttttacaga 13860 actacctgta acttcatcag aagttaaaat aagctgttcc tctttgttgt agacctttaa 13920 ttttttagac ataatgttat ccctttctgt tgtgtaatac actaatata taacatataa 13980 aaaacaggta aggtctttca aaacctttac ctgcttattc tttactgata atcatacca 14040 tcaagaaaat catctgaaca gcttactct atagttatat catttataag tttagtagct 14100 tcatctttac ttaatgactc tatatcaaa gtaactcat catataaca atctatatgc 14160 tttaataa aatctttg ttttccgta gctttgttt attcattgct ttttttactt 14220 aaattgac taaagttac actcatttaa atcttccctct ttaaagg taccattaac 14280 tgttctctcct tacgacctt taatttcatt ataagcaac tctaacact cttgtaatga 14340 catgtcgtgt tgctgagcta aaatattaa agtaactaca gtgtccccaa taccacttt 14400 aagagcttct aggttaccac gtgataatgc cgatgctact tcacctgctt cttcgtagaa 14460 tttaagagct tgtctatcag gttgttatt gttcaatcct tttacttac tccattcctc 14520 tacttgacta actaacctt ctagcgtgcg gtctctgtt tcaccttcat taagttagg 14580 ttttcatcg ttttgtatat ggtctcttg ttcttattcc tctattgtaa taaataagt 14640 gtctatttct tttcgtact tatttctctg catataatta tactgctcat actcaggata 14700 aggtacatat acagtatcgt ctgtaccatc ctcataattc aaacaaacac aaacaatatc 14760 tttgccactt agtctatcat ataatgtcat gttgtagggc tcatctaaga aaccatgaaa 14820 ctcttcaaag tattcatcct tcataccact tacctcaata gaaacttttt ttgctgattt 14880 acttgtatct acttcactat ttccatatat catagtttt tcttcactaa tgccttctag 14940 tatcaactct acattttctg gttctaacat tgcgctatct aagttttcaa aaacaatttc 15000 aatattttta attttttag tcattaataa tcattccttt tttttagtat atagtaaata 15060 taacacataa gtaatagaa gtcaataaaa agacacctac tttaaaaata agtaggtgta 15120 agatattttg acaggtagct tgtggaaaaa aatcctgaga gaggactcga accccaacga 15180 ctaggtagct acaactagcc aataccatta ctcaggattg atagtaacgc taatagagt 15240 cataacgtta ccatagacct tttctacgct tggtatatag gtagaatata atgattttac 15300 agtacccata tagttagact gttactctca ttataaggtt aaaaaatgct aactttgttt 15360 cgcattgtca agaggcgtta gttaactact ataataatat agcatatatt ttattgtttg 15420 tcaagttctt tattccattt acttttttct tttagtaatc cttttttaat tagttcttca 15480 ctaatatttt tatactcttt atttctttg tagaaaactt tagctaaata tctaccaaaa 15540 gaatcatctt tgtatgtttg attaaaaca tctttttcctt ctagcatagt tgttgtaaat 15600 tccttagctt cttggtaatt atttgtttc ttttctggtg tgtcgacacc tagtaatctt 15660 attctttgct cagaatatgt tctcattccg tggtcaatag ttacatgtat agtatctcca 15720 tccactactt tgtccacatg tgctttaaat aaatataaat tgtcttctat catcattaaa 15780 tcccctttt actaatttaa aattatccaa tcagtattgc ttgatgtacc cttaactaca 15840 tatacagatg aacctattat agcaatttga cctttattta cagatatcat ttagatgaat 15900 atggtcttgt actgaaaagt ctacaatgac atgtttatgc ttttcttttt ttgttaatac 15960 tttatatgtg ataaagaatg atatatagt taaacatata tttaattttt tcataaaatt 16020 tctcctttaa agaaggtatt taccatctca gtagttaatt ctttgctttt aaagatacaa 16080 tattctgtat ttttattcaa tatttctaac atattttgca tactacttgc tttttgtaaa 16140 tccgttaagt ctataacaac tgttatttct gcgttatcta ttagaatatt acctatgtaa 16200 taatttttaa ctccattctc cgtagcatga gaggtaacat tatgatttaa aacaactata 16260 ccttttgatg gtaagtactc tgaaaagtat aagtaacaaa agtatttgtg tatcttttt 16320 ttatctctt ccattactat taccatattc tatgaagttt aatagccttt cggtataggt 16380 tttaattttc tctacttctt ttctttcatc gtcttttctt cctaatcttg ttgtatattt 16440 aacaatatta aatagcatgc agtctataaa gccaataatg tagaaatatt cttctaaaaa 16500 tgatataaca tcttttttac ctttataatg gttcggtgta ttagtggtag aattgacatt 16560 atagtataac tccagttgtt ctacattttt cataagcttt ttagcataat ataatgtgtc 16620 atctaaagaa tgtgtcacat ctaaagatgc ttcaacaatg tttatcttta attcttttaa 16680 ttctgttgcc tctttgttac ttcaatttg tgaatcaata atttctctag tatccatatt 16740 ggtgtcctttt cgtatctaaa aaaaaccc tatctagaat atagataggg aaaaggaaag 16800 atattatgga agtgtactat aaagtacaca tatatata cagttccttt gccttttaat 16860 ctatatcatt tattttaact tcttgtactt tacataatc tgataacta ttacgacga 16920 tattatcttc tactaatcg tttcttat ttgtaacatc atatgagtct ctataaggtg 16980 tttgtactaa tgctctaact gtaatgtcta tatctacata ttcttacta taccttttcca 17040 ttactcaacg tagttcctt tagcagctg attackttg tgtattctt catataattt 17100 ctccatatct ttatatttc gtacatctc ttcaaatga cttaaatact ctattaatgt 17160 cttaacttct ttaggttcta aagttataac tggttttacc attacgcac atcctcacta 17220 aattgtttat ttatattttt atatctttt atttattcgt cttttaattc tttaggtaac 17280 tcatgacttt ttaaagattg ttgttgacct aacgtatatc catattttgt tatccttact 17340 tctacagtat accatgattt ttctaatcg tcaacttttc tagctagtaa tattaaacat 17400 ctgtcattta tatattcga agcataactg ccgacacaat gagatagctg ttcaccttct 17460 cttttaatt tttcagtagt atccgcaggt aaaaatttaa ctttagagcc atcgtttaac 17520 ttatatctt tatttgtgat attatttaat ttattatcat atttttgttg taactttaag 17580 tcatcgactt catctttaac tgttaaatac tcatcagtaa caatatcatg ctctagtttt 17640 aaagaatatg gtgttaagtt aatactttct ttagttctat atccaagaag tactaggtct 17700 gaagcaaagt ctatataatc tctatataaa ttattaacag cgtatgaatg tatacgttgt 17760 ctgtttctga catcatagtt tatataattc accatttttc taaagtcaga aaatgaaaag 17820 ttaagaactt cttcgtagt acctttaaaa gataaagcat ttcctattga atatgaatta 17880 gtcaccatta taaagtcgtc atcgaatagt ttgtgtaagt tagactcatt atataaacta 17940 ggaaatttat tttgataac tcgaagtata ttaaggtaat tttcttgctc ttctttacta 18000 agagtaataa acttattata tgtttgttta cttaaattta aagcttcatg taatttccat 18060 ttatttttgt ttggtattac tagaaactct ttgtgttctt taaatatatc acaatcttcg 18120 ttgttataaa ctttatcaat attagacaca actaatttta acatattgtt taaattatca 18180 gtagcatttt cacctttact aactgtgcga taaccatcag gtctatctat catagagtat 18240 acatcaaagt tttttacatt aagtctactt agatttaagt aataatcatt attctttagt 18300 gtttggatta ttatgttaaa agctaaattt tcctttccat atttactttaa aataatattt 18360 aaaaggacag gtaaagtaat gttattttt agtttatcct tattaaaatc atcttcatac 18420 atattaaatt taaattcttt atgttgtagt gtatttgata ggtgtaggta tacatttcca 18480 tttttattat taaagtcacc gtttactata ctccaatctg ttgttactat acttatgtct 18540 tttaaataac aagtcttaat taaaaacgga gtattattat cttttatagg tgttaatttg 18600 ttaagcccta tttttatgtt tttaaaact tcattgtagt attcgtagtt attatcataa 18660 gatttaccaa atgcataagg gtcaatatta ataccaaata tactatagtc acccattaat 18720 aatacatcaa gtatatcatt agttgtagta tttatttgtc tttttaagtc tcttattttt 18780 tttgtaggt aattattact attcttattt tgcgtattgt caactgttt tagttcattt 18840 tcatagtttg cacggcagta tatatta cgatagtgtc tttgttata taaggaaat 18900 tcagacctat cgtcactttc tatatactca ctatatacag tattacac tgtaactgtt 18960 ttacttaact cttgtacttt tttatatggg tctcccttaa acgtagtaag ttttttatt 19020 ccacataatg ctataata aagtaaattt aaagcgctag ataaaaaa ggtattatta 19080 atatctctta atattcttt agagccaata tctacaata ttttatt tattttaaa 19140 tatactcttt cttcacctat aaatacta tttcttta ctttagacaa tttaagaatt 19200 tcttcttccg ttaatctgt ttcttatt tctactgaca tgtgtcatca cctcatttat 19260 tattataa gtagataac atagttaaat ttatagtca aaaaaaga agaacttttt 19320 tacagttctt ctagataagt ttcatattta atttttg ttctcttac gggtacaata 19380 tcgggattac tcattagtc ttgtactc ttagaatttt taagttaat agtattaggc 19440 attgctaaaa cttccctctaa ctcatctgtg tacatagtaa ctttagatat tatatctatg 19500 tcactaataat aataattttt agatttactt tcaaaata tctcatcggt actagttact 19560 tctttattat ctattaaatc catatagag tcctttctag tctacataaa caagtataca 19620 atctttgtct gataaagaca ccgaggtcat atcattaagt tctgtagtt gtttaataga 19680 cacatcatat ttcttactta tagtccataa ggtatcacca tttctaacct tatataaaa 19740 tttattacct tttgtatta agtctttcat tgttactac gcctttatat tcataataag 19800 atgcctgtag gtaacatatc gtaataagaa taaagttagc tactctgta tatattacat 19860 gtggtgtcgt atttgttatt aacatactaa taattaaca agctaatgca atacctataa 19920 taagaaataa atatttgcta gttccatttg tactttagt tttataaaat ttatttattt 19980 gggataata agctacgata atactaatag tagccattat ctgtccatat tcacact 20040 agttagctac tgaatagcca atataataa cattaaccatt tctaaaatac 20100 taacttctgt tgttctaaat aagtata taaaaacaat atacctagt aaaatta 20160 tacttactga tataatttga aataggggtg catgtgttac aaataagctt gttaagctaa 20220 tacttactgt aacaacaata taaaaccaaa atagctatc tacaccttta acattcttat 20280 ctcttatcaa acctactaaa gcaggtatat atcctacagt aactaatata gcatatagga 20340 tgcttaatat atgagctaaa ttattcatat gaccctccga aattctctat ctcatttaaa 20400 acttcttccc atgaaataaa acctttaccg ttggttaatg ataaaatgtg cttggtaaga 20460 ttattccatg ttttattatt ttaatatattt gtaattgtag tataagtaac tttaaatttt 20520 ttagataaag tagatgcctt ctctttgctt gtgtaaatca agtagacatc atagtctgtt 20580 aatttgaat ttataccaaa aatattgtcg ttccttagac tggtttttat tgcatgtaaa 20640 gtgttctctc taggagtaac cattctaag ttttcaactc tattatcatc tttatccca 20700 tttttatgat tcacttggtt tctatcaata tttttat agtctagcaa aaagcattct 20760 gctataatcc tgtgtacttt gcattgaata cgtttgttat tttctccaaa taacgttact 20820 attatatacc catctttatc tttcttgtc tttaatacat tttacgctt acctttgatg 20880 atacctgcta tacttataga atattctttt gcaatggaa tagtagacca taaaagacca 20940 tcttcaaat aaataatttct aggagtt ttcaaagggt atacttcat agaatctttg 21000 tagctctag gagaatagtt atatttttta atatagttc tcagttccgt atactact 21060 ccatactttg tagcaacttt cctcatactg agaccactct cataatctct tattgcatta 21120 tcaatcttgc tgtcccaatc ttcaagttc taatatacc tcctcccacg aaatgaaacc 21180 tttgccatcg gttaatgaca gatcatacc aaaaataac tggttcgttg aaaactccgc 21240 tctgtctggg tcagtgtatg gttttccgtg cccttgacga atcagagc aaaattaa 21300 aacaggttta ttgacgacat gatacgctc taatatatca tcttgtgtgt ttttatctaa 21360 ctctctaaaa tctacatctt catatttgtt gataatttgt tgagctgt gttcattcc 21420 taaaaata ctaagttctg ctattgtacc taatccctca ttcaatacat caatacaa 21480 tatatctgac tcttgcatag ccttaaagtc attatttaga atacgctcag ccaaccctc 21540 ctgtctagca tttgctttgt cgttaattga gccatcttga tgaggagagt atggagatac acctacaatt ccttctactt gattgtgttg tttttctcta tattctatca ttgcttgatt aagtagatga cctcccatat agcaaatctt atctttgatt ttatttacca ttgtttttat ctccttttta tttatttaa agttacttta cccatttcca atacttgtat tctcttattt ctctgattgt agttctattt acaccatact tttttgctaa ttctgtatga cttaaatcac tcactcttac ttcttttatt ttttcttcat ttaacttaga aacagggttt tttcttttac cacttatata father ttatgctctg father attagtacac cactctagat Tagagcata gttgttactt ttatcaaaat ccttatgatt gacttggggt aggttgtag ggtttaaaat aaaaacacta gcaactaatc tatgcactat ttgagtgtta ctcttatctg agtagtttct taaagacaca atatgatacc cttttttgtt tatcgtatgt tttagtatct ttttggtttt atcactgtat acatttcctt tttcgtttt fatherccg tag aaagggta aaatacctttt ccatcacat ttttatatt taaaggctct tgatttctat 22260 taacaaaacc atatttattt ttctcttgt atgctgagta acaaccaa cttctaatag 22320 ttctattttt atactggtct ttcttacct ctactatatt accacactta cataagcatt 22380 taacatattt acgctttcta tttttacatt gtttaatag tgttttatt gggattaacc 22440 atgtttcttg taattccatc atacaactcc cttatatctt ataatttctc cttttcttt 22500 tcaactcat ctcttagtgt gatgatatct ttattagtt catctgaatc ttcatttta 22560 gcccaatagt aaagtctct aagttcagga ttctgcta aaatattg cttaggtctt 22620 acatctcttc cttgtgataa gaagtaagct atatctctca tatattcca gtctttgtaa 22680 tagtcagact tatattaa cataaatcct ttcaatctt caatacata cccttcatgc 22740 atatattat aagagccatt attatcctta taccatttat aaaattctc ccaactagca 22800 aactccaact ctttttcttt tagttgtaat cctacttcat cagcaact ttcaataa 22860 tcataatctt tctttttcat atttaacgta tttgaaataa tatcgagtaa gatatatcg 22920 ctttttcgat attttcgat atgagggtct tcttcgat caactacttc aaacactaaa gtaaaactat cgtcagcaat ataatgattt tcaaggaatg ttgttaatgt ctgtatctgt cttttagtta aagttttttc taccagctct father atgcgtattt attcccatgt 23160. ccttaat gtgtttttga tttacttgca tatacaattc cttctaacgg gtcatagaac attatccta aaaatccatt ttctttctta tatccagtta aagggaattg gatagtgtct ggcatattct ctaatttggt ttcttctact tcattgatat taaagaactt attatcct cttcctaata ctgtatttct accttcatca father ctctagagct father tgattccatt tctttttaga aaaagctctt tttgtaaagt taactgaga cacatctcta 23460. tttgtttat tggttttgat gatttttt tctttttctag ctatatctaa gtattgatta ggagtgaggt ctttgtcaat actatcattt cgtctgtttg ataaaagga tttagggtcg 23580. tagcagtgt tttttatttc atgtttctca atgttgttgt ttttgtctat tgttactgct cttaaacaac cacctttttc tacgcgccct tctaattaatta ttgatttttt attatttt aaaggttctc tatataatt tctataccca tgtatttgga ttacgtcaga atgttcccat tggtcatca cattaaatc atatcccccg attccat tagctgact tgttgaaatc ttgtttaaat taccaagaac ttcaggaagg actccgccat gactaacaat atagtcctga cctttaaac taagtaagc cacctgttgt aatttctaa gaatagactt tactctattt tgagttattc cgttctctat gaggattc aaggtaggca taaatcctct tgcatgaaac agatttagag catgtttata aaaataactt ttcccaaaat ccaccttttt gaaacttctt tgataatttt ttcatcataa tattctctcct tatattccaa ttgctttttt tgctaatgca 24120. tctacatatt cattccattt gttattatca tgagacttta cttttataaa atttattatct ataaactttg agtattccct tagcatatta fathergttt tacttaaatt gtttttagtt ttccacgaac cttcatacca ttgaataagt cctatataat ctacatgaat aatagcctgc ttataaccta gttttatagc ctcttcaata ccataacaac aagctagtat ttcacctgca acattattat acttaattaa attactattt tcaataggtt tactgatttc ttttacaatg 24360 ttctcatttt tatctaagat aatagctcct gctccaacaa gacctttatt ataagatgag 24420 ctaccatctg tatatattaa tgcagtctta tgcatattta tgcctttcta caaagcaagg 24480 gaacatctca cttgtataaa tctctttgta gtcttgtaat tttatagtag agaaatcaaa 24540 aaacttataa caatgttctt ctgcttcgat atagtcatct gcaataacat taacttcaaa 24600 accatcaact aaaataacga acaatttctt aaacatttaa aaacccctt tataatttaa 24660 taaggtactt aattaaatca atttcagtgt acttttctga gtgttctagc tcttctaatt 24720 tttctttac ttcttcaagt ctgtatgact cttctaaaag ttcaaactgc tctaataatg 24780 tgatactatc aaattcacta ctattaataa tgttgtgtat atattctaga tgtgtgtctt 24840 tataacgtt tgttaagtca tcaccagtat aataatcctc gatatacgat aggtctccta 24900 ataactcagc cgtacttcta ataatactat atttagatat attagggtaa gattgatata 24960 aacaattatc taatttatta cttaaatgct ctactacttt ttgcattgta ttaccttttt 25020 cttcagtact atatgaaatt ctaattag ggtttttaga atcataatca actaaagaac 25080 tcctattagt gtttaataac ttatctaaag aagttaaaat aatagctcta tcttctatat 25140 tatctaaggt taagatagta tctataatag tataaaatgc tttgtctcct attgctttat 25200 taacatcttg aagttcaaaa atattaatca tatcctcaat ctcatgacgc tcaacaaagt 25260 taataataga ttttgtaaat ttatcatca acgtcaacat ctttaaataa ttctacacta 25320 ttagtattta aagctttttc taatttcata agattagcac tcttaggttt tcttttacca 25380 ctctcccaat aagaaataag tgagtagtga actccaatct cttgtgctag acttctaact 25440 gtatgacctt tttcttctct tacttttttt aaatttaata ctttattctc ttccataata 25500 aaccactacc tatctttctt caatttttaa aatactatag ttatttttat tataagcata 25560 cttatttaaa acgtcaagcg ttttttcttt agcctctact ttacctttag ctttcatatt 25620 aacatagaaa acattacttt tatttgaacg tgtatgctta atatatactt tgtactgcgt 25680 aacctcactt tttaatacat tacgtttaaa ccatttcttt aatttttcca tttattataa 25740 ccacctttaa aacttatata tgtattgtag catatgataa atacattgtc aacttaaaaa 25800 taaaaaata ctagggaatt ttccctagta aattatttcc attaatacg accccaatac 25860 ttctctttta gcatacgttc ccacttgtca gtgattttac atactgccat atagaagttc 25920 ccagctgacg ggtttgtagg atatttaaat ctaatccacc atagccatc tgctttaata 25980 acttggtcaa agtttacata ttgaccacta taaataaatg attcagctcc tacgattgaa 26040 ccacttaaac ctggtgttcg tcttacctta atcgttctat cagcagtaaa tttacctctc 26100 caattccaag ttgtttgtac ctcgtctttg aaattaggtt ctataaacca cataggaaag 26160 tcgtaaccat gggctctaat agtagctttt tcccagccac cgcctccttg agcatctccc 26220 caagtccaac ctccacctaa ccaattattt tcaattacta taatttggtt ttggtttgca 26280 cttagtaccc atgcgacatg accatgacca cacccgtatg aattattaaa gataaccata 26340 gtgcctggtt taggaatgta ggatagtgta ttttctacta ctctagcttt atcttttaac 26400 atagctttat tatcccatgg aatattacat gcacttgctc cacctaaga ataacctggg 26460 aagagcttgt taaatccata gttagctaag tcgtaacatt gctgaccata ccaaccatca 26520 aagtctattg ctttgcctt tagacttttt aaaaatcgaa caaattcact tctagtcatc 26580 gatgctttca aaagttttca ctccttattt ccaatctatt tttccaaaat attttcttt 26640 cttaatacgc tcttgtttat ctgttatctc acatacagca aatagaaat aatttttact 26700 agagcctggt tttggatatt taaatcgaat ccaccaatag ccatctgctt taataacttg 26760 gtcaaactca acccaatcat ccttatcgta tagccatgaa tctctattta ctatagtgcc 26820 tttaagtcct ggagattttc taactttaat agctctatct ggataaaaag tacctttcca 26880 gctccacata gttttagtag attgtgtttt tactctaggc tcagcattac ctgatttctt 26940 tacatctact gacttaataa ctttcttgta atacttagct acttccttat ctaagttact 27000 agtgtttcta cctaatccac atgcttctaa taagttacct gggtcttgtt tgtcgttttg 27060 gatgtcttgg tgacctggca tatttgtttt gtaatcaaca ccccagtatt cagctaaata 27120 agctaagaca cgagctccat tgtctaatga ttttttagaa cgttctttat cactaaagta 27180 acaaatttct acaccaatag caccatcatt agcgttaatt ccgtaccata ggtcatccat 27240 aggagcgtta tacaacacat gccaagcttt ttctgtagta ggaacacata tgatagcttc 27300 tttatcatct acaaagatat gtgcggatgc agtggaagcc caatcaatgt tatatgtatt 27360 tttgtaataa tctacattat tttgagctgt agtattaata ttccctgtat catgagctac 27420 aataaaaacg ggttttttaa ccgccatagc ttgacctgtg cgtcttgttc caataggcag 27480 taaatcatat ctaacattta cacctttcca aatttctatc attactgttc acctacttct 27540 tttgggttat cttctttatc taattcagac actaagtctt tttctacttt accatgttct 27600 aatggttctg catgacttgt atctatgtct tcattattaa ctccttcagg agccatcggc 27660 atctttgtag gaggtaactc tgaggtacta ttcattgctt cactcttgta tgttaaagct 27720 ttatctgggt cattataatc tctaggtttg ttaaagtcct gtacaatagg gctatccgct 27780 atacctttag tgtcatgact tacaagaaca cctaaaccag tcaagaaact aataactaca 27840 cctgcaattg cagtgccttg gttacaata tcttctgcac ctttgattc tagtaaacta 27900 catacactaa caataaacgt agctaaaaca ggtacaaaac ctgtccaaaa tgtagcactt 27960 tttgctttg cagtaatatt gttacctgct attaataatg gttttttatc ttttttgac 28020 ataaaaaat accatcctttt ctgttattgt aaagctaata ataatataac aaaaagaatg 28080 gttttagtta ttaaatttta agttattgtt cgttaatttg agaaagtgtt ttgattactt 28140 ctgacatttg tttattatct aagtcttcta acttagtgtg tggaagtaaa tctaatttat 28200 cccaaatatc ttttttagtt gtgaattttt cattaataat tgctctaccg attaaacttt 28260 cggtataata aatttgtttt gcagatgcca tattagtatc taccgttgtc aaaaatttat 28320 aaaactttat aaatcctatt cctttttcaa cgtatcccct tttgagtacc ctcatcatta 28380 ctgattactc ttatatactc tactcggatt tgtatgatac tccaaaggct taaattccca 28440 tacaacgaat ggtacacata tttagtatct tatttgtgat aacttaaata ttatagttag 28500 ctaaattaat actagcatta aggtctctat caatactaaa accacattta cattaaata 28560 ctctgtctga tagttttagg tttttatgga tactaccaca tgtagaacat gttttactag 28620 aagggaaaaa tctatctaca ataacaagtt caattccttg tctttcacat ttgtattcta 28680 attgccttct aaactcataa aatccttgtt tttgtattgc tttagctaaa tgtctattct 28740 tcatcatccc ttttacattc aaatcttcaa taacaattct tctaggtttg gttttcacga 28800 tagaagatgt tacttgatgt aatagtttt tacgaatatt agacaatctt cgttgtagga 28860 gttaatttg ttttctagt tttatgatat tgcaagtttt gacaaacgta ctcccttct 28920 tattttttg gtatttgaaa gataccttac gttgcaacct acgtaatcgt ttttctaatt 28980 ttttaacctt tattgtttta ttaatattac cataaatagt accatctgaa catacagcta 29040 actcttttat ccctaaatca atacctaagg actcgttggt caaatcttca tatttatttt 29100 cttcttctat agagatactt atataccagt atttaccatc aaaagtaatt ctaggattgt 29160 agtacttagt gtctataggt agttgttcag aagttctaac ccaacctacc ttttctatta 29220 gtacttttt ctcttttact actagtgcat acgtgtcatt atagaaacta ggtctttgttt 29280 tctttttaga tttgaactta gggaaaccag atttcttttt aaaaaatttt ttatatgcat 29340 tgcatgcgtc tttaactgct tgtttaggaa cattgttact tacttcatgt aaccaactaa 29400 actctttagt tttctttagt tgtgtaattt cttttcttaa tactgtgtct tgtataaatt 29460 ttttaccttg ttcgtaattt tcttgctgtt ttgctatagt ccaattatat ataaatcgtg 29520 ctataccagc tgatttacat aattttaatt tttgttgctt ggtaggttta agtctgactt 29580 ttttcgttat cactattcaa ttcacctact atttttttag cgttgttctt gtgtcttatt 29640 tgatttactt ctaagaactt atttggtttt atttctgttt tttacggagc atataggatt 29700 tgaacctatg agtgaaataa atcacctatt gagttagcaa cccaacctct taagccactt 29760 gagtaatact ccttagtata attaaacata catacataaa ccgtctcact ggtaagtaac 29820 atattagacc tattgttaag ttaatcacta cgcttgactc tattaggtag ctaacctaag 29880 tccatctcac gtaacctact aaagcagtac aaccataggg ttgagtccgt ttaatagtgt 29940 aatgtgatac taacatatta attagtaact ttcacatggt atgaagaatt ttaacggcat 30000 ctttatattt ttaccaatta ttattttgca ggtttatgct actcgtacta gtatcgtatg 30060 ttatcaaaca tttttcaatg ctccaactgc atgtacttgt taaggtgtat ttgtaaagga 30120 taccaccaaa accccctaca aaaattaagc ccatcggata ctatacttta taaacctaat 30180 acattactgc taagcattcc gattgtaata aacattacta ttgacgaatt accttaccga 30240 cgtataccga taagttttaa ttcgttcgac aatcttacgc cttacaggta ccaccctgtt 30300 taaatcagcc attatgtatg tatgtttaat tatactacat ttaaagtata acatattatc 30360 attcatttgt caattaaaaa atgtgttacg ttttatagtt tttttatact agggtaaaaa 30420 cgtaataaaa gacctagttt cgacaaataa aataaggag aagaatgttt attatgcaaa 30480 atgaaattat agctctttat gagcttatat samaataac atactatttt gagtttgtca 30540 agttatttt tactttttta tcttgataat tcttcttgta ctctatccca atatttttct 30600 gattctgttc tattatcctc aatgtgagca gtagtacatt tacatttgat acagtataaa 30660 tgctttatat gtccctcttc tcttttctga gctctttttc ttggtactgt aaaagtatta 30720 ccacattttg aacaaactaa attactgtgg aacattttct gtctttttt catgattatc 30780 aatccttttc tttaatttg ttttatattt agattatatc aggtgttgag tattaggtca 30840 acacctttat ttaatgtttc tagttaattt ttaatactca agctttaaga aacaagatgg 30900 gtattcttct gatactggag tagtatattt atcttctaag ttatctaggg ctttgaataa 30960 tttatcaacg tactcaatat cagttcctat agtgtcaata attttgtat tatctattgt 31020 actttgagga acgttattac ttttcattt ctttaatctt cgagtatgtt ttgatttaat 31080 attgagattt tgagaatata gcatttcttt ataaacctca ttccatgttt taccaaagtt 31140 ggggttgata atactactaa ttttaggtgt taattttcta acccttttat ttgcttcttg 31200 tttccaatca ttattttcag gtcttttttg taaaaactct agtttatttt ctaattccat 31260 aacttcgttc tctactgaag ataacctatc attttctttt tgtaaatcag tcaccaattt 31320 atttaatctt tctgactcct caaagtactt aagcatttct tttttagctt cttgaggatt 31380 atctataata gctttagcaa aatcatcatt catgtacatt ccatactttc taatatcagg 31440 tagaacttct gaagttaccc aacgcttgaa tcgtttagct tattctagtt ttgatgaaaa 31500 gattaaactg tataaacctg attcgttgat taatgtcaca ttccttaatt gacctgcgta 31560 cctaatttgg gtacgtagct tatcttcatc ctctgcatgg ttatttatag cgtttcgata 31620 atttgaatat cctaatatct tagctacttc gttacctaca aagtaagttt gattgtcttt 31680 aactactgtt cttactgatt ctccttcaaa attaaacatt aattggtttt ccatgttaca 31740 tcagtccttt tcttttaatt gatactctta ttctaacgta agacttaata aatgtcaatg 31800 ctttttgtta aattttatgt aattattttg agaaatcctt ttatatcaag gtttttaaag 31860 atttttttac ctatttggaa aaaggagg attccttatta fatherfather fatherfather 31920 atactaaat atatacta gttattattattattaatattaggaaa gtcaacaag 31980 agtaaaaa agtgactta cttaaaagtc actaattttc aaatactaat ttaaatgatt 32040 ctatgataa agggttaatg atactgtat cagaattat atcctcagag actctaactc 32100 taactgatgc tgtccatgt cctctaattg ttccatttat ctctctttgt gtatactcaa 32160 tactatcgtc agagattaa taatatttt ttccactaat cattgttacc tcagcatgtt 32220 ttaccatatc aaaactccta actaaattta ttgaaatga agttatat agaacctaac 32280 actagtaata gtactttctc ggtagtatcc ttctttctg tgtccttaac aactgtattg 32340 ttagtgagtt cttttatctt ttcgtctaat ctatcttagct gtatgtagat agacgattgt 32400 ttctcactat taacacctac ttcttgtct aaactaacta ccattttct tagttcatca 32460 acttcatttt ctaattcctt atacgtattt ttatcaat agctaccatc ttgtatttta 32520 tcttttatct tatctacttg tcctacaag tttttagtt cttcattca ctaaagtcac 32580 ctcttaatgt ctaactttc agattctgaa tggacgtcat agttttcgaa aaagttatta 32640 ataatttgca tataatcctc agtaactatc tcaccgtatg acgttttagt atttattca 32700 aacctaagct taccaacctc atggaggtct atttctttaa taacggtatt aggattca 32760 gatggtatgt aaataatc aaatatata atagagccgt tgataagcaa cctatcaatc 32820 ctatagacgt ggaagaattt tctatctcgt ctaaagtgag ctaggcatc tttaactct 32880 aattttaata tatctttata cttagtcaa tcaacttacc cccttataat taattttgag 32940 ctacactagt ttgtgttat atagttatt gcagtagcag atagtat tatgtttaat 33000 aaaattagca accaccacc acctgtactt attackaccata atgaaaaca agatagtata 33060 taaacaacca ccaagtagcc tatatatttc ataatgtttt tacacttt taatactact 33120 acgtagcta gtgatttaga tagctaac agaaaaaaaaaaaat aaaagaggt 33180 atagcttaa tgcctgctag tataaccact aattacacct aatttctttt agctagataa 33240 33300 ttacattaat agtgtacggt atattttaaa ttaggaggac tgaactataa gggtgaataa 33360 taacatagct gtatttatat ttaaaactct aataattat atttttattt tgtttatttt 33420 gtctattatt aactcactgt cattaatata ctctattcga cctagtacag ttatgactta 33480 ctttatattc ggtgggatag tttctaatgt ggcattaaca ataactgata aattattatt 33540 acacaaagaa gaccccttac ccgattatat tctaaaagaa gtagagctaa ataacaatga 33600 33660 agtaagagca aaagcacaac gtcgaatact aaaagataaa aagagagatg ctgtcgatga 33720 aaacgaagaa ggacattaag gaacaacgta aagagctaaa agataatgca accgctgttt 33780 ccttaaaaa aaaaggagat aaacgtattg caagtcctag tagggtgtgt tgtttatgtg 33840 gtcaatctct ttcagggatg aactatacta aaggtaaatc tatagctaaa gttaatcatt 33900 ttcatttaca gtattctaag tacttatatt ttgacatatg cgcagatatt aataactgtt 33960 acaagaattt aaagaagta ggtgaattga tagtgagc gctgaaagtt taggat 34020 gttatctaag aagaaatttg aagacgaga taacgtaa tatatagctg atggattt 34080 gtcaggtatt actaaactta tgtagactt taaaaaag attgatagag gggaaataga 34140 agtaagagac cctaatgatt tgtacaagt atttgttatc ttccacaaa tgcaaactt 34200 aattacagat ggttctgatg gtggtggtgc ataccccaa ttcagac cacaacaga 34260 gctctttgat gaataaca attagatag taaggtgag aagaagtag attagaga 34320 gttatctcaa ctatctgctg atgacattac tgctatgatt attgataag aaaaggttat 34380 gaacgaagag aactcaata helpctaaag aaggtgtat atgaatggac gggtaagaat 34440 tattaaaaat aacacaagaa acatcggta cacaaatgt tacgcagaa caagttgacc 34500 attackcatcatgttaaac cctagtactt attackatcatacg tcgaggtc 34560 acccgataac ttttagttatt ccaacagggg acagaagtaa agcacaagct catagacctt 34620 ggcaagtccg taaacatact gtgcggacta taaacctttt ctaaacttgg aaactctaag 34680 tgcttaaaca agcatatgac aatcaagtgc taaatttagt agtgatacta ataaatgcct 34740 aacgactaaa cttactggta aacttataaa tggataagtg tagaaacgta taaaagggaa 34800 accgtaacga aagagggcgt atacacctaa atgtatacgt atgatatagt ctaatcccct 34860 aataatatc gggaaaccga gggtataaa tgatagtaaa tgacaaccat cctaataaag 34920 34980 gaaaaactct aagggataat atcctatgac aattccttgc taaaaaaatg cctaacgact 35040 aaatttctag gtagataaac gaataggttt attgagaact agataaaagg gttaatgacc 35100 cgtaacgtga aagagttaat gtcttttcat tagctaagat atagtctaaa ccgattctta 35160 aatgaatgtt aaagtattac gaagtaacg gtagtaattg taagtgagat gggtgtaatg 35220 gaaatggtac attttgctga tatgcatagt tatgcaagtg taaagtgtct atacacattc 35280 cctagattat aagttgggga attaaaactc tgttaaacgg tcataggaaa ataaagaata 35340 tcctggtaag agagactaag tcctaatgga tagagttaat accgtgctaa atcaacctaa 35400 taagttgtaa atgccgaacg actaaatttc tagagctt attaaaagga ataagtgaaa 35460 actagataag aaagtcttga caaaaatacc aaagtaagtt aatatattaa ataggaggtg 35520 gaaaaacaaa tgcctagaaa aaaacacatg aagaatttgt aaaacaagta gaagacatag 35580 caggaaatga atacgctgta atagggcatt atgaatacgc aaatcaaaat ataaaaatgt 35640 ttcataacga atgtaaggaa gaatttgaaa taagaccaaa taatttccta caaggttaaa 35700 gatgttctgc ttgtagaagt aaaagaataa gtaggataca agataaacca cttagtgaag 35760 ttaaaagaca actaaaagag aaacataagg gtactataga gattataggt gagtatacaa 35820 atactcacac taaaacagat tttaaatgtt taacatgcaa ccatactttc tcttcagaac 35880 ctaattctgt tttaagactg agtggatgtc ctaaatgtaa agtttctaaa agggaaaaat 35940 taatagctga attccttaaa gaaataata tacgttttaa agaacagaaa agatttaaag 36000 attgtgttca taaaagacct ctaatatttg atttctacct attagattta aatactttaa 36060 tagaatatga tggattacag cacagtaagc caatagatta ttttggcggt gttaaagctt 36120 ttgaagaatt gaagtagata gatagcttaa aagatgatta cgcaaaaaga aataatatta 36180 ggatggtaag agtgtcctat aaacaaaaag agaaagagat aatagaagaa ttagaaagtg 36240 ttttgggtgt ggtaacccgt caagaaagta aagcagagag ctcaacacca aaaagttgag 36300 ttaagatata gtctagtccg tatgtaaata tcacgaaagt gacggtagta acgactaatg 36360 aacagatgaa gaaattcgta caatcaagac ttaatccagt attagaaaaa ccttatttta 36420 gagatattgt taattgggat aagactcat taggttataa acaaataaga aattctagtt 36480 tatttttcag aactagtagt aaagctagta ctgtcgaagg tgtggatagg taacaagtcc 36540 acattaaact ctgttaaacg gggaaacccc taacgtaaag acgagggcaa tcccgtgcta 36600 aatgttgact ttataaaaaag aatatgatat aatgtattta taaggttagc taaatgccta 36660 acgactaaat ttctaggtat ctatacaaaa gggtatagtg agaactagat aagaaaaccg 36720 ccagattat ttttatag taaataattt tatgaaaaaa agcgtgtaaa gcatattact 36780 aatgataga aataagtaca agccttaattt aagattatc aatatatgga cttacatgga 36840 tgagttattt gaagggaat aataattttt agaaccttat aataatagtg accagctat 36900 gaagtaagc aggaacctt tcacctaata 36960 gaaaggttat gatatagtct aaacccactc ttaagtaagt gttaaagtac taggaacta 37020 ggggtacaa ttgattgact atctttcact tgacgagtac gaccgtgtaa atatttagc 37080 tgagagctca gctttagaat ctatgtcaag ttcacctttt aaatagtaa gaaggtggtc 37140 tacaccaact gtaagagatt atgtataga taaactgtat aaacaatcag accaatggtt 37200 ttatggttat gattgtgaac actgtggtca ttttaatga atgagtatg ctgattataa 37260 acctgatgac ttagaaata gtggtaatgt attackagta atccagatg gatagatga 37320 gatagctaaa actgtccaag atggtactta ccaatgtt tgtcaaaat gtggaaagcc 37380 tttagatagg tggtactctg gacgttgggc ttgtaatat gccgagagaa cagaaaataa 37440 taaaggtatt cgtggatact ataagtca attaaacgca acgtggataa gctgtgatga 37500 gattaagaaaagaatga atacagaatc taaaaaagc ttttatact acatcatcgg 37560 agcccctttt gacgatgtaa aaatgaagt aacaagagat gatgtattca ataataatc 37620 tgaaattgca aaaacacaat tattatag agataaatac aaatttatt cttgcagtgt 37680 tgactggggt aatttcact ggtgtgctgt acacggtatg acagagatg gtcatgtaga 37740 ttatatacgt ttattttctg ttagagaa tagtagacct gatatgtag aagcagacct 37800 agaaagaatt atttggagt tctctaagta cgaccctgat attattgttg ctgataatgg 37860 tgattctggt aaataatcc ttaattgat taatttttt ggtaagata aagtatttgg 37920 ttgcacttat aagtccagcc cacgttcatc agtcaatg tacgcacagt ttaatgagaa 37980 tagtaataca gtaactgtag ataattaat gcatataaa cgttatatac aggatttaaa 38040 agctaaacgt attagtgtat accaacagt agatgaagg ttaaaaactt atctttaaca 38100 ttggcaaac gttattata tggatgaga agatgataag acaggaaa tgtaccaaat 38160 tattaaacgc agaggagacg attttgtaat atggtcgtct ataacagtg ttaaacgggc 38220 atagtaaat atgtataga aaaacaat actggtaaga aaccctaaat ctgactatac 38280 acagacagtg ggaaccaacc gtgctaaatt cttaatttaa atattacat tatatttt 38340 aatgttatta ttaaattaag aaaagccct acgactaaa ttcgttacta ttaacgtaag 38400 agattaaat aatttattga gtataactaa aaggaggta gttaagtggt ttatgataac 38460 gagtggttta taatagaat taagatgtt agaccagagg actagaga atatgaattt 38520 ttagatgact atgttaatca gtacacaaaa ctaagagcta ttcataaaaa atgtggtaac 38580 aaatactta taacaccatc aacatttag agtaacgta agacaggttg taatacatgt 38640 tctcaaaaaa gagtccatag taagcaag aaaacacatg aagaatacca aagaatta 38700 cctgaaggta taatggctat aaaaatat gaggtgcat ttagagat aactttacac 38760 tgtttctttt gtgatagtac ttatactatt actgcaagag atattttaaa gtataaacaa 38820 tgttcgagat gtaacaggag atttaatagg acatggaag atattaattt tgaagtacgt 38880 aaagaaacga aaggaaacta tgaagtagtt tcaatcatt aaaaatgc acacaccccc 38940 atagaataa agcataatga gtgcggaaaa acatatcgggg gaactatggc aaattttaga 39000 aaaggtagaa gatgctcaca ctgtagaat tccataggtg agaattagt agaaagttat 39060 ctagagcaa aaagtataac atatgaaaaaaaaactt ttgaggctt aaagttaata 39120 ataacttat catatgattt ttttttcct gatatact tacttatcga atacaggt 39180 gaacacacg ttaaacctgt caagcatttt ggaggagaag aacaatttaa gctacaaaaa 39240 aagatagata gtataaaag ttcttagca aagataacg gttatgagct tttgagata 39300 ttctatacaa ctaaggatta caaagtata gagaaattgt tcaacataa attattttat 39360 tcgtaaagca ctgagttatc aatcagata actaagatat agtctaatcc cctaataaat 39420 atcgggaaac cgagggtatg aaatgcatta cgcacagtct tcagtattg gttacattgg 39480 tcttactcgt ttaaaagaat tgtatgataa aggcaacggt acagcattca catccacttt 39540 tataccaacg gattataata atacacaaaa caactcgtct aatgagttct attttgatga 39600 ataagaaagg actgacgact tgacaaatat attaaattat gatacaatac aagaagatga 39660 tataagcaag gagacattta atttattaat tgaagagcct ttaacattat catatgtttc 39720 tatacatagt gattttttag ataataaata cgattacata tataaatcct taggctttga 39780 taatttcatg gactgttat tatacgtaac aagagaacca gaacgtatat ataaaggcgg 39840 agctaaagat ataggctcat tgaataaaagt aaaaagaact gtagtacgta atgggaaaga 39900 aattgaaatg acaatctatg aagataataa aaacgatgat aaacctaaag agagtaatag 39960 tgaagaacca aaagaaccta aaactgctaa aggttctagg gttatactc acggtgatga 40020 tgagaaacct aatcctaaaa agattgccag ttctctatct accttaaaga ataaaggtgt 40080 gaacactgac cacatagatg gcaacgcatc attataataa gaatttgtag atgataataa 40140 windows ggactagctt cctttaaga gagattct ggtattat 40200 tgtatcagac tttgaaacta ctggcgtagg tgctaggtct atatagagt taatttatt 40260 agcaataag aaacaaga acgctgttgt ctatgctata gatttaccctc aagctataga 40320 gttcttaaaa ttgttagggt ttattaaaaa taagattac tatgttaa aaaaaacaaga 40380 tataaagtta ttttgtg agtacagtga gcttatttag cactgtactc attackacaa 40440 ttatatat aagtattatt attattagtag ttgtaatgt atagtaaaaaaaaagat 40500 tgaataatgc taagcagtta cttatacaag taaaaaagga tattataac aacttaaaaa 40560 aggagat gatgatta agatatat aaaaacat tggaagtt attackacacct 40620 atttctacag aaaaaga aaaaagtt aaagaattta gtaaacatt atgtgagatg 40680 attaatagc tatatagttc ttacaatgta ttaggcaag accctattga tgaaacacaa 40740 agatagacg gttctctaat gtgttttcaa agtagattag atgatacatt aacaggtgaa 40800 gaacaccaaaactttttaa attagcttt gattataata ttgatatttt tgaagctaac 40860 aagcagttta aagaagatgt acaaaatgga gaagctatta agttaggtga tgttgttgta 40920 accgacacag ctttaagtaa tgttttatct agtaatgagc ttaatgttag tattacattt 40980 atgttaagca aagactatga agaaaagaaa cgtattgaag aagaagaaaa ggaaaaacta 41040 gataagttat aatagatatt atgagacctt tatggatagg taggaataaa taatatgaaa 41100 cgtaagttta gtagtaatga gattactata acacttataa ctattgtagt tgctctattt 41160 atagtattaa ttacagtagc atttaacaag taccaaattg ctaaaagaaga taaggacaga 41220 tatcaaaagc tagtagaaat ttatcaaaaa gcagatgatg atgacggtaa aactaaaaaa 41280 aggtatgttg agaagttaaa tagggctgag gaagaactta aaaaggttaa agaagaaact 41340 aattataaag gttataatga taaaacagaa aaagaaagag ataaagagga taagagtgta 41400 agagaacgta tttatggtaa tgataaggat aaagatttag tattagtaaa taataaggtt 41460 41520 gtagtacctc ctgttgtaag tcctgttgag ccaccaagtg aacctagttt atcttctcct 41580 actataccta aacctattat tcctaatcct attaacccta aacctattat tcctaatcct 41640 attaacccta atcctattct acctaaacct aacatcccta cccctaaccc actaccccct 41700 atagaacctg aaaaacctat agaacctgaa aaacctatag aacctgaaaa acctatagaa 41760 cctgaaaaac ctatagaacc tgaaaaacct agctcagata ctacaatacc tttagttcca 41820 ttggaaccta gcacacctgc agatgaaagt aatgatacta atggagaggg ataacctctc 41880 cttttttttg ctatattaaa agagtaataa aataaacatt atagttggtg attttttgat 41940 aggattaaac gtacttacag ctatatccgt agtttttgct tgtgtaagtc tactagcact 42000 aatggtattt gcgtatatta aaactgaaaa aagtagtaag ttggttctat atttgatata 42060 tgctataatt gctataggtt cttatgtagt attaacaatg tttcaagcca cgtcaatcat 42120 tataaaaaat gatgtcatag actctattga gaatacggag cagtatgtag ggtttaataa 42180 ccctttaatt gtttttggta taagtttctt tggagctgta ataggcagtt tttggttttt 42240 agttagag attgtaata ctaggaattt aaaaaaaaaatgagg attgaagcat 42300 ttgctatttt haaagacga taatgggat gaagcaaag actttaataa aggtcaagga 42360 ttagcagata attgataga agtagtgat tattatagac agataggtgg taaacatgta 42420 gctatgttta ttgctattga taagttaaa tatatggtac tagagctac aaggataat 42480 aaagtatat tggtagaata ggatataat attgtgttag aggattga tattgttatg 42540 gaagtaaga aatgtttta ctatataga gaaccattcg aagtaag aaatattccct 42600 aaacatatcc agacattac ctataatac actgttatac taactact tcgaggaggt 42660 aaaaaaag ttgcctgatt tatttaaag tctaggtta ggtagtagt aaagaga 42720 cactgaagac cttatggttc ctatagatga cgaataca gcatacatta cactgaataga 42780 axagataca aaagagatgc aagaaattac taaatctcta tatggtaac agcaagctta 42840 cgcagaacca ttttagaaa tgatggatac aaatcctgat tatagagata agaagagcta 42900 catgaggaat gctcataact tacatgaagt gttaaagaaa tttggtaata actctatact 42960 aaatgctata attattacaa gagctaacca agtatctaca tactgtaaac ctgccagata 43020 ttcagaaaaa ggcgtaggtt ttgaagttaa attaaaagac ttagacgcta cacctggtat 43080 taaagaaaaa gaacagatga aacgtattga agaatttatt cttaatacag gtacagataa 43140 agatatagac agggattcat tccaagagtt ttgtaaaaaa atagtaagag atacttacac 43200 gtacgaccaa gttaacttcg aaaaagtttt tagtcctaaa aacaaaacta agatggagaa 43260 gttattgca gtagacccta gcaccatttt ttatgctact gataaaaacg gtaagataat 43320 taaaggtggc aatcgctttg tacaggtcat agataagcaa gtagtagcta gttttacaag 43380 cagagaactt gtcatgggta ttaggaaccc taggtcagac ttaaattcta gtgggtatgg 43440 attgtcagaa gtagagattg caatgaaaga atttatagct tacaataata ccgaaagtttt 43500 taacgatagg ttctttagcc atggcggtaa caataagtta caattaaatt aaaataaaaa 43560 aatatttaat ataaactttg ccgtgcatgt ttagtaataa gcatgtatca agggttaaat 43620 gctatgaat cctaaagctc aattaactaa aacaaaga gaatcttag acggaaagt 43680 tacgaaagta gaaaaaata ttgagatacg ttaggttaa atcctagac gagaacaat 43740 ggaagtatag cagggaagt cctaagttca atgaatag gagaccctc aacgactc 43800 tcctgacgggg agagtaaagc cacaagctat tggtggaaga aaatcctta tcctacgaaa 43860 agtaggaatg acaatagtc tccactcgta tcgaaagata gagctataga ttaactatag 43920 gagttatag tagcgttata actchaagaa agttaaatt taggata tachaattta 43980 ttccaaataa ctgttgacat tattttccttt atgtagtata ttatatacta taggaggtg 44040 attaataatgt cggagagaa ataataacgt attaatatta gattactacc aaaaagaa 44100 cagagaat tatgtgga gtccgtaat atgttagat tattagaa tattttatt 44160 gctcgatgtt acgaggaaaa agataaggt acttttaata atttgtcttt ggaaaagac 44220 tttaaaaag aattacata tattaactaa ctaaacgaat aataatggtt aaccgaatcc 44280 gatagacatt ctaaagtagt agcataaa gatgttttga atggttttgt tagatactat 44340 aagggcatag caggaaacc taatttaga aagagaggggc taacaccta taccttttct 44400 gttagaaatg atgtaatgcc tagtggatta tgtagtttta gagagatgg taatacattt 44460 aaagtatctg tattaagta tctaaaagaa gctttaata ttcaacat 44520 atatttgata ttatagagga taaagataa ttttattctc ctgtaataag acatgatggt 44580 aagtactggt atattcatt gttatataaa gataacttag ttacaatca aaaaccaaga 44640 gagttaactg atgaattat aggtatagat tttaa gacattaat gacttgttca 44700 aatggtatta aagtcagaaa tattaattta gatagaaaag ttttatact agaaaaaaga 44760 gaacgacgat tgaaaaca gttttttaga aaatatgaca tgaaaaca aggtaaaa 44820 tatgttaaaa ctaaaaaat tattaagtta gaacgtaaa taagacaat aagaaaaa 44880 cttaaaagta tgaaata tcatatacac acagaaacta aaaaatagt tgaaatgtta 44940 ccgaaagaaa tagttataga agatttacat gttaaaaaa tgttaaaaa taaatggaga 45000 agacatgaaa tacaatatgc tagattcttt gctataagac aaatactttc atataagtgt 45060 aaagatagag gtattctact aactgttgct aatagatggt acccttctag tcagttatgt 45120 agtaattgtg aaactagagt aactggtaaa caaaaaacaa ctattaagtc gggttatcat 45180 acttttaaat gtaaaaactg taatcataat ctagatagag atttaaacgc tagtattaac 45240 ttaaagaact atagatactc caattggtat cgaaataata ttattgagaa acaacaatag 45300 tatattata tgtaccgttc catgaacggg agtttaagcc tttggagtat ctagttagta 45360 gaatattaaa agtaactaac ttagttagtg aatgaatgaa tggattattc aaaaacagtt 45420 acagaataag gaataaaata tataattatt tataaatttt aactcatggt actactcggg 45480 gcatattaca gattagagct gaccaacagc aatctcaaca tgcgttagaa aattttaaaa 45540 gagaatggaa atctagtttt tcaggtataa atggtagctg gcaggtgcct gttatgatgg 45600 ctgatgatgt taagtttgtt aatatgacac caacagcaaa tgatatgcaa tttgagaaat 45660 ggttaaactt tttaatcaat attatttctg ctttgtatgg tatagaccct tctgaaatag 45720 gattccctaa tegggagga ggagccacag ggtcaaagg cggttctaca ttgaatgagt 45780 cagaccctgc windowcaacaacagtcta tgaataagg tttacagcct ctattagat 45840 ttatagaga attattaat agacacatta tatctgaatt tggtgataag tatactttcc 45900 aatttgttgg aggatact aagtctgaat tagatagct tagtatctta caaaagaag 45960 taaactgta aatgaagcaa gggagaaca aggattgaa ccatagatg 46020 gtggagatgt aattcttgat tcagcatttt tacaagtac agcacaagaa attackaaag 46080 accaatattt agatactaa CAAAAAAA gactcaatt acttatgagc tatacacaac 46140 sparrow tgagcctact sparrow gaggtaaaaaac aactaatca gaggtagga 46200 cagataatca gttaaaggt catagatacg tatatagaac aacaatca ataaaggac 46260 aaggaaaa agtgagaaa tctccgact ttgtaat atactaca acctattaa 46320 tacttaggtt gttattttt aatttggagc tataaatatt ttatgctata ctatgtgtgt 46380 agtaatgaat aatgttgatg atatacttt tgttatta tgtagtaca tataaaataa 46440 cattaagtg aggtgtataa tcactttgga agaaatgaaa tttaatgctt ttgttcctat 46500 ggacttaaag aaatccatag atacggaag tgatacaaat aaatattcta tcgtatctgg 46560 ttgggcttcc acaccagctg ttgatttgca gatgacatt ataatccaa aaggtattga 46620 tatagaatac tttaaaaaaa atggatat taactacgaa catcacaag ataatgtagt 46680 aggtataccct acagatact gttatgttga tttagaaaa ggtttattta tagagctaa 46740 gctatggaaa gatgatgaaa atgttataa atgttagac ctagctgaga actagaaaa 46800 gtcaggtagt ggtagacgtt taggttttc tatagaaggc gctgttaaga aacgtaacat 46860 aaatgacaat agaattgttg atgaacttat gattacagggg gtagcactag taaaaaaccc 46920 agctaatcct gaagctacat gggagagtttt tgttaaatca ttccttactg gaacggaac 46980 aacaccagac acacagtag atgcaggagc cttacgtaaa gagtcattag caagctctat 47040 tactaattta acctagtaa caaaattta agatgttaaa gagtataatg attattgga 47100 taatgtagta gaggactta ctaatcta taatgggt tatgagaat cagttattac 47160 attack gccaaggac tatcagaaa agatgctgag attagtta tgagtattaa 47220 taaaaaaaat ttagatagg ggattattatt atatgcctac ggaattaca atattctac 47280 aagaatga taacttagac aaagaag tattcaaatc tgtagagag tctaagaag 47340 aagtaaaaaaaaaaaaaaaaaaaaaaaaaaaagggaaaaagg 47400 aagaattta aaaaatgaagta gaagctacag aagagcag aggagaagct aagaagaac 47460 cacagaacc tgcaaggtt actgagaag atgctaag agcacatgaa cacagaaa 47520 atctgaga agaagtatct aagtcagcta aggagtcgaa agaccctgta gataaaaaag 47580 attackaaac agagaaaaaaaaaaaaaaaaagaaaaaaagaag 47640 aaaaagatga agagaggaa gaaaaaacat ctaaatctat ttctgataa gatttgtag 47700 atggtttccg tactatcttg aaatcattcc aagacattaa aaagaaat gaacaatg 47760 tgactaaatc agatttagaa gaagtaacta atctattca agcttaact gataaaatta 47820 attctaatga agaagttttct aaatcagttg agagcaacca agagaataa gagaagcag 47880 tagaaaaatc cgtaacgact ataacactt cgaatgaaca agatgtagtt ggttatgtag 47940 ctaaatcagt aaaaaaaaahaaaaaaaaaaaaaaaaaaaaaxagg 48000 taagttaa agaagaagt agagacttat ctgtagaaga ccgtgaaaaa ttcatgagta 48060 cctataaaga aaatctcaa aaccacata cgaatcgttc agagtattg atgcttatc 48120 aagcttactt aaatatccgc aacaatccag agcaagcaag tgaaaagac tttaatattg 48180 taaaagaattt tgctaatctt taattagaa aaagttgt gttatatt agtgtgtaaa 48240 aaaaaacat aaaaaaaag agcatatatg aaggtgata tattaataatg aaccaaaatg 48300 aactttcaa aaagcaacat gcagttgctg atgaattaca agaaaatta tcgaaatcct 48360 tccaaactgg atatgtatc actcctgaaa cacaagtgga tgcaggtgct ttacgtcgtg 48420 aaattttaga cgaccaaatc actatgctta catgggggaaa taatgattta gtattttacc 48480 gtgatgttgc acgtagacca gctgaatcaa cattattaa atatgatgtt ttcttacgtc 48540 acggtaaagt aggtcattct cgttttgtac gtgaaatcgg agtagcgtca gtttcagacc 48600 ctaatatccg tcaaaagacc gttaacaatga aatacatttc tgatactaaa aatatgtcat 48660 tggcatctag tttagtaat aacattgctg accctggtca aatcttgact gaagatgcta 48720 tctcagttgt tgctaaaaca attgaatggg cttcattcta tggtgatgct tcattaactt 48780 ctgaagttgg tggagaagga ctagaatttg atggactagc taaattaatt gatgctgata 48840 acgttatcga cgctaaaggc gctcacttag atgagaaatt attaaaccta gcttcagtta 48900 aaatcggtaa aggttttggt acagctacag atgcttacat gcctatcggt gtacattctg 48960 actttgttac taatatttta ggtcgacaaa tgcaattaat gcaagacaat agtggtaatg 49020 taatactgg tttcagtgtt aacggattct attcatctcg tggattcatt agattacatg 49080 gttctactgt aatggaaaat gaattaatcc tagatgaaac tttaatccca caaccaaatg 49140 caccacaacc agctacagta aaagctgaag taaaaacaaa ccaaaaaggt aaatttacta 49200 aagaagaaga ccgtgcaggt ttatcttata aagtagttgt tcactctgat gaagctgaat 49260 cagcaccatc agaagcacaa gttgctacag taacaaatgc tacagatgga gtagaattaa 49320 agattactgt taactctatg taccaacaaa gcccacaatt cgtatctatt taccgtcaag 49380 gtaaagaaac aggtatgtac tacttaatta aacgtgtagc acttaaagat gcacaagaag 49440 atggttcttt agtattcgtt gataaaaacg aaacattacc tgaaacagca gacgtattcg 49500 ttggtgaaat gtcaccacaa gtattacact tgttcgagtt attaccaatg atgaaattac 49560 cattagctca aattaatgct agtattacat ttgcagtatt atggtatggt gctttagcgt 49620 tacgtgctcc taaaaaatgg gctcgtatta aaaacgtaag ttaccttgca ttaaaatagt 49680 aaatacaatt aaaaattgaa tacaatagaa taaggagtat acctaagggt tgctccttt 49740 ttattactac ttatagtata caagaaagga atttaaaat caatgttaac ttataaatta 49800 aaaaatatta aaatggctac tgtacatggt caagtagaag tagacgata aggcgtagtt 49860 aaaggactaa ctgctaaaca agaaaagat ttgctatt taccaggtttt tacacatatg 49920 gagaaaaaaaaaaaaaaaggtagg agaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa'aaggaaa 49980 ccaactaaaaaaactaaaagagat agtaggttg aaaatggt aaacagtag 50040 ttggtgta gtttagaccc tctttatcat tgagtatcc tttacaccca 50100 tctggaaacc ciaacatat agataaaga gattagata gtattactct agctgatt 50160 ggttggtcag cagatgctgt gaagcctat atgttttgta taacagtaca aaccccgat 50220 acaggacaac ctatgggtga tgatttttat aatcatatat tagagagc tataggtaaa 50280 gcggaaagag ctttagatat atctatttta cctgacttac acatgaat gagagattac 50340 tacgaaacag aatttatag ttatatgttt gtacacgcat aaaaaacc tatattacag 50400 gtagaaaatt tacaactaca atttaatggt agacctagt atgatttacc agctaactgg 50460 tggaaagtgg agcatttagc agtcacgta cagttattcc ctacagcttt aatgcagacg 50520 ggtcaatcta tgtcttacga tgctgtattc agtggatacc ctcaattagc aggaatgtac 50580 ccaccaagtg gagcaacttt tgcacctcaa atgattacat tagattatat tagtggtatg 50640 ttacctagac aaagagcagg tagactaaa ccatgggaag taccaccaga attagagcaa 50700 ttagttatta aatatgcact aaaagaaatt taccaaatat ggggttacga tgatattacc 50760 ctgtgtgtag cgtaagttgc acattttcaa aggttaactg ctaagaaatc ctaaagctaa 50820 ctaaactaca aagtaagtcg aaagactaag cttgaatgtt gagaaatcag aaaaaattag 50880 ttatagactc taaggttaaa tcctaaagag aagagcaatg gaagtttagc atcgaaagtc 50940 ctaagtcaat agataaggaa tacgttcaac gactattctg tatagacgac agaagtaaag 51000 ctccaagtga ttgggagaag aaaaatcttt accctagtct tagggataac aaatagtctg 51060 cacacgtctt gaaaaggagt gctaggaatt gacctagact tatttagtag cgtaagtaag 51120 gaaacaatgt taattaaatg aaaacttcct aggaagttaa tttaattaac atatggtaat 51180 ctcattatcg gtgcaggaat agcaaaaaactctagatg tegtggtat tacagaaca 51240 ataggtacta cacaatctgc tatgtatggt ggcaagtg ctcaatact acaatcaat 51300 gaagatataa aagagctatt agctgggtta aaatcttact ttggctccaa tatgataggc 51360 atatagtagg aaggagat taaatgcaa aaccttttat gataggtact father 51420 cttctatatat attaataag tctactagt atacatacac aacacaagca gatgaacaag 51480 aacaaaagtt atctacagct agactagagt ttgacacta ggatatgaga agatttgtca 51540 atgatagagg tataaaggta ctgtgggaaa gagcttactt tgtccttgc cttaaccctg 51600 acacaggaca tcctagagta gattgtccta gtgtcacgg taaaggtatt gcctatttac 51660 ctcctaaga gatataatg gctattcaat ctcaagaaa aggactaac atttagata 51720 taggaatttt agatactggt acagctatag gaactacaca actagaaaaa cgagtatctt 51780 atagagacag gtttactgtt cctgaagtat tgatgccaca acacttata taccatgtta 51840 ctaaagagcg tatacaaaa ggtattcctt tgtatttaga tgtcaaagaa gtaacttta 51900 ttacatctaa cgatggtaat gtttatgaag atgacttaa tattagagaat atagattat 51960 tcatggacgc tagtttga aaaaaacta tattccttaaa tattttaatg gtacttagat 52020 atgtagtatc agatatta aaagaaagtc gataccaata tactaattt atcaccta 52080 attackaagtt tgaaaattta cctcagaagc tattaaaaggaagc gttattgtac 52140 tacctgagcc atttaagtt aatgatgta taggagagga cttagagata caggtagaag 52200 accctaaaa agaatctaaa gatacatt caggtggttt ctttggagga atgctataat 52260 gcctataaaa gcaactagac ctaagttatt tagagacaag acataaaa ataggtaa 52320 gagaacagta gatgctatgc gttctgatat tttagataga ttacaagcta cagcattaca 52380 agtagataat gtaagtgtca aacgcatgcc tacttacta caatactg agaaaaagct 52440 agagaagcaa gtgtaatag accttaagaa agctttgct cattcatcta aaagaaaag 52500 gactaagat ggtggttggt atctaacggt gcctataaga aaaaaaaa gtagatgaa 52560 taataaaaca taccaagact taaggtcttt aaaaatagac agttcaagta attcagtatc 52620 tactcttact gattatctag aaggtagacg aagtaatatt agtcacccat cactaaagcc 52680 tgctagtaaa tcaagtagaa ttactaaagt aagaaatggt aaaaaatcta gttactttat 52740 gtttagaaca gtatctagta aatcccctgc aagttcatgg atattaaata gagataaggt 52800 taatgaaaac aacttctcta aaacaacatt aaagtatgtt agaaatctga tgaactggaa 52860 gattaagaat ttaatgtaga aaggttatgg aagtaggatg gcaataacat gactc 52920 atatttatta gagcaaataa agcccagatt acatacagta ctaagtaatt gttatattat 52980 agatgaagtt ttaaaagact ttgattatca aactagggaa atgttcaaag aggctttttg 53040 tggtaagaac gcaaagcacg aagtaacagt agggttcaat ttccctagct ttaaaaacaa 53100 ctacgaagct cattacctaa tacaactagg gcaaggtcaa gaggttaaaa actctttagg 53160 tagtatacaa gggtcttatc tagaagcttc gggtaacaca tatagtgaac aatcagtagc 53220 taaaagagaa ggtaatcgtt tagtatttca tgtatctaaa cctatttcta atgtaataag 53280 agtagaagac atagcgttttg attcttacga tgatgttaaa gtacagata acacctgtatc 53340 ttttaatt actacaatg agacttatga aggctacaac gcaatattg tatatgtaga 53400 aaaaaaaaaat gattaag gggttaaaaagtattacc atagagaac agtaacaat 53460 tgtgggtatg tcgtataatg tagatgttgc tagatgttta gatgccgtat taaaaatgat 53520 attgatatct atgagagaca gtatagaga acaaca ttccagctac aaaatcttgc 53580 atttggagat atcgcaccta tattccaaga cggtgagtca tctatctttg gtagacctac 53640 tatattaa tacacagtt chattagattt national atacacag atattaata 53700 gattactttc aagaataag gaggaaaag atatggtta agaaaacacc taaggtaaa 53760 acctttacag gttatgtaca tatagataca ttttaaaa cagcacagac cttgttttaat 53820 atgaaaggt cacaggtagc aggttttaaa gcctacatgg aaggtaaca ctacctgttc 53880 aatgaaaag actttattcc attttagaa aagtattag gtagagaattt agaatttaa 53940 tatatagata ggagaattat acatggcagt tgaaccgttt ccacgaagac ctgtcactcg 54000 tccacatgca gtcattaatg tagacagtac aggtatcggt aaatcagcta gctccagtga 54060 aaagatttta tgtttaattg ugaragctga aggtggtaaa cctgataccg tatgaatt 54120 aagaaactac gcacaagcta aaagactatt ccgctcaggt gattacttg atgcaattga 54180 attagcttgg gttctaatc cacaatacac agcaggtaag atttttgcta tgcgtgtaga 54240 ggatgctaaa ccagctacag ctgaagtagg cggattgaa gttactcac agatttatgg 54300 taacgtagct aaaacattc aagtaggatt agaaaaaaat acatcagta attcattacg 54360 tttacattta atcttccaag atgatagatt tatgaaca tatgataata ttggtatat 54420 cttcactatc aaatataaag gtagtgaaag tacagctact ttttctgtag agcacgataa 54480 agaaaaaaaaaaaaaaaaaaagctat aaaacaaaaaaaaaaaaaaaaaaaaaaaaaaaaaagg from there 54540 tgacttaca ggaggagctt acgctactac taatgccatc attacgata ttaccaatt 54600 acctgatttt gaagctaagt tatcacctttt tggataag aacttagagt cttacttatt 54660 agaccctatg acagatgtta acattaagga taaagctgag tatgtaaaag cagtatttgg 54720 tgatttagag aaacaaacag cctataacgg acttgtgtca tttgaacgat tagtatctga 54780 acaagcacct aaaaacgtag aagtagacgc acatgaagaa tctgctactg taacagctgt 54840 gtccccaatt caagaaatca caccttttga attaacaaaa ctttcaggtg gtacaaatgg 54900 tgaacctcct gctacatggg cggataaaat cgaaaaattt gcacatgaag gtggatacta 54960 catggtacca ctatcttcta aacaatctgt tcatgcagaa gtagcttctt ttgttaaaga 55020 acgttctgat gcaggtgaac ctatgcgtgc tattctaggt ggaggattta atgaaacgaa 55080 agaacagttg tttggtcgtc aatcatcatt atctagccca cgagttgctt tagtagctaa 55140 ctcaggtata ttcacaatgg acaatggtcg taagttacat gtaccagctt atatggtagc 55200 ttctgctatc ggaggtttgg taagtggttt agctataggt gagtctatta cctttaagca 55260 actacgtatt aataatgtag accaattata tgaatcatta gacttagatg agttaaatga 55320 aaacggtatt atcaccgtac atatgttcg tatagagct atacattct ttagattac 55380 agacgatgtt acgacattta atgataaaaa tgaccctgtt aagtcagaaa tggctgttgg 55440 ggaagcaat gactcttat gttctgagtt aaacttgag cttgaaata actttattgg 55500 tactcgtact atcaatacaa gtgcttcaat tatchcaagac ttgtacagt cattcttagg 55560 acgcaagaaa cgagataacg aaattcaaga cttcccacct gagacgtac aagttattgt 55620 agaaggtaat gaggctagaa ttcaatggt tgtataccct atcagaagct tcaagaaat 55680 ttctgttagc ttggtatacc aaaacaac attagagcc taaactagggg CAggagtac 55740 ctagtttagg tactcctatt taattta ggagagtga ttatatggc atcggaggct 55800 aagcaaagtg tccatactgg taataccgtt atgttaatgg taaaaggtaa accagttgga 55860 agagcacaat ctgctaaagg tcaacgtgaa tacggaacta ctggtgtata cgaaattggt 55920 agtattatgc cacagagca tgtttactta aaatatgctg gtacaattac actagaacgt 55980 ttacgtatga aaaaagaaa ctcgcagat ttaggatatg ctcacttgg tgaagatt 56040 cttaagaaag atattattga tatcttagta gtagataact taacgaaaca agttattatt 56100 agttaccatg gtttaactaa atagacccct tgtacagtga tgtgcattga samaaccctt 56160 aaattgctag aacaccgtaa agctaactaa actacaaagt aagtcgaaag actaggcttg 56220 aatgttgaga aatcagaaaa aattagttag atggtataag gttaaatcct aagtactaca 56280 taattggtaa ttagcatcca agctcctgta aaatggagaa ggttcaacga ctataatagg 56340 taagtcttag ttacatatta agattatggt atagtctagt ccctttaaaa tatatcgaaa 56400 gatagggtat aaacggttca gcaaacaact acaacgagac ttggcagaca aatgaaattg 56460 taacagaaga aattgagttt agctaccttt aactaataga ggctatgttt ggtgacaagc 56520 atagaaaaca ctttaaattg cgtgaaagtc ttaaagacta gataactaca aagtaacctg 56580 aaagggtaag cttgaatgtt gagaaatcag aaaaaatatc tagtatagta taaggttaaa 56640 ccctaagtac agtaaaatag atgatacgca ggcaagccta cgagagtggg aagcttcaac 56700 gactataata agtgagtctt agttacacat tagattag gtatagtcta ctccctttaa 56760 atatatcga aagatagggt atagaggaca gcatcagata aggctagac ttaaatttcg 56820 tattaagacc taacataaa agttaggtct ttttatac ttgttttt agaagtactg 56880 tattatatt aaaaaaaaaaaaaaaaaaaaaaaaaaaa hasggtgtac taaatgaca achaggaaaaaaggtaa 56940 gtagtatt caagggcac atggaatt aaaaccaacaaaaagtaaaaagaaa 57000 aaaaatatt ctagaaaaaa taagcataa ggtattgaca attataaata actgtaatac 57060 tatagttata taggagatg atgactgtg aaaacttttt attcaggcag agaacaaca 57120 agtaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaacatta 57180 tgtaggaact tactaaaga ggcttataat aaaaatatt acttaagtt aaaaatcac 57240 ttcaaggta aatgtaagaa accagtaaat ttcaagcgt ttgttcatta tatacataat 57300 aagaacttag atattataga attaatgaa accattaca atacaaat acaacgtagg 57360 gtagttgtta gataccctta tgtagtaaaa gtaaataata attatctta ccaatattta 57420 gttatagaag ttgaaacagg tgaagttgta actatgtact ataacagagt cacagataac 57480 cacaaaacat taaatttaaa tgattattat gataaaaatt taaaaataaa gtattgacat 57540 aagtaaatac ataatatata ctaaggttac attaataaag aggagaataa aaaatgacaa 57600 ataaattaag agctatccat gaagaaatga aaattgagtt acataaattc ccacagaatg 57660 tagatttaac aagtaagaca actgctattg caatcaatca aattcttgac aagtttaaaa 57720 ccttaacgga acaagcaggt aaaatcacta aaaagtattt tgagggtcaa gagattttga 57780 cgattgattt tgaatattat gactcacttc aagatacta catttactta cttaaaaata 57840 gtgaaacaat tgaacaaagg ttacaagaaa ttgaaaaaag agtagctgaa tatgttaagt 57900 aatttggagt tataccaca ttatgttata ctgtatgtgt ataaaaaaca taagttagct 57960 gttatattaa ttatgagaaa samaaaaag atggataaag aattggaaaa agaacaaaaa 58020 gatattaaag atatgacacc tgaagaaatt gatgagttaa aatatcagca acgaaaagat 58080 aaagagcgtg ttattaacaa agtaattaaa ggtgttaatg atgtatggga gaaagaatac 58140 aactttgaag aattagattt aaaattcaaa gtaaaaatta gattacctaa tgctagagaa 58200 caaggtaata tcatggcttt acgttctgca tacttaggtg gaatggatgc ttatcaatct 58260 gaccaagtta ttaatgctta tcagatgtta gctactctac aagaagtagg ggtagaagta 58320 cctaaagaat ttagagaccc tgaagagatt tataacctaa ctccacttgc tattatgtgg 58380 gatgattggt tagacttat gacgtccttt cgttactagt aacgtaaaga agttaaatga 58440 agatatagaa cggttaggtg gactttcaca tatagctaga gagcctttat caagaaactt 58500 atgggctatc atgcgtgagt ttaatgtgct acctaccgaa caacgtttta aagatttaga 58560 tgactatcaa atagagttta ttatagctaa catgaattta gatacaaaag aaatgatgga 58620 agctagagac ggtaaaaact atgatatgaa agcggaagac gtagacacat catggttcga 58680 agcgccgaca gatgaatttg atgttgttcc tgatttctta gacttagatg atttaaatac 58740 acaagtagat aaaagtttaa gtgagaaaga aaagatagaa agagatagac gagttgaagc 58800 tgagttagaa gatgaaaccg agggattaac aactcaacat ttagctatga tggaacacat 58860 aagacaaaaa caaaaagagc ttgatgaaag tttaggtatt gataacaaag aaacaacaca 58920 agaagatata aacaaagcaa tagaagatgt agatgattgg tacatgtagg gtaatggtat 58980 aacaccaata cccttatttt ttgattaggt ggtgaatact gtttggcaat gaatgacgat 59040 tataggttgg tcttgactgg tgatagttct agcttagaac aaagtttaaa agctatagag 59100 atgtacatgg atgcgttaga gtctaaaaac atagatgcac cattaacaaa cttcttagag 59160 aaattaaaag tatagcaaa agaagtaaaa tctgtacaaa acattatgga taaacaaagt 59220 gataagtctt tatatcacc aaaagctatg gatgaggcta ttagttctac acagaatgta 59280 actaagaata taaacgacct aaagaaagct ttaaatgaca tacaaacaga tatattaca 59340 aagggtatag ctcctgaccc tgaagtagag aaagtatata gtaaacttaa taagacacta 59400 aatatakac aaacagaact agagaaagta gcatctcaaa agattggttc agactcagat 59460 atacaaaaaaaaaaaacaaaaaca ctgaaccaag ttacaaga gtataaaa 59520 ttagtaaag atgccagttc agctaagg tacacaagc aactaagagc taatcgtaat 59580 atggttagag gtcatatatc taggtctgaa ggctctatata gatgtccta tgaccaggt 59640 gctagagtac gttctgaatt aggtaagta bakactttg aaaagcaacg agagctaac 59700 atagagaaaaaaaaaaaaaaaaaagaaaaaaaaagat 59760 ttagtaggca aagagctcg tggtgaaata agttctgagg attataaaaa acatcagct 59820 tctattaaaa tgatgattga tgaagtgaa aagctttctg aagtttatag aaaaacaggt 59880 gctgaattag acagtcaat cacactat aaaatagtg ctaaaaaaca gtttgctcag 59940 cgtgagatag aacagcaacg aggacaatg ggtaaattgt tccagatag attackactct 60000 attggtgcac atgctactat ggcagtaact gctcttgcag gtggtagta tatgaaaggt 60060 gcctccttat ccgaggcaa taggactg gtacatcat taggacaaa ttcagataat 60120 atgatatag acgcagtag aatacatat ggagatttgt caatagata taagctttggt 60180 tataattcaa ctgacatgct aaaaatggct acgtcatatg aaagttctat aggacataaa 60240 agcgatgcag atacgtataa aggagctaaa cagttagctg taggtggtcg ttcattaggt 60300 atacaagacc aagaagctta tcagcaatcc atgtcacaac ttatgcatac aggtggcgta 60360 aactcagata atatgaaagc tatgcaagat gctttcttag gtggtatacg tgaatctgat 60420 atggttggta gacaagacga gcaattaaga gctttaagta ctattgccga gcagtcagga 60480 caaggtagaa cattatctaa aggggaaatg tctaatctta cttctttaca agctcaagta 60540 gcgggtacag gtagtaaagg tctacaaggt gcacaaggag ctcaagcctt aagtagtatt 60600 gaccaaggta ttaaaaatgg tatgggtaat tcttatacta gattagcaat gggatggggt 60660 actaagtacc aaggattaga aggtatgcat gacttacaag cacaaatgga taaaggtata 60720 tcagacccta ataacttagt tatatattt gaccaagcta ataatagg aagtacaaca 60780 aaagaaaaac aagccatagc taaaaaaggc tttgaaagca tgggagctaa cttaacacaa 60840 gagcaaacag atgagttgta caatctttat gcctcaggta aactatctaa agaagagtta 60900 gctagtaaag ctaagagcat ggaacaagaa ggctctaaag caggagataa aaataaggat 60960 aagtattccg agtctaaagc aggtagaaat gaccagaaca aagctaagac agatgataaa 61020 gctgaggata tttgactt agctcaacct attagagatg ttcatagtgc tatggcaagc 61080 ttgccagctc ctttatacct agcttcagga gcagtacttg cctttgtagc atctttagct 61140 aaatctactg ccatgatggc tggtggttct ttattaggta aaggtcaaaa aggactaaaa 61200 gattggttta ataaccgtaa aggaggttca acaggtaaga ctggtggtgg taatcctaac 61260 ggtggtggac gctttggagg acttaaaaac ttagctgaca ctatactagg tgataaccct 61320 agaggtggag accgaccatt taagaccaa gcaaaaggag caggacaaac tgctaaaggc 61380 atgggtaaa ccttatttga tacctttgga aaaagagatt ttacttttgg tgaatatatg 61440 ggaagaacca aagacctagg taaaggtgta tggaacaaag gtaaaggagc ttttggtaaa 61500 gctaaaggta aatttagtgg taaagactct aacttaggtt tttgtcaca agcacctact 61560 gctaatgcag gcggtcttgg taaactaaaa ggtcttacaa gtaagctagg ttggattggc 61620 gcaggtctat cagcctttga cataggtagt tctctaaatac aaggagatac taaagaagct 61680 tcttctaaat ttggtaatac tataggaagt gtcatagacc cattaaaacct aggttatgga 61740 gacggcttaa gagattatgc tacgaaaaca gcggaaggtt ctatgacaag tgatggttgg 61800 aaattatggt ctaatggaga taaagatggt aagaataaat tccaagactc tcctgtaggt 61860 aaactatggg gtggcataac agatttcttc acaccagata acccttctaa attagacgag 61920 acagtgaaaa ataaaaaag taacataatt agttatatac taattgcctt gcttatagag 61980 caatctgtaa gtaccgagtg ttaactgcta tgaaactact aaagctaact aaactacaaa 62040 gtaagtcgaa agactaagct tgaatgttga gaaatcagaa aaaattagtt agatactcta 62100 aggttaaatc ctaaggagaa gtacaatggg tgtatagcat cgaaagtcct aaagacctga 62160 aaggtctatg gaacacgttc aacgactatt ccgtataggt gacggaagta aagctccaag 62220 ctattgggag aagaaaaata ctcaccctat actaatagggg atacaata gtctgcgcac 62280 gtaccgaaag gtagtgtcta gaataacta gagaatac agtagcgtgt attackattaac 62340 attgttaaaa tatataaata attaaaattt gtattctact tctgcatata aacctttctt 62400 attttgtaag gtaaacttgt tattaata atacataa ctaatacgat aggttatata 62460 tgaaagtata ctattgtttta tatgttttaa cttatggtat taatgataa tcacaagta 62520 aagacaggca aaagcagaaaaaaagag aaaagaaa tgattctga gaaggaatg 62580 window ctcacattc ttagaccatt tagcagata cctacaat aaggtagta 62640 gttctaacga cagttcatca ggaggacac tgatgtaacct tgatgtaaa aactttacgg 62700 aaagacgt aactaagcat gacctaggta aactgctaa aggtgtaaac gccgaatgt 62760 taaataatg gattgagtct caagcaccta gtaattctaa atgcgtggt ttaggtgagc 62820 tttatatgaa agcaggtaaa gagtcaggac ttgacccaag gtatttagta gcacatagtg 62880 ctgttgagac aggctgggga acatcaaatc ttccaagg cggaccct aaaaaggta 62940 actggttcgg tataggtgct tttgataaca atcctaataa tggttttaac tatggtttgg 63000 gtattgttgg tggtgctaaa tggattagag acaacttcta caacaaagga caaaagaact 63060 tacacgatat gagacacaac aatggtgttc atgaatatgc aacagcaggt aattgggata 63120 ctatgattgc cagtattatg aaaggttcag acaagttcat aggtggcgga ggtggaggca 63180 gtgatgttat gcctagacat gctctaaaaa acgaccatca accaaagaat cttaaatata 63240 acatagaagt acctaaaagt aaaaacccta atgaaacagg gaaagcaata ggtagaaaat 63300 taaaacaatt attagaatct aatttttaga atacaattat aatacttata tactttaaca 63360 aatggtacaa ataataaaaa acagaaaatg tctacagaac aactaagaga aaagaataat 63420 aaatcagaaa ctaaaaactt aaaaacttac agtaacctat tagatagc acaacaaatt 63480 atagaagatg ctaaagcgct agactcagga ggttcagaca gtagttctga ctcagggggt 63540 tcagcttccg atgtagatgg agaaggtgcg ggtaagattt acaaattcct taaaggtaaa 63600 ggtttatccg ataccaagt aggtgccgtt atgggtacc ttaagcaaga atcaggggctt 63660 gaccctaatg caagaacgc ctctagtgt gctttggca ttgcacaatg gttaggtagt 63720 aggaaatcag accttgatag ctttgctaaa tctaaggta agagtctaa tgacttagac 63780 gcacagttag atttcttatg gaagaaatg agttctggtc aaatagtga tatgcttaaa 63840 aatgcaggat ggagtaaag tggtagtttta gaaaaaaata caaagcttt tgcacaaggt 63900 tttgagcgta tgggtgctgg agaggctatg atgagtactc gagtaataa cgctaaagt 63960 tatgtaagca atatgtaa gtcaggtggc ggtggcggtg gcggtggagc tataccatca 64020 tcatatacgt ccgtattaag aaacccgata cttagtagtg ctcaggaag tactgcatct 64080 caaataatg tatctgtgaa tgttagcatt acaggaaaaaag ggatgctgaa 64140 gaataggta aaggcattaa gtctactttt ggtgacgatt tagacactt ctcaacacg 64200 tataaacgta attattagggg tagtattatt aagtactacc ctttatataa aaaaagga 64260 agtacatata tgtatagaat tagacgacct agtagact aacagatgac 64320 aatacattta cattaaggtt tgaagatact aaagattaca caggaaatca gtttgcttca 64380 aaattaata acttccaaac taaaaatgca atggaagaatg acagtgcagt attccaaata 64440 acaatggcag gggatacata ctgggataag ttagtaatgg caaatgatat tgttaagata 64500 tatattacac ctaacaatga ccctaaaagat aaagaaggaa ataaagaa acttatacaa 64560 gtaggtatgg tatctcaagt ttctaaagta ggaagctata gtaatgacca ggttcagttt 64620 agaataac gtcaatcttt tgtaaaacct tttatgaaat ttggtttagg tgttatacaa 64680 gaagtacaag ctgtattacc aactgttggt tggttagttg atggtgatgg agagaaccaa 64740 gttaagttta caggtagttc agctaaagat gtaatgcaag gtattataca acgatttatc 64800 ccatacatga aatataatta tacagataaa acgtataaca cactagagag ttatttagat 64860 tatgatgatt tatctagttg ggatgagtac gaaaagttaa ctgaagtttc cgcttttact 64920 aacttcgatg gtacattaaa acagctaatg gacttagtaa ctgctagacc tttaatgag 64980 ttttttta gaaattcaga taaaaaaaa ggtaaagcac agctagtatt aaaaaaact 65040 ccttttaatc caacgaatg gaagcatta catatatag ttgtacctac ggaagatttt 65100 atagagaag atgttggtaa gagtgacgta gaacatact ctatattac agtaaaacca 65160 gcaggtagt tAAagaatt aacagggat gtattctcta aacctcatt ccatcagaa 65220 ttagtagata gatatgggta ttctaatat gaacagaaa acctatacat aggactaag 65280 agtggtagtg ctacagagaga tagtgaact acaggtggag ataacggtca tgaacgagta 65340 acttatgaca gactaa agatttaat aactagta gagagtctat atctaagga 65400 ttagataat actctagta gatcatca aattacaa atattacta actgagta 65460 aagagtatttt tagaatctta taaaaaaaa ggtaatctaa gtaggaga attgaaaaa 65520 atacaaga acaatacttc aagagagtca gtatctgata ctagaccaaa actacaaaa 65580 gaaaaattta agtctatatt agcggaaaag tttaaga aagaacttt tgatgataaa 65640 gatttaata agaaacaac aaagctgta atgatgata ttchaaga tttaagtat 65700 ggtaatccta cacatgctaa gaaactacta gaggattaca ctagatttaa aggtaaccca 65760 cctacaagta ccacaggtga tatttat aagtatctta aagccgtaga aggagtagct 65820 aatgttgcta tagatacagg ttctgacgca agtgatgacc ctttattat atttactaaa 65880 atgctattta attggtatca ctcaaccct aattttg caggtaatat tgttgtatta 65940 ggtgacccta agtagacct aggtaaacgg ttttatta agataaca acgagggat 66000 atatgggagt tttacataga gtccgtagaa cataagtttg attataaaca aggatacttt 66060 actacaatag gagtacaag aggacaaa gatgctatta taaagatgg tgaggaagc 66120 aaacataggt ttaaggt tgaatcag tcatctgact tctgggtgg tcttaggt 66180 gagagacat ctaagaatt aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaahaaaaaaaaaaaaahaaah 66240 aagatggag attctgacgg aggccacaa gatggaggta ccttagctc actagaaaaa 66300 tataatggta agttgcctaa acatgacccc aactttgttc aaccaggcaa taggcattat 66360 aagtaccaat gtacatggta tgcctataat agacgtggtg agctaggtat tcctgtgcct 66420 ttatggggag atgccgccga ctggattggc agtgctaaaaa gtgcaggtta tggtgttgga 66480 agaactccta aaaggggc ttgtgccata tggcaaagag gtgctcctgg gggaagctta 66540 caatatggac atgtcgcttt tgtagaaaaa gtattagacg gtggagctag tatatttata 66600 tcagaacata attatgcaac tcctaacggt tacggcacaa gaacaataga catgagttca 66660 gcaataggta aaggtgctca attatatat gataaaggat aattgatatg gcaacggata 66720 aacaagttaa agatgttata gataaattta tagataatct tttcaattttt gaagtattaa 66780 ccaaagaaaa ggttgaagaa aaagataagg aagttaaaaa gataactaca gaagacgtat 66840 acaataaagt tgtttatatt agaccatatg taggtgttat acaaagtata acacctagac 66900 aggtaacata tgatagtttt actaataatg gtacagatat agaagctaaa ctcacactta 66960 gaaaaataag ttatactact gataatctca cagtacctac tgatgcatta tcaacttgta 67020 tggtacatat ggtagaaaga aatggtgtac ttgttataga ttactttgat gagttacaga 67080 acatactgta tggtagttac atggataatg agcatatatt tgatgagat gttccagtta 67140 gtacattagt aacattagac ttgaagaga atttaataa tttaaacat atacagtata 67200 tgtttaagg gatacggat aaaaccctt ttgaagtaa ggatatagta cctttagata 67260 catacaactt attatattgg atgtataaaa agagaatgt agagctaaaaatccattaa 67320 cagttaacta cttcttcaca ggtaaagct tttatactat atttggtaaa ggacacaaat 67380 aaagttga tattgacaa ttcaaatag gtgatatact attctttgga cgtagtgatg 67440 atatatagg gatatacata ggagataaga agtttatttc tcttatgggt acatttccta 67500 agataacac ctctattagt acctataagt tagacgatta ttgggatgac tttaatgta 67560 gggttatgag gtttgatgag gatgatatag catggtggta agattacaat cttctttagg 67620 taagtttta aaaagatag actcagaga acttaatgtt aaggctct tattaggtac 67680 agtaagcaa ataattata agtaccaac tgtagagtt aaaataata gcttaacatt 67740 aggacataac cctagtgatg atggcaagtt agctgttcct tatcctaaag attatgtagg 67800 aagaacacct gaaggtagcg tgtatggcag taatacttta ataacggaag gaactactgt 67860 actgttagga tttattaatg atgacattaa ttaccctatt atactagcta tctatggtaa 67920 tacagaagca aaccaactca taaatacgaa tcctttagag ggtggtaaaa tgagtaatga 67980 tgatgtttat aaatatagta gtgctttgta ttctatatta cctgacctaa cttacatata 68040 taaagatggt gaaggtacat ctataaaaac attcaatggt aaatctttct tatccattac 68100 ttcaggtgat aaagaaaaac ctttatcttc agacttttat acaggtactg aataccaaga 68160 cttatttcca tcatactata gtaacaaaaa tttaatagaa cctagaatac aaaaggcacc 68220 taacatgtta tttaaacacc aaggtctata ctttgatgat ggttctgaag ataatcatgt 68280 tacaacttta tttatttccg aaaaaggtga tgtaagagct tcagtattag acaaaagcac 68340 acaaaaaaga acaacacaag agatgtctca cgatggttct tatagagtta taaagcaaga 68400 tgatgaccta ttattagact cagcgcaagt atgggtagag tttggtataa atgataataa 68460 tgtgttttac aaaaaacc ctaagcatat gtttgaattt aatgataaag gtatatattt 68520 agatgataag ccaatttttag atacgttaga tgctagcatt acagagtcta tagatagact 68580 Taggta Caggagat Taggtactta Cttgaggttg Taggtaag 68640 aaacttagag gagttaatcc aagactaa aaatctata gaagttttcta gtaggcaag 68700 tagcgatgtt acgactatga aatctcaaat atctaatgta agtagtag ctgagggtat 68760 tattacacag ttcagagt ttagagacaaacattaaa ggcttatatg aagatgcttc 68820 tactatgata aaataca accaagaat acctgagtta aaagtagat tgaatactct 68880 agatacatt acattaccta acattaata acattatta gagaatca gtaagaccta 68940 tgttaataat agttctcaa gtgttagtag taattatcta gttcattac tgcattaga 69000 tagtacctt actatttatc catacacacc tacacgtatt acatggaata agatagtttt 69060 taatattct gagtttgtaa ataagactaa ggatgctttt gttattccgt taggtgtatc 69120 taaagttaaa gtttctatta atctttaatg ggatatatta caagataag taaaaactat 69180 tagtcaag agaatagta atacatacaaacatact aatgtaata cacacgaata 69240 tataattaca aatgttatac ctgttaaca aggataca ttcacagtag aagtaxaca 69300 agatactta cattactaca agataacta taggtatt 69360 agaaactact ttagcaccta ctaacactga gttaggt acaccatccg aaaaaacaga 69420 window stormtg windowtctaa tgttgattta tgagtttga storm 69480 tactaagac atcagttag tctgtcttta tgatctaa ttagataa taacaacagg 69540 taaaggtaat gtgtctgatt acactaca acaataag tcattttcat ctaagaatgg 69600 tgagagtatt ttactctttag aagatgtatt agctaatat aaaattcta ttagatatag 69660 tattaattta stormg storm agaactactg aaaaaata atttaattgg 69720 tataagagca cctaggaatc aagtgtattt gaagttaaa gatttacaa tcacacaga 69780 agtattaaat aatttttcta attaccagt attatataat acttcctac taacaagtac 69840 agatattaac aaaggtatat atacaaatat atatggagta ctactaccat atactagtat 69900 cactcaagat acagtaaata cagcacataa tataaccta tctatatatg ctagtggtga 69960 tatgacaagt gacattataa ataagcttat tttatggt atagatggtg tagaaacaaa 70020 taaaatatta gagtttaaaa aagtttaaaa gtcctattaa tagggcttttt ttatatatgt 70080 catgttatat taaacttgag aaagtagttg tatttaaata ctatatatga tataatacga 70140 tatagaaagg tggtaagtta tgcctcaatc agatggaaag aatacaataa gacgtattgc 70200 attacgtttt ccaacagcaa gcggtaaata tatatgtac cgtttcaaag taaaccctga 70260 aagttatgaa atagatgcac cacaaagaac atctataact aaaactaaat cagacattat 70320 tgttgaagac tatggtaaag atatagagac aataactttt tctggtacta ctggatttag 70380 acctgtaaaa gaagtagatg gtactaaaac aggaaaacaa aaatagagg aactacaaga 70440 acaagtagaa gcatacgcta agcagggtgg agatggtagc gtagcaggag cttatataga 70500 gttctataac tttactgatg attaatatta caagtacat ctagcaccgc aaggtttaaa 70560 aaaacagg tctaagatg aatccttgtt atatagatat gaataactt tagttgtgat 70620 aggtaacctt gctgaagcag atagaggttc cgtaacatct gctgagtttg gtaatgtaaa 70680 acctaatgct aaacaaagag ttgatgagggg tgttaatgat ttagatagta acgcacgaaa 70740 aacaagaac aagaataatc aaatagtatc acaatttgaa aaaaagta gtcaaagctc 70800 ttctaattct agtagtagcg gttcacgata tggaacggca ggaacattaa gaggaggtag 70860 tggcataaga acaggtggtt ctgaggtaa tagagacggt atgagtaata taggtatata 70920 taaccctaga cagaatacta atggtcttag tagtactgtt gatgatatgg cacttaaat 70980 aggatacggt gatggaggtg tatctaggta atgaatatt ataccctca accacaagga 71040 ttattaaggt tttaaatgg attagagtta gatagtctt acacacatat gaacttatta 71100 gatgaggaag taccttttgt ttctaaatttc tatacaccac aaatacaact aagtgaactt 71160 gcaagataa attaaaaga gattaagtct actgatatcc ctactttaga aagaacattt 71220 aacaacaata caatagttaa taaagtagaa caaacaagtt taaagttaca atcacctaga 71280 atgtatttaa ttatgcaatc tatcgtaatg gaagcttacg ctattgtaaa ctgctttgta 71340 gaaagtcctg aatacttaaa atatttaaca gaaaaagatg tatctatagt aagaagtaat 71400 gttaactacg tagctgacta tttaagtgat tatgaagaat acaatagtat tgttctcgat 71460 ttaagagact tagacttatg ttttggctct ttggaattac aactaccact aattaagagt 71520 gaggtggtat aatgagattt agaaagcatg aagtacaatc agaagaaacc ttacaagcta 71580 tatcacaaag gtattatggt gatgttagtt actggttaga tttaatagaa cataacaatc 71640 tacaatatcc ttatattgta gatacagatg aagaaaagaa acagaacccc gagcacttaa 71700 taactaaagg tgatattatt atcatacctt tagattctga gttaacagac tcggtttcta 71760 aagaaataac atcaagagac aaagatgtat tagtagaatt agctttaggt agagacctaa 71820 atatgacgga tataacgag tatatagacg ctcatggaac agatgatgaa atattagccc 71880 tatctcaga tggtagagga gaccttgata tagttaagg catagataac attaagcaat 71940 ctttaagagc tagactattg acacctaaag gttctttatt attacatcct gatatggtt 72000 ctaacattca taatttatt gggttaata tacctgaaca agctacgtta attgaagtag 72060 atgtattaaa accctaaca tcagatagta gagttaatc agctaactta aaggttggg 72120 agataaagg tatgaatac tatgggtcat ttatgtaga atcaagtcc gtagaagaat 72180 ctatagactt tgtattaggt caatgatt caggtgtctt tgctttatt gactaagaaa 72240 ggaaatttat atgagaaca gaagttaac acagatatta tctaggttaa tggatagac 72300 gatacaggt acaagcaaaa tacagactt tacaccggt tcagctgtac gctctctttt 72360 frequency gctttagaaa frequency frequency acattaattg 72420 gggcattcaa gaagggatta ttgaagcttt tgatttca aaagaaaag ctaagcgttc 72480 ttatggtaat gtagatattc aattttacca acctttagac atgagaatgt ataccctgc 72540 aggtactaca ttctcatcta ctaggcaga attackcctca catttgaa cattagttga 72600 ttactatgct gaagaaggaa ccactgaaat tacagtagaa gtttactgta aagaagttgg 72660 tattgtaggt aatacctg aagatatcat tatacaata gcctcaggct ctagtttaat 72720 tcgtacaatt acaaacccga cttcctttaa tacaggaaca aaagaagaat ctcaagagga 72780 ttttaaacgt aggttccata tgtttgtaga atcgagagga agagctacta ataaatctat 72840 tagatatggt acattacaag tacctgatgt tgatggtgtt tatgttatg aagaagtagg 72900 tcatgttact gtatatgcgc atgataaaaa cggaaattta tctgctactc taaaaaatga 72960 cataataacg gcattagaag attacagacc tagtggtata aagttagatg ttgtaggcgt 73020 agagaaagag gaaatagatg tgtctgcagt agtaacaata tctaataaag ctaggatagg 73080 tgatacatta caaagacata ttgaaagtgt tattagagga tacctaaata gtctgactac 73140 ttctgatgac ttaattatta acgatttaat tcaagctatt atgaatatag atgataattt 73200 aatttatgat gtagcattta agaatttatc tacaaatata gaagtatctt cgaaaggtat 73260 tattagagca ggggatatta aggtagaatt aatataaggg ggtaaacaat ggctaatttt 73320 ttaagaaact tacacccttt attaagaaga aataagaata ataaagataa ccaagaccct 73380 aactatgctt taataacagc acttaatgat gagatgaaca acatagagtc agacaccatt 73440 aaaagcaaac ttcaatcatc attaaaact accacaggag attacttaga taagtttggg 73500 gattggtttg gtgtatacag aagaataaat gagaatgatg acagctatag aaaaagaatt 73560 ataaatact tattattaaa aagaggaact aacaacgcta ttattagtgc tattaaagat 73620 tacttagata atgagaatat aaatgttagt gtatatgaac cttttaaaaa tatattctat 73680 accaataaat caaaattaaa tggtgaagat tatttaatgg gttattatta tagatttgct 73740 gtgataaatg tttctgttga tggttacttt cctttagaga ttatagatgt aataaatgaa 73800 tttaaacccg cgggtgttaa gttatatta acttatgatg gtgctactac cataaagggt 73860 gatggtgttg ttaaatggct taaaaatcta cctaaaattg aaacatatac ggatttagat 73920 agattattag gttatgatga aactttctat gggcatttaa acatgagtga agcaacagct 73980 gaacaatctg ataaacaag gttcagaaca aataagagta cattaaatag tgaagatatt 74040 ctatcaggct cttctataat tggacgtaga tttaataaatt atgcttatgt tacgacatat 74100 gcatatgaac ctactagtac atcagccgtc acacatatagg cttctttaaa tgataaagga 74160 aaagaagcac ctttagatta ttacttatat acatccttaa agaatactaa tgatataaat 74220 atatcaatgg aaactgctta tggtgtgtct tatttataca ataactttaa tgtaggtgag 74280 tttatcagta gatacaaacc taatatagat ataactagag ataatgctaa aaaacaaata 74340 tccgattttg taggggaact aacaattgat ttctttgcaa aagctttagt ttcacctgat 74400 gaatcattac ctattaagtt acaaatattt gattttcgta ctaatgaatg gttaactgta 74460 tcagaaacag aactatcttt ttacgagaaa aacataggtg taaacatagg ttatataaga 74520 gattacttaa atgatgacct taatttattt acaagattag aggttaatat aggtaaagat 74580 gagcaaaaag atataagtat taactacatg gatttacatt tttataatta taaaaaagat 74640 gtgtatacta tcaaccttt taagcacta gttgaaact acatagattt answer 74700 acttatattg aaggctttaa agtagccctca ttattaatg gagacataat taaaaaat 74760 ggatatcaac ccataaaata tttaggtta catgctactt atgattcaac taaacctatt 74820 gtaagtatta caggtaaaa cagcaataat gaggtacaa atatacacc tatagatta 74880 tataaaaata caactaatag aaacttattg caatcatata aaggtgatag tagtatattc 74940 aagggtgttg taagcacaa agagttttat atctcatcat ggtctgacac cttatataac 75000 tcaacgtatt tatctaagt actagaaccg caaaagtat attackttgtc attcgagatg 75060 gaatcacag atgctatat ggacttaaaa acatattctg acatcatgg tatattatta 75120 tatagtagta ctaaaggtat tgttgctaat ggtgttaaaa gcatgcaaag aagataggt 75180 aaagattg atgtatctac cacatttaca gcacctacaa ttacagacca tagacttgtt 75240 gtttacacag gtagatatac agcagatggt actgcctcta aaacacctat tgcttctaat 75300 acggtaaag taacaacct tcaactaaaa gaaggagcta ctagaagga ctacacggta 75360 gcacctgaag atgtaactaa tgttatagac aaagctattg tgtttgataa catattaaca 75420 gatatacaa chaataggaat aatacaca acacctta aaatattga gctaagttat 75480 tcttattatg gggatattg vakaaacta aaaaacataa gtaatttaag tcaggtgaa 75540 acaatacac ctaataacct agtagattta tatggcttag aacaataga ttactcaagt 75600 attackacctt tcttagggt tatacttaaa actatatgga atgctaacct gatataattta 75660 acaataaaa aaggtagtat ttctaacatg agtaatact atttcaatgc tgtatggcaa 75720 gaggtagata tgatatata cacatacatta agtagcatga gcatacttac tgatagtgaa 75780 ggtaatgtat ttgatagttc aacaggacag gtataaaat tagcacctaa gatataccaa 75840 ggatatactg atgtagatag attgctaacg tctacgactc tatatacga gatattaca 75900 ttaggttcaa atagatttat ttatgactta cgggatgt tactatcaag tgatacattc 75960 agatagata aataatta agatacacag aagtacagta agatattga 76020 cataaagta ttatatgat atagtaggt atgcgtatta tgtatacct tgttattatta 76080 atacagaata ctagacatga aaggataa aaataatggct atagcaacaa atgcttcaca 76140 tgtagaatta gctaaataca ttgtaagtaa ggctgattct atttatta caatggtaa 76200 aagtacagcg tggtctaatg aaacaagtcc acctcaacct gagaaacag siacaatcatt 76260 acaagagtt atcggatata aaaaagcaac taggtagca ttagttagac ctgcaaaac 76320 aacgggtgat gaagtaaaaaaaattac atatgtaat aaacgatgggg tgaatttga 76380 ctcagctaat gcagttgctg aaggtgctaa gtgggtgtac ttagaagta gtattgttgg 76440 agatgagtta cccttagta cgtatagaca agtaggattt gttatggatt tgttagctaa 76500 agatagtatttctaattta acttattacc tagtgagtg caatctacag gaactttatt 76560 attttatgat aaaacaat tccaaatag aagtgaacaaaactgtaa aagagcgctt 76620 tatcattgaa gtttaaaag gagaattgaa tatatatggc aattaatttt aaagttctc 76680 catacttaga tagattgac cctacaaag atagacaag agtactttt atccagata 76740 gaccactaca acaatcagaa ctaaatgaaa tgcagtctat tgaacaatat tacttaaaaa 76800 atttagggga ttctattttt aaagatgggg ataaacaatc aggattaggt tttacattaa 76860 ctaaagataa tgtactacaa gttaacccag gttatgtgta tataaatggt aagatacgtt 76920 actatagtag tgaagacact gttaaaatta cgggtgtagg taaagaaaca gtaggtatta 76980 aactaacaga aagaattatt acacctgatg aagataatag cttatagac caaacaagcg 77040 gagttcctag ttattttct aagggtgcag accgtctaga agagaagtta tctttaacag 77100 tcaatgaccc tacttctgct actatttata cttttatgga tggagacctc tatatccaat 77160 ctactaatgc tgagatggat aaaatcaaca aagtattagc agagcgtact tatgatgagt 77220 cgggttcata taaagttagt ggatttgagc tattttcaga aggaaacgcc gaagatgata 77280 atcatgtatc tgttgttgta gatgctggta aggcatatgt aaaaggttat aaagtagata 77340 aaccagtttc tactagaatt agtgtagaga agtcaaggga actaggtaaa gcagaaaatg 77400 aaagtactgt atttaataa tcatcaata atattacttt agctaatacc cctgtaaag 77460 atgttcaacg tgtaacagcg caagtattag tagataaga gcgtgttaca agaagttca 77520 caggagattc tcagactat ttactaata aacagcttt tgagtagtt agagtatgga 77580 cagaaaaag tccaggtcag aaaaaaaac aggagac tatagacta 77640 ctgatggtca aacaatagac tggtctcctt caggtcaaga acctaatgga ggtacatctt 77700 attatgttttc gtataagtac aagaaaga tggagtagg taagattat gaagtactcta 77760 cagtaggtga gggagtaggt aaacgttggt ctattaattt cacacctgtt aatggtacta 77820 agcctattga ccaagtgtt gtacttgtag actatactta ctacttagct cgtaagatg 77880 ctgtttttat taataagtttt ggtgatattg ctattcttaa aggtgaacct atattatga 77940 gattagtaac accacctta atacagacc ctgagaacct acaattaggt actgtacag 78000 tattaccaga ctctaatgaa gcagtatgta ttcatatgc tattactga ttacttatgg 78060 aagacttaca aaagtaaaa actagagtag atatttaga gtataatca gctgttaatg 78120 ctttggatga tggtgcaatg gaaaaaacaaa acccattaac attacgttct gtatttagtg 78180 aaggttttat atctttagat aaagccgaca ttacacatcc tgactttggt attgtatta 78240 gttttgatga tgcagaggct actctagcgt ataaagaagc tgtgaaccaa cctaagatta 78300 ttcaaggaga cactacagct catatatggg gtcgactaat ttccgcacca tttacagaag 78360 agcgtacaat ttatcaagga caagcatccg aaactttaaa tgtaaaccct tataatatac 78420 caaaataaca aggtgtgtta aaattaactc ctagtgaaga taactggata gacactcaga 78480 atgtaacaat cacagaacag aaaactaaaa aagtaacaat gaaaagattc tggagacata 78540 atgaaagtta ttatggagaa acagaacatt acttatattc taacttacag ttagataaag 78600 gacaagagtg gaaaggtaag tcatacgcat atgatagaga acatggtaga acaggtactc 78660 tattagaggc tggagcag cgtacacttg aagaaatgat tgaatttatt cgtgttcgtg 78720 acgtatcttt cgaagttaat ggtttaaatc ctaatgataa taatttgtat attttatttg 78780 atggtgttcg ttgtgctatt acaccagcaa caggttatag aaaaggttct gaagatggta caattatgtc tgatgctaaa ggcacagcta aaggtacatt tacaattcca gcaggtattc 78960. gttgcggtaa tagagaagta acaatgaaaa atgctaactc tacaagtgct acaacatata cagctcaagg acgtaagaag actgtacaag atgttattat caaaacacgt gttacagtaa acttagtaga cccattagca caatcattcc aatatgatga aagtagaact attagttctt tagtttata ctttgctagt aaggagata agtctagtaa tgtaactgta caaattcgtg gtatggggaga tacaggttac cctaacaaga cggtatatgc tgaaacagta atcaactcag atgatattaa agtatctat aatgctagtg ctgaaactag agtatacttt gatgacccta tgatggctga agcaggtaaa agtatgcta ttgtcattat tacagaaaat agtgattata ctatgtgggt cggacaaga acaaaaccta agattgata acctatga gttattagcg gtaatccata tgtacaaggc gttctattta gttcatctaa cgctagtact tggactccac accaaaattc agatttaaaa tttggtgtat attack gtttaatc acagctacaa ttgaatttga acctattaag aatgtatcag cagatagat agttttaatg tctacgtact 79560 taactcctga aagaacaggt tgtacttggg aaatttaaat gattttagat gataggcta 79620 catctactac atttgaccaa ttaaatggg aacctattgg taactacca gatttagagg 79680 tattaggttt agctaacaa gttaaattta aagctacatt tgagtctaat aagtatattt 79740 cacctttatt aagttctaat gacttaacgt ttactacatt cttaactgag ttaaaaggtt 79800 catatatcgg tagagtatt gattagacag aagctccata storm agatttagtt 79860 atgaagcatt cttacctaag ggcactaatg ttattcctaa gtattcagac gatgatggta 79920 aaacttggaa acatttact aagtctgctc aggtagttaa gctaataga gactttaata 79980 tatgtta tttgagaa gtaatcaat ctactagaa windows 80040 tagacttatc aactgaaaat agttcttta gacctcgtgt acgtagactt atggttacaa 80100 caagagatga gtaagtttaa agagggttttc atacccttt tttattac taggaagtg 80160 atattatgcc tacagaatat agagaccctt actcacaagc taaacttt attcctactg 80220 tagagaaa agctaaaa gaatggaac aacatataa agataacta cagagtta 80280 atgagcttat tgatgagctt aaaaaattga aaggtgatta cacacatgac gtttaactac 80340 acacctctaa cagaatcaca agattaag gatatgtacc ctaagtaa tgaatgggt 80400 aaatacttaa aaagaagt taacttactct gatttaaaa cgattagtta tcctgattta 80460 aaatgtttt taaatttcat acagactca ggtgactact ttgtacaca agcaagaac 80520 accccgcaag gtgtaagtaa tatagggtttt ttacacttag aaaaaggg tagtacttat 80580 tataagttat attatgcccc gtctaacaca aaaattgt ttgtgaaac tattatataat 80640 ggtactgtct atgattgggt tagttttaaa ctagatgaag gtacattata cgattcagga 80700 atacaatta atgtaaaaaa ttacagag tccacaactc aatttgcaac actcataaat 80760 ccccctaaaa gtaatttaaa cacaggatgg attaattata aggaagtaa aaatgtacc 80820 tcagctttag ctgaatttaa tcctattaat tctacttca catttaaaat gattagaaag 80880 ttaccacgcc aagaccaaca acctaactta ttaagagata gtttattcac attaccaatg 80940 acggatgtag ctaatataag aacggattat atagataata catctttttg gggttttact 81000 aataatgcat ctacctcaac agttagatat atgggtgaaa atactattca attagatgat 81060 ggaggggaat catatcctac agttatgtca aaacgattta gaataggaga cgaactatat 81120 gtaggggata ctgttacaat gtctgttat attaaagtaa atgaccctaa tttgttaaat 81180 ggtaatttcc cctactttga gattgctggg tataattatg tttatcaaga caataaccca 81240 tacacaggag gtaggagaga ggttaactat tatgacttat ctacggagtg gaaaaagttc 81300 tcctttactt ttactttaca atcatataac caagagtcta gtaatgatag ggttaattat 81360 atatcagccc tactaagatt taactgctct aattctacta ataatggagc tattgtgtat 81420 tatgcactac caaaattaga aaaatcatac tcggtaactc cttttattac tcatacttat 81480 gataaaagaa aatatgatga aatatggagt aattggactg agacaacaag taaagatgag 81540 cttcaatcac acagtagcgt agatacatat agtaatgact actataaata cgtatgggat 81600 taccaagct cgaatggtag aagtctgcaa caattagcaa tgtctgtacc tcaaggtttt 81660 tataccttct actgtgatgg ttctataagt ggaactccta gtataaaac atacaggc 81720 acaatacaag tagcgtataa aaataat aaacacta aaataagt atacaatg 81780 gattttagtg attackaagg caagaatt tctttaacat ataataaga taataatggt 81840 tggcaagcca tgaaagttca aatggctagt atagccttt gggaaggaac gcttgacctt 81900 gcttcaggaa accagtaaa tctatcagat tcgttatata actatgattt tattgacgta 81960 gtatattgga ctagaagttc tggacataat gcaactagaa gattccctgc tactacatct 82020 agtattgtaa ttagagactt taacttagta atgatggct ctattctag cgtagatttc 82080 tttgaaggat attgtgacat tactgataag aaacgtca ctgctaaaat gtcaaaaca 82140 attackacctag atggaatag aaataccaca acagtcgcac attcaatca aacaggtcac 82200 attgaagtac windowagtaat agggttaca tatttag agaagggtt tattagatga 82260 taaagtaga cattggtaa gacgaaattg tgttacactt aaagaataat aatatatta 82320 tgggatatac tattgtaggt ggatatgaag agaacaatgg tgatgtaaaa gtatcaaggt 82380 ctattctacc tgatggattc ttgttgatt ttgttagtaa tagtatgcg tattataga 82440 acactaacga agatatatat aaaaagct ttgagata ctcgaagagt gtagaggata 82500 taggaatacca accaccagaa gagtttgtac ctaagaga ctacaaaaa ttagagagtg 82560 aagtagagga actaaaaga atgttacaag attgttatc taagaagga taatagtat 82620 ggcactaaat tttacaccta ttacggaaaa cagtacaata gcagacctaa caacaagt 82680 taatacata ggtagtgtat taactgagga tagaataatc tttgagtaa ctacagactt 82740 ashaattagg gtaagtaag spider aactaag aactaag attagcta 82800 agatagat tattaccatt acttaagaga cattaaaaaa gtaggtttat attacatagg 82860 agcacgtaca ttggctacta tgtatgataa accagatatg gaaaatag atgtattact 82920 gcaagtatta acattagata ctgaggatag agtaataca atattgtata cattgtcaac 82980 ggaggacagt aaatcaaag tgatgcaccg attcgttact aactaccaaa catcacaatg 83040 gcaagtagta caagtttac ctaataata atacatca catataggtg gaagtcctttt 83100 tgatattaat acacaagta catattacgt gtctaatg tcggatatgc ctagtggtgt 83160 ttcttacag ttccataga cagtaatgat atagaatgt windows 83220 ggatagtaac acgggaaaag atatcttta tgttaagaaa tcgtatgaca attggggtga 83280 ttggagaact gatttagacg tacaagat aagcaagtat cttgtatcta atgtaaatgg 83340 agatgcggaa aacaatatt actcattatc cgtatataca tcagacaata taacattcca 83400 acagctata gctaacata tgagaac aagtaaaact gttttactt tctatataca 83460 aggtggtgtt tcaggctctc cgtctacggt tagttgcaga gtatatta tatcagactc 83520 aaacaactat actaatttat atggtgtata taccgcaata ggtactgacg gtagaactat 83580 taatggttcc gtaaatgta atacatggaa cacaaaaaacattaccctg gttttaaga 83640 actatggaat ggagcacata actttaaga tacaataa aagaaacta tgtctgattc 83700 tatactaac taccatacg tagagatata cacagatac agagccttac aaaacacaaa 83760 aggtacggat aaaacaggta ctttatgtca taagttttat atagatggag atggttatta 83820 cacatgttca ggagcttatg tatcaggaga ctctaatatt ggagtagagt actacgagt 83880 aactttatct attactggtg atacatggac aattaagat agtgcagtaa atataataa 83940 agaccaatat gttacacgtg ttgtaggtat ctctttacca tagactagga taattcctag 84000 tcttttttt ttcttgacta actttaataa atatgtaag atataaagg actaaaaga 84060 aaggaata tatgcagtta agacacaga atatatatac attagtagat tttgaaa 84120 gtgacgggta tattaagat atcatactta agcgtgttca taaaacgtta ggagctaaga 84180 aagagggcta tcacatagc ttagcttta aacgaggtgt gtgggatggt tatgtggatt 84240 tctacgatta tgctgagaac aaattcccta gcggggttgtt acctagatg atacattac 84300 taggtgagtt acaatcaaga cataactttc aatacgaaat tattgatgaa aaatctgaaa 84360 gctttttagc tgaagaagat attgatgatg aaatacaact actagataat aacgtaggta 84420 agattacatt acgtgactat agaatgaag ctgtgtttaa tagtcttgtc aattataatg 84480 gtatatgcaa gcaagctacc aatgcaggta aattttgccc cttatagtag aaatattata 84540 agtgtaactc ctttaattca tgggaactct ctcatttgag acaatcatga gccaagctta 84600 ataaattact aggaaggtgc aacgactatt atgtacaatc aagtgattgg aaacagggag 84660 aacctaagtc tcattagata tggttaagat atagtctgaa ctttgtagga gactacaaga 84720 aggttaggag taacgaacct aatcgtaaca taattgaaaa cagaggttgc tagcggtatc 84780 atagaccaac tattaccaca actagaaaaa ggagagcgtg tagcttttt tacaagttct 84840 actgagattt ttaatcaatc tgctgaccgt ttaagtgaac gattgaatat accagtaggt 84900 aaagtaggtt ctggtaagtt tgatgttaaa caagtaactg tagttatgat tcctactgtt 84960 aactctaact taaaagaccc tacagaagga gtaaaagtat ctgctaaagt aaacttaagt 85020 aaaagatag ctaaagagat acttcctaaa tttgaggtg gtaaaaatca aaaaaggtta 85080 cttaagttat tattagaag tacacacct aaactaaag taggagagaa tgtgcttgat 85140 atactcaag atattca taattcaag acggatgctg agtattaat ggcattaac 85200 aatcataatg ttattttcca aaagaagta agaaaaaa atcaaagag ctatgataaa 85260 tatcataaaa tgcgtgagtt cctagactct atagctgtaa tgagttga tgagcacat 85320 cacagtaaat cagattcatg gtatacaagt ttaatgtcct gtgagaatgc actatacagg 85380 atagcactaa caggctccat agacatgaaa gatgagctac tatggatgcg tatgcaagca 85440 ttattcggag atattattgt agaacatct atgagtttt taatcgagaa tggctattca 85500 gctagaccta cataaatat tatccctatt gctaaccctg atgatataga taatattag 85560 gattacagggg atgcatataa taaggtatt gtacataacg agtttagaa taaacttatt 85620 gcaaactaa cagctaagtg gtataatcaa cataagcta cgcttatta tattatttt 85680 gttgagcatg gtgaaatact atccactatg ttgaatgaaa tgggtgtaga gatttcttt 85740 ttacatggtg aaatagagtc ggatatgcgt aaaaaagt tagat gcgtaatggt 85800 aaacttaaag ttatgattgc tacaagcctt attgatgagg gtgttgatat cagtggtatt 85860 cgttcattaa tcctaggtgc aggtggtaaa tcttacgac aacactaca acgtgtaggt 85920 cgtgcgttac gtaaaaga agagaat acacaga tattgattt tatgacatg 85980 acacataagt ttttatataa acattctaat gaacgtagaa aaatatatga agaagaaaaa 86040 tttgaatta aagattagg aaagtaggta tgagtagtga ctagacaga aagatta 86100 tatgattaca ttgaaaaaaa atcaaaaat atacttatc aaatagctac taaaaaagag 86160 ttagcagaag aactagatgt ctcagtctct actttacta aaaaccttaa agattagag 86220 caggataaca aattaatgt tgtctctaaa agaggaata aaggtggtat tgttatatca 86280 ctagtaagag attatgatac agatagtctc ttacatttta atgacacaa tgataatgtt 86340 attactcta atctgaata cgctactgaa ttacgaata gatttttcc tagctacgta 86400 tatgaaagaa aagaaaataa acgtagaaca aaattagaaa tggttcaata taatgctagt 86460 aaagataaaa acaggaaaat aatatcagat atgaattttt samaaagtag cttaccttac 86520 cctactaaag atatttttaa tatgtcttat gaccctgagg gtttttataa agcttatatc 86580 ttatgtaagt tatatgacca atatgctata gcacacatga atgctaaata tatacaacat 86640 ttaacattat caaatggtaa tgaagacgta gatagacata agcatttatc tgagtactac 86700 agaaagaaaa tgttacagaa tttatcacga gatagtattt gtaaagactt ctttggtagt 86760 aagacattta atacattcta caacttttac ttaaagataa aagataagaa cattaatgtt 86820 tttaaataca tgcaaaatgt ttttaagaat accacatttg ggtttgagaa taaaacacaa 86880 ccttacccta tacctgcacc aaattttttt agttccgata aatacttaac taattatgaa 86940 aattatgtaa aaggtattaa acgaggtgta aataaaacaa atagacaaat tgggggaagta 87000 gagtctttaa ttaagtcatc tgattactta ttaaatcctg ctgtagcaca attacatcaa 87060 ctatatacaa caccttaaa tgagagata catgatattg atacaatgtt taaaacagct 87120 ttagatatag agatactat tattgtata tttaatggca tgaacatat tatacttta 87180 tcatatatata atatataga acatctata gaaaaattac ctagtaaca taaaaactta 87240 ttaataat ttattaaca atgtattgta atgagtatt cacctactac atacctac 87300 aatgctagac tatctatgtt tttaatgca aaagagtata aagcaatat cgcagaatta 87360 aatggtggta tagatagaag agacttaata gatataagtt tagtaacac tacagactta 87420 agtaacag atttgtaaa tagaaaaaacaa attctaca tatgaga 87480 tttactcaa catcatatat tctacaaatg tagtatt atttaggata tgaggtaat 87540 87600 aaagaggta tgatagaata caataggtt attgatatag aaaggatga cacatatgag 87660 taaacgaatt aaggatta tcctacataa gtctatgaag gatatacatt ttgcaagaga 87720 agtactagat aagttaccta aaagtctatt tgctacagaa tcagagaca tgggttactt 87780 attcacagct aaaaagaa cagcacacat tgctgataaa atgtcaaacg atctttagc 87840 tattagatta gagaatta tggtagtga windows gatgaaaag window 87900 atttaaatat ttagatagtt tatatacagt agacatgaat aaaagacg attctgtaaa 87960 ctatgaagta gaaaaata ttaaaacaga atgtctaaa gaagtattag ttagttcat 88020 agctgagaat aagcaagagg actcagataa cttacctgaa ctagtagaga actaaaca 88080 atagaagtt agtgacatta atggtactga tggtgaattt attgatttct ttgaagatat 88140 agacaagaag agagaactat taagtactt agtattaat aaatattcta caggttttcca 88200 ttctatagac cacaattg aaggtggtat tggtagagggg gaagtaggac tagttattgc 88260 acctacaggt agaggtaagt ctcttatggc aagtaattta ggtaagaact atgttaaaca 88320 aggtttaaat gttttatata ttgccctaga ggaaagatg gatagaatgg tattaagagc 88380 ggaacaaaa atggtaggtg tacaaagaa tcattactt atggtgact tatctttaaa 88440 cacagatgct tataaga tacagaca ctataaaag atagacaac tgctaggtaa 88500 cttttatatc gttaaacata tgcctggtga ggtaacacca aaccaattag aacaattat 88560 attataca ashattaga agataagca tatagatgtt gttattattg attacctaa 88620 acttatgcgt aacccttacc ttaagtatca aagtgaatca gatgctggtg gtcgtatctt 88680 tgagatatt cgaaattat spicaata caatttgtt tgttggacat tagcacaac 88740 aaacagaaca gcttatggtt cagaattat tacaagtgaa catgttgagg gaagtagaa 88800 gattgtcaat gctgtagagg ttgcttttgc cgttaaccaa aagatgaag aatttaaaaa 88860 tggtttttta agatgtact tagacaagt aagaaacagt tcaacag gtgagagatt 88920 tgttaatctt aagtagagc ctactaaaat ggttgttaga gatgaacac cagaagaggc 88980 agagaacat agcaatac tagcggact tgtgtgaa gataaagta gattaag 89040 aaaacctaat aaagctgaag ctattaataa ttctttgga gggctgagtt tttaatggat 89100 gactttacta agctttataa aaagtacgt agacattta cacgtataata agcagaatgg 89160 gattataca atacaggatt aagaaccttc cattaaaag gaactaatgt atgtgttaca 89220 ttactagact ctatagcaag gatataca acagatata agtacaacgt tatgtctaat 89280 aaagtaccttg ctataccttg caatacacat caagaagtaa ttaaagcaat tgaataag 89340 ttaaaaaatt gagaaaaagc ctgacaatg tattgtta ggattatact tttattata 89400 acaataaga ggtggtaga tttgaactta atgaagcaa agtaaaattt aaaaaacttt 89460 aaagtcattg tagtgaggga gatatagtat ttgatggttt catgggtagt ggtaccactg 89520 ctattgcctg tatgaatact atagaaattt ataggtttt tgattagat gagaatact 89580 attaatttagc cagtgaaaga atagaaaaac attaaaacat gaaaatgaca 89640 tacgac tacgata cactgaattt tactacg tacgatac 89700 gcaatggata tccttgaaga tatattaga ggagagcctt accagatga ggtatgtgaa 89760 ttgatacatt tttattcaag taagctacta atgagatta atgacaatca tatgtttaaa 89820 ttacaggagt ttgctaatca tgatgttata ggaattagtg aagagggt aaataatga 89880 taaaattatt acaggggt tgcctagagt cactagatac agttgagat atagtagtcg 89940 atgctattgt aacagaccct ccatataaca ttgcaaaga gaacaggttc acactatgg 90000 gtagagctgg tattgattt ggggaatggg aaaaattt tgaagctact tttaggatta 90060 aaagatat accaaagtt aaaaaaggtg gtatatcgt tgtgttttgt gatagagac 90120 aatttacacc tattattgat actaggaag cattaggctg tgaatttaaa gatgttatac 90180 gtatggaaaa atctaatcct atgcctcgta atagagatag acgatttatt tttgatactg 90240 aatttgctct ttatttgtt aaaaaggag ctaaatggac ttttaaccgt ttagatgaa 90300 atatgaaag accttgtatt aaaaacaagtg taacacctag aagtgaaaaa ttaggtaag 90360 gabacccaac acagaaacct ttatatgcta tggaatggtt gttagagcgc ttaactaatg 90420 aaggagacat tgttctagac tgctcatgg gaagcggaac aacaggtgtc gcatgtaaaa 90480 agttaaatag gatttttatt ggttgtgaat tatcagaga attacktcagt atggcacaag 90540 atagattact aaataataca aattaaaca aaacccttga cacatgttt gttaagggtt 90600 atacttttat cataacgtac taaggagga cactaatgaa atttatattt tttacagata 90660 gccattttca tatgtttacg aattatagta aacctgatga agatatggt atgatagat 90720 ttaagaaca attgagaca tthaaaag tattttgatt agctagagaa ataaagcta 90780 aagttatatt tggggtgat ttgtaccaca aacgtaatgc agttgatact agggtatata 90840 aaagtgtt tgaaacattt gctaataatc aagatattca agtttacatg gtacgtggaa 90900 atcatgatgc tatttcaaat agtttgtata ctcaatctag tattgacatt tttgaaacgt 90960 tacctaatgt tgagttact aagtctttgc gtagtgaatc attaagttca aaagtacagt 91020 taactatgtg tgcatatggt gatgaggtac aggaattaa agactttatt agtaagtcat 91080 atgttaaga tagtaat attttagtag cacacttagg cgtagagaat agtttacag 91140 gtaaaggctc ccatagatta gaaggtgcat ttggttacca agacttatta ccagaacaat 91200 atgattttat tcttcttgga cattatcata gacgccaata tctaacaat aatcctaacc atatgtatgg tggttcttta atgcaacaat ccttttcaga tgaacaagaa gctaacggcg 91380. 91380. 91380. 91380. 91380 ttattacagt acaaggtgac aatgtaccag fathercatga tgatttagta aaccaaggtc actttattag gtttattggt actccagaac aagctaaagt aattgaatta gataaaacag aagatgaatc taatgtacaa gtacaaatga aagaatga cacagtaga aagagagtcg acgctgacgt gtctgacagc cctataacga ttacttctag ttatgcagac aaatactatc cagaagcaaa agatgagctt ctagagtgtt taaaggcggt gttgtagtat gatagatatt attachment attachment attachment aatctaac ctattttaca gttcttacat aataaaagaa catatgatgt atgtaatgtt aaaaatattg atgatgcgat gtaccttatt aacaaagtat tagaggagc taactacgct cattatta cgagggttat tgaacaagaa gattgttata ttctagatta tggttcacat caatgtttct ttaaattgtt aaaaagaaggt ggtacaaatg gttaagttta attatgtaga gatgaataac ttttagcta ttgagcatat 91980 caagctaaat ctggataagc aaggtcttgt acttattgaa ggtattaata aaaacaatga 92040 tagttttgaa agtaatgaa caagtaaac aagcatgata tcctctatca catatgcact 92100 gttcggaaag actgagaaag gtttaaggc agatgatgtt gttaataagt attagaagaa 92160 agacacctac gttaagcttt ctttcacat aggtaagac gagtatttaa tcgaaagata 92220 tcgtaacac aaggaacaca agaaaggt taagctgttt tgtaataca aagagataac 92280 aggctctaca aatgatgtta cggatactca atacaagag ttttgta ttccttttaa 92340 tacatatgta aatgctatta tatatgggca aggtgacatc cctatgtttt cacaagctac 92400 cgacaaggt aaaaaaaaa tattagaatc tattactag actgatattt ataacaagc 92460 ccaaaaaaaaaaaaaaaaaaaaca 92520 agaatagaaaactagaat aaaaaaaaaaaaaaaaaaata aatgaagt 92580 aaaataat ataacttat tagaggta gagcagaa gaggacagt ttchaaaa 92640 gaaacagag tacgagaata attaaaga tttagacaat cagattggtg ttgtaagg 92700 tagtattcct aaagttgaag actttgaatt tgtattgt gaaaattata caaagctaa 92760 ccaaggtatt gaaagatta acacaata tatgataa ttattgccat tattgagtca 92820 agaaacaaaatagaata caactctaa tatattaat cattaaaac atctattaa 92880 taaactagat acaatgacc attgtcctgt tgtggttct cctatagata atacacaca 92940 aaaaagaaaaaaaact tagaattaca aaaaaaaaaaacaaaattactca 93000 gtacgaacat atgagcagg ctatatta taagaagaa gagtactag ctaatctaa 93060 agaattaca cattatac agcagaga tagaaaag aaaaaacatg atgatgat 93120 tcaacggcaa acaacagcaat acaaccaat acaacacac 93180 taaagctaat ttaaaagac catattaaa tgattactct tatatagaag aacctaatga 93240 agaattacac aaagaac windowagat tgacatact attgashaac attagaaaa 93300 atagtaaa tagaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaachaaa 93360 taaaggatta cgttctgtaa tattagactt tattacaccg ttcttaatg agaagctaa 93420 tgagtattta caatattag cggggttcgga tatcgaattt gatttcaa cacaagtaga 93480 aatgctaag ggagaactta aagataagtt cgatgttatt gttaagaata acatggagg 93540 agagtcttac aaatctatt cagcaggaga gcaaaacgt attgacctag ctattagtttt 93600 tgctatccaa gactttatta tgagtaaga agatatatct acaatag ccctttacga 93660 tgaatgcttt gatggtctag acactattgg ttgtgagac gtagttaaac tactaaaga 93720 tagactaaaa acagtaggta ctatttttgt tattactcat ataagagtc tagcaccttt 93780 atttgagaat acattacgg tgtaaaga aaacggtgta gctacactaa gaaggaatt 93840 aaataatgaa actaagatt aagaatacc agttttgcatc ttacagta aattataca 93900 acatgcaaa gttacatata gataattc ctgtttctac tttagtagac tggtaccct 93960 taagtaatgc atacgagtat aaagctagta atgactttgg atatattga ctaaagagat 94020 tacgctctag cttacctgtg tcttatgggt taactcacca aaccttatat aaatgtgaaa 94080 ctgttaaatg taattagga ttatgtata acgaaaaat aaagagat aatgagaaaa 94140 ttattgagaa agctaagttg tacggtttac ctactataga tgaacccttc acagtaag 94200 atgtaagca aggatttagt gacttaggtg ttattttcca aacactaaaa acatcagta 94260 wind cttgaagat aaaaacattg gagatta windstorm aagaatcag 94320 aggattca attaaatgaa gtactcaagt acagtacaac actggtagat gatacttata 94380 gtgatttaag tcaatctat atatgttac tattaatgaa gaaattgtt tctatatagg 94440 aagtgactga aaatgaggtt tgaagacttt tagtcaag agatggac accaagag 94500 atactgtag gagaattacg atattgttgt cctttttgtg gagacagaa atacaagtttt 94560 tatgttaagc agtctttaga ctctactaat ggtatgtatc attgtaagaa gtgtggagaa 94620 catggtaatc ctattacttt tatgaatct tattatagta ttacaggtag acagctttt 94680 gagttattag aaaaagaa tattgatta caatctcac gagttattag atattaac 94740 acagattaa ctgacagtga gaactatta ctaggctta atggatatac aaagataat 94800 agtagtataa atcaaagc acctgaacta cctataggggt tttaattgat windows 94860 ttaataata agatagt accgtattta agatactctca agatagagg tattacacta 94920 cagcaaatcc tagactatag tataggtat attaaatg gttattgcta ttcttatggt 94980 attaatg agaaaagaa atagtactt agaatagtg tattatttt tacttatgat 95040 aatgaaggta agtatatta ctggaataca agaagtattg aaaaaatcc atatattaa 95100 tcttaaatg caccttctaa acctaatgag tatgtaaaa gcgatgttat atttaattta 95160 atatagcta gtaaacaaaa gtttgttgtt atactgagg gtgtttttga cgcccttaca 95220 tttgataagt acggtatagc tacgttttggt aaacaagtttt caagataca agttaatac 95280 ctcatttcaa gtattcctaa agaacacct atatatatta tgttagacac agacgctaca 95340 gactttagta ttaatttagc tatagctt atctcacatt tcaatgtagt gtattagta 95400 ccacatggta atgagatgc taatgatatg ggtatggaa aagctttag tactttgaa 95460 cacaatagat ttttagttac acctgaaagt attcaagtt acagttaca aaaagtta 95520 aaactttaat cttgcattat atgtatagt atgttacaat acatatata aaaaagga 95580 agtgttattt tggagagaa agatattcta cattttgtag atgagtatgt tacagcatta 95640 cgtgtaggta atgacagcg tatgcaccaa ttagagagt taggtaag acaacagca 95700 actttaacag atgtaatgaa gctattact aacttattgt taggtgtta taaacaatg 95760 gttgacctag agcaaatac agagttaac ttaacattc taattgatgc ttatacaaa 95820 gctgagttag ttaacgatga cgtattaaaa tattattgagg aagcaattga agaatcaaa 95880 gaaaaggg aagaataatg gaaaaaaata ttagtacaca tacaaaggt atttcacaaa 95940 aagatatgga catgtggtta gaagctatta cacaggaac agtagaggc aaggatta 96000 ctgaggacac tgctaaacaa ttacatcgta ttggagcacg tagtgtatca ttagatgagg 96060 ctactagaat tgcacgagca attaatgccg ttacagttca agagtatgca tctgccttta 96120 atgatgcttt taatgctatt gatttgttaa tgatgtta ggaagataac ctagatgtaa 96180 ctactgagca agtagagaag gcgcaactta aattaaaga aaacgtgaa agtattag 96240 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaagg 96300 aaaagtagt gcagttgag aaacatgaca atagtaaa aaaaggtga tgtattcgaa 96360 agaaagattg ccaagaact ttctgattg tggtttc cttttag gtctccacaa 96420 tcaggaggtg catcatgggg agctacaat aatgctgtcg gtgacattgt agcaccttta 96480 gagtctaatt ttccattagt tgtagagtgt aacatagag aaaattggat tatggataat 96540 gttctactta ataataaga acctcataca tggtgggaac aagttatagg agatagtttg 96600 caagttaata aaactccttg ttatatattt acaagaata gagcacagtc atatgtagca 96660 ttaccttata taggagatgt atatgttaag ttaagagatg aagaataccc tattatgaga 96720 acggatttta ttgtagaaaa tgttagaaaa gataaacatt tttatgatgt tcttataact 96780 acgataggtg ggttgactaa cttaacacct tcttatatta tatctgcta caaaaaaa 96840 gagattaac catatagagt tgtcaagtct aaataatcta aagttagta aaagagat 96900 aagttgattg atgatttact tgatgtata taaggaaggg attackagttg attacacaa 96960 taaaaaaacg tgatggttcc gttgtagatt atgatttaag taaagttact aatgctattt 97020 taagagccaa ctcagaaaca gagaata ttgaagatgt tattgattct ctgtagatg 97080 acgtagactc tttactgaa gacagaca cttacattac tgtagatta atacagata 97140 tagtagaga agttttatt agtagtagt aaagatac tgctaaagct tttattt 97200 Aataggtaaaaaaaga gaggctaaa gagacttatt CAACCAAAAAAAAAAAAAAAAAAAAAAAAA 97260 aaccctatga ataccctgaa ttattagaat aaagatgc tatacgcca agttactggg 97320 tacacaccga gtttaactat acatcagata ttcaccta windows gttaactac 97380 atgagcaat gaccattaa aaagctatgc tagcaatgc ccaagtagaa gtagcagta 97440 agactttctg gggtgaccta tatcatagaa tgcctaaatg ggaaactgga gctgtgggtg 97500 caacttttag tgagagtgaa gcacgtcatg ccgacgctta ttcacattta ttagagattt 97560 taggtttgaa tgaggagttt aaaacaattg acgatattcc tgctcttaaa gaacgtgttg 97620 atgagttagc gatgcatgta aaactaagta agagtgagga tgatagagat tacgtactat 97680 ctgttttatt atttctata tttattgaac atgtatcttt atttagtcaa tttttaatta 97740 tgatgagttt taataaatat aaaaacttat ttagaggttt atcaaatgct attgaagcta 97800 catctaaaga agagcaaatc catggattat ttggaacaga aatcattaat attcttagag 97860 aagaaagacc tgagtggttc aacaaagaaa tggaagatgc agtttacaca gcctgtaaaa 97920 aatcttatga atcagaaaca cggttacttg attggatgta tgaagatggg gaactagagt 97980 tcttacctaa gaaagtagta caagaattta ttaaaaatag gcttaataac tctctagtag 98040 ctgttgggta tactaaactt tttgatgttg atgaagagtt actaagtgaa gtgtcatggt 98100 ttgatgatga agttattagt actaagttaa cggactttt atctaaacgt tctgtaaact 98160 atacaaaattt tagtattct gtaacggaag attackattt ttcaacggaa tctgattttg 98220 aaatactgg taaacgagtt actaagata aagtaaacgc tattttaga ctaaaaatga 98280 tataaaggca gtgtatatatag atgagtatt ttgaatggtt aaataatgat tctagagtttt 98340 ttctagaacg tggttatta agtgatggtg aaacaccaga aaagaatt aaagatattg 98400 cagattatgc tgaagatatt ttagatattg atgggttttc tgacaagtttt tatgattata 98460 tgagtaagg ttattattcc ttatccagtc ctatatggtc taatttcgggg aagatagag 98520 gatttagtat tagttgtttt ggtagttggg tagatgatac tataccatcg atacttaata 98580 ctgctagtga agtaggtatg atgagtaaat acggtggtgg tacaagtggt tacttcggta 98640 acatcagacc tagaggctca gaatcactg ataatggtgt aacaagcggt tccgttcact 98700 tttgaagtt atttgagcaa atgacggaca aggatgtta gatgataaaa 98760 ctgaaatact cacagagaat gggtatgaat tattatctaa tgtagttagt agaaaagatg 98820 gaacaaaat tgcacaggta acagataatg atgaataga gtttgtagag cctacagatt 98880 atatggaatt tgtacctgaa gatatgaat tagttcattt tAAagatagt aaaatattg 98940 acttattagt gactagaac catatagttgg tttttaata cagaactaa aggactaa 99000 aaaaacagg aaaagagaa aggttttg tacctgagta tgaataga tgcagg 99060 attgccatt acatagagac gtttatttag cacattcttc atttgctaaa gaaggcagag 99120 gactcacatt taaagacgt cttttggtag ccttgcaagc agatgtagt attattaaaa 99180 ataccctaa atctttgaag tttagattta gtaagaacg taaaaagat agactattat 99240 ggatattaga tggtctagga gttgaataca catataatgt agacaagac ataatcata 99300 attattgt taatatggggt gagaattac ctaaagaattt tagtaatgg gtaatttac 99360 aaaatgtcac acaacaatgg gcttatgat ttattgatga gttgtctcat tgggatgcta 99420 gtagaagaac ggataaatca tttactaca tgagtgtggt tgaacataat gtagacattg 99480 ttcaagccat agctctatg gtaggttata aatctcgtaa atcagttgat ttaagggaaa 99540 gagaacctaa taaagccact atgtataaaa tatatctatc tgaggtca ttatttggag 99600 gctcaaatat tactgtggaa acggtacaat aaaggtaa agtatattgt gttgaagtac 99660 ctactcataa acttgttgta agagaaag ggcatacatt agtttgtggt aattctacac 99720 gcagaggggcg tttagccct tatctaccta tagacaca agatattgac gagttttttag 99780 agattggtac cgaaggtaat ccaattcaa acttacaca tgcagtaca gttactgatg 99840 attggttatt agacatgatt aatgggaca aagaaagag aaaaatatgg gctaaagtat 99900 taacagaag aacaata ggatacctt atatctctt tcatgataat gcaatagta 99960 atacagtaga tgtataataa gataagggt taactattaa taactcaat ttgtgtaaaa 100020 atttgcacct ttagtaagta attackatcg aaaaatccat ctaaacggtg atatctaag 100080 ttaaaatata cgacaacacc gtgctaaatc agattataaa tctgtaaatg cctaacgact 100140 atccgtaacc tattcacata agtgaaggga taggttaga gccaagtggt atagtattg 100200 agtaataatc agtaatct tatttaatc gaatggtgg acttccttat taggagat 100260 gatatagtct gctctatatg gaacatata gaagttcata ttacaata tattaagg 100320 ggtcgaaaat ggagtaccat atttataaa ttacaaca aaacaataat aaaataca 100380 tcggaattac atcaaaaca gttcaacata gatttaaaaa tcattattaga aaagctaaga 100440 taggctcaac aactaattta caccaatcaa tgatgaaca tggtgagag atttttatg 100500 tagagaatt atacacttt agtacagagg aaaaagtt tgcttacatg gtagagcaaa 100560 tttttataga catgtacgaa tctgtaaaa aaggttataa tatggata ggttttggggt 100620 ggaatataat ggatagacga ggaaaaaaca atccgatgta tggtaagaa agcgctaatg 100680 ctaaaaaagt tattgttgat gggcgtagtttt aaaaatat gggtatatgc tctgaagagc 100740 taggaaaa cagaataca taggaaccaa gatgtaattc tgaaaaatttc cctaactata 100800 atattgtta attagagaac tggtagtgat aacgaccac tattgacat gtaggagtga 100860 aattatgtta cctaataaag aagattggtc atttgtatgt gacctatcta gtatgaacct 100920 tgttaagtat gatgaatgga aacacacgga tgctttagag acacttgttt actttttaga 100980 tgctgtttatg tctgagttta ttagagactt agaatatcta agaactcag ctgaaaaaga 101040 taaacaagaa gcatttaaat ttatggagag agcttataac tttctgttg agaacagagc 101100 cttaggaata ggcgttcttg gatatcattc atacttacaa tcaaaactca taccttttga 101160 aagtattaaa gctagtcaaa ttaatgaaga gatatttaaa ttattaaaaag aaaaaactta 101220 taaagctagt gagcagttag ctaaacttta tggagagcct tctattttaa aaggttatgg 101280 tagaagaaat tcatgtttga tggcggtagc accttaattt atagggcgta tatggattaa 101340 catatatgat aacactcttg aatttctgaa aagcctaagt gtgtaaacat aaggtaatca 101400 gaagctaaga tttatttata gctaacttga caaaaaacaaa tatatacatt atactagtta 101460 ctaagaggtg samaaaaatg tggaaaaata gtattagttt tcctaggctc gaagtaacta 101520 aggatgaag agtaagatg tggaataat catggaaag atatgtaga aaagacata 101580 ggtatgataa agatggttac tcaataattt ctacaagaaa agagatggt acatccacat 101640 cagcaagagt tcatagatta gtagcagag cgtatatacc aaacccatac ataaacctg 101700 ttgtaaatca taagaatgggg atttaagatg attaagggt tgaaattta gatggggcta 101760 ctatatcaga aaatactaaa catggttatg atgttttagg tgttaaacac gctaacgctc 101820 aactaatttt agtctactta gatggcaaac ctttcttag ttatgactcc tttaactttaa 101880 tgggtaaaac attaggtata atagaaatc ttatacgtag agtagaaaaa gaactgatg 101940 ggtacatctc atttaatgg atagaaaaac catataaagt acacataa gatttttgga 102000 aaacatcaag aaatttaat acgagaggct cttgttatgt tgtaataat gtatactata 102060 atagtgcaa gaagctatg gaggctctta aagtaagaca agatgttttc tataatagac 102120 ttaaaaaga taaaaatgta tatagtgtaa gtattaaga gtacttaaa aactgtcaag 102180 ataataag ataagttca acgactatcc tgttgcgggg agtacactca agtgagtgga 102240 agtgggagtg gtcttacatt tagtagatg tgatatagtc tgctctat ggaacatag 102300 agctgttatt aaattaacgc atgtaagta acgaactaca tggaacata aggacaaca 102360 gttcgtcatt tatcctaggt caagttttcta atcaattga acctttg agtaattatt 102420 acgttgtaga cactgctaaa gtaagaaaa ctagattaa tccttacctt aaagactat 102480 taaaaaaaaaaaaaaaaaaaag ttattgagg tattagggac atgatggtt 102540 ccgtacaaca cctaactttc ttaagtgatt atgaaaaga agtatttaaa acatagtg 102600 aaattaatca atatatata ttagaccaag cttctacaag aaaaata attgaccaag 102660 gatactat aacattatg attackacccta aacatgttac agcagaggag tttaatgaac 102720 tttatctctt tgcatggtct aatgtatta agtcattgta ttcacat ggtacaaatg 102780 catcacaaca attcaattta tctaaaattt gtattaattg tgaagcctaa agaggtgact 102840 aaatgaata aaagaagcg ttggattac taagtagaac tgagatata ttcaatca 102900 atgatatttt ctcacaagta agtaatgtac aagaccctat taagatttt atagggag 102960 agatcagta aggagatagt aaatcaagta aatttcagct agagtttatt tatatacat 103020 atgtgtacat tcttatatat gaagtacat taagctatt taagctgat ggtacggagc 103080 agttaacaca tgtagctgat attgaaacat ttaagat tattgacaca ctagaaaagg 103140 multiply aatgaaaa attacagt tctacaac attacaac 103200 aaagaagatg ttattgtcat ggttacacaa gatgagtgtg ctaaatgtga aattttaaaa 103260 agtgtgattc ctctttcga agcagaagga gatattacta aacctgttta tgttattac 103320 ttagatgata aagatgtaga tagagaaaa gcggtcaagt tatttgacat tatgagtaca 103380 cctgtactta ttggttataa agatggggaa cttgctaaga agttcgaaga ccagtaca 103440 cctaaaaact tatggatt agatttactt taatttgta tacctacta cttatgctat 103500 acttatatta gtaaaaggta gtaggttttt tcatgaaagg atgaatagtt atcgcaaaaa 103560 ataagacatt aactatatat aatagtgata gatatttata tatacatgta aaaaacaaag 103620 atgaattatc taaagctatt aaagttacaa ctttaaatga agatgatata gaaaaagata 103680 tggatatctt agctaataaa tcaactaggt atatactaag agacaataaa cattacatgc 103740 tatttaatga gaagtataac aatgataagt tgattgaaaa aatatgtaag catggtggac 103800 aagtaacata ctataccgat tcagtagttc cttactatgt gcttaaagac ttatcagccc 103860 accctaaatc ctcagttgta tacagaatgc gtagtaaatt caatagcaaa gagatggata 103920 atatagcctt gagtttcatg ggaacaaaag tcattattga tatttcagtt gtatttcctt 103980 acgtcaatcc ttacgatatt attagaagtt tatatgatgt taaaacaaat gtagacgagg 104040 ttcatctatc attccctcgt attagttcta tagacgctaa acaaggtaag tactatacgt 104100 atgataaaga agcttataaa ctaaatcctg agtatacact tgattttgca gataaattaa 104160 gagtttcttt gtccgtgtgg aaaatgtata tctatattct tgctagtaaa gaaaataaag 104220 attatgaaat aatagaagac ctacttactg aattaaaaag acaaagaaag attaagattt 104280 aggtgatttt gtgagtacag caatagaag agatatagca agaaagatat ctgagagtac 104340 agggtactat atccaagacg tagaagagat actagaagca gaaacaaaag ctatttctga 104400 attgttactt gaagattatg ataaggtaaa gaatcataag tactttcaaa tagaagtagt 104460 agagcgtaaa ggtaaaaaag catgggatgg actaaataaa acatacttca ctttacctaa 104520 tagaaaggca ctaaagttta aacctttgtc tgaattagat aaagttatag atgtattaaa 104580 caaagaggat taagttcctc tttttttat tgactactat gattagatat gctatactgt 104640 atttaagtta aagaagggat tggtaataac atgaaagtttt taattttata cgactatatc 104700 agagaggaac acttttcagt tagtaatgat ggtagtgtta agaatgtact actaaataca 104760 cctaatggta gagtattaaa acaactatta tctaatattt ctggtattaa tcgagataga 104820 agtacaaag attatgatat tgagttttta tatcctatgg tgcctacacc tattaagaat 104880 aattatggta aaacattaa gtaccagac gttaagttat ctgaagttaa accttactat 104940 aagtacgata ttattattcc tttaggtag 105000 ctaggggtta atatttatt aaatgtatca gctattggta aagttagagg tgtacctaat 105060 aaagtaacta tactagtga agataaaaaa catgatgtttt gggtattacc tacttagc 105120 atagagtaca caacgttaa windows gagcgtcatg tagtag ccttaagtta 105180 ttaggtagt ttgtagaca aggtgagac gtatttaaac ctaagaagt tagtaga 105240 cttgttacaa gtattgagcg tgtagagaa attattaata aagagtaaa gatgataat 105300 catgacggtg tagacattac cgcatgggat ttagaaacta actcacttag tcctgataga 105360 gaaggaagta aacccttagt attatcaatg agttgggaaa atggtcagg tgttacaata 105420 cctttatata atcagactt tacttgggag aatggacaac aagatattga tgaaatttctt 105480 tccttaactaa aagaatgggt agctagcaaa gaagacatta aggtactaca taatgctact 105540 tatgatataa attttctaat gacaacacaa ggtttcacag actttgaaaa taatcaagac 105600 actaaggtag gttggtattt agctgtaaca caagaacaag cagagtctct aagattatca 105660 gaccttgctt acgaagtaac agatgtagga ggatatgaca aaccccttga agattttaaa 105720 gagtggtatg tattgaagct actaagattc ttatcagata aactaaaaga gattaaaaaa 105780 gaaataaaaa aagttgttaa gaaagaatat aacataaaag caaatgagta tgatacttgg 105840 ttgaaaaata aactcgataa cattgatata gaactaacag atgaagaataa gtattatggt 105900 atcacagaag agcaaaaaag atatttagag ttaaaactaa cacctgaggt tattacaaag 105960 aatatgctta tggattctga atttaaagaa gtagccgaat catcacctga gtatatgagt 106020 ttatctaaca aagctaaaga ttatgtatta ggtacatcta ttaatttaat taacacgtat 106080 aaagacaata ctaaagttat taatgaggta gatggaggtg actttaatta tgattggatt 106140 ccattagagc ttatgcatcc ttatgccagt ggtgacaccg atgtctgtag aagaatatac 106200 tgtgatgtta ttgaaaagtt aaaagaacaa aatagaccta aagcattgga cttaatgtca 106260 ataagttacc ctagattaat tagaacatta gctagaatac aatcaaatgg tttacattgt 106320 gacctagaat acatgcataa aaatgatgaa tttatatta atgagatgga aaaaacccac 106380 caagaaatta gagaacattg ggctatccaa gaatttgagg agactaggta taatttatac 106440 caattagcct tagcagaaca tgagaagaaa ccatctgata gaaataaaaga aatacatgag 106500 tatagagcta aatttaaaga tgaaggttgg aagtttaaac caagctcagg tgaccataaa 106560 ggtgaagtat tgtatagcat tttaggtata cagttacctt atagtaaaga gacagttaag 106620 gataaacctt tcagtaatgg tactaaagaa gatgagttat catggaaaga ttacaaaaca 106680 gatactaagt ctataaagat ggcattatct ttggttgaga atgaagaataa taaaaagcta 106740 ctagacttac ttatttatta tgcctctttg caaactaaaa gaaattcttt tactaagaaa 106800 ttacctaaa gagtaaata gatacacat atttacatg gtactaa tagtacagga 106860 actgcatgta ttacaggtga ttcttgtt attactgata aaggtataaaaaaaayaa 106920 gacttatca attatagaaa agaaaaagta tttagtagttgatgtagg tattgttaat 106980 agacagggaa atttagaaaa agctcacac ttttatta gtggtgtaag aaatggatta 107040 aagattactt tagagatgg tactacatta actactactt taaaccaccc cttattacga 107100 aaattatt atagtaatac tggtaggggtt ctaataaaaaaaaac aactaagcat 107160 ttactagata atgattgggt tgtagctgaa gatttaaaaa taggtgatta tataaaaatg 107220 tcttataatt ctaatcttta taatatagt tattatgat tagatacta agattttata 107280 tatagtaag aaaaagtat tacaacaca aaagctata cactacctaa ttgtatct 107340 gaagattttg ctgaatggta cggtatgtat acagctgatg ggtctttttc tacaataac 107400 ggttcattca gtataagatt aactaatagt aatcttgag ttaggatag attctttaac 107460 ctaactaag atttattga tattacacca tactacatta gtaataaga tagattgat 107520 tctattgaat ttcttcaat tggtttaggt agatgttag aacatatttt taatatgcaa 107580 agtaagcat taaataaga atccccaca aaattag atagccctaa aagtgtaca 107640 caagcatttc ttaagggtttt aagtttagat actgcaacag aaagaaaaa gtatcctagt 107700 ttgtactata atactgtatc tataaaatg gctttacaa windows gctaatgaat 107760 atgggtatct attgtaggta ttctataggt aaagtttata aaatattaa tagaaagta 107820 aaatgaat gctattctat acaatact tatgatgcat tagaattt ttacgatgaa 107880 ataggtttta ttgagagtat taagcgtgat agagtaagt aatcaga aaatctaaag 107940 gcattaggca gagaaacgg tattcttta tatgataatg ttttagg taaaataag 108000 aaaattgaaa aaaaaaga tattggaattt ttgatttac atgttcctag tagccattca 108060 tttgtagcta ataatattgt aaatcataat actagcaggc tttctagtaa caaccctaac 108120 cttcagaatc ttcctgctca tacatctgat gtaaatagt ttgattca ccaccctatt 108180 aaacgttctt ttatctctag atttaaat ggtgtaattt tacaagccga ttacagtgcc 108240 ttagagatgc gtattacggc actatataca gatgataag aatgttaga gatgtttttta 108300 acaggacaag atattcataa aaatacggca agtattatgt atggtaaag tatgaggac 108360 gtaacagcag aagaagaca agccagtaaa gctgtagcct ttggtttaat ttacggttaa 108420 caaaatag ccgtagtaaa actaggtaaa cctattgagt atagggtgta tagttcacgt 108480 taggagctac aggaatggt agttagac tatgctaca gggaggctt taaatgcta 108540 atcctgtgta gatattta agtgtatttt aaagtaag gatgattta atagaattta 108600 aaataggaga agatataat cacaataagc tatattctaa attackcat gtatggtctc 108660 atatgataga taggattat atcctaat gtaggata taatattat ggattactag 108720 gaatacagt agacgataga tggcatattt tcttaggt gtagagttaa 108780 ttgatggttg gagtttagag aagtataaaaa atggtgagtt agtgttagat aaggatatta 108840 aagaactagg taataaagta tatagcttag ataaatgtaa atgggctact agaagaagaga 108900 acttaggatt tgtaccttca agaagtaaaa agatattagg tatagaccct acaggtaaag 108960 aatatacatt cttcaatcag tctaaatttg ctaaggaaca taacttaatt caaagccata 109020 tttctgcagt tcttagaggg gaaagaaaac atcataagaa ctgggttttt aaaacactac 109080 aagaataataa ttatcaacct gtagaaaacc cttctaaact ttatgcacct cactatgttg 109140 cttataagaa tcatgtggaa attgattatg atagagtaaa aactaagcta ctaaaagagac 109200 taaatatacc tacgtcaggc actaacttta gaaaaatgga aaccggtgaa gattgttatg 109260 ggattacatt caaaatagag aaaagagaac gatttgatta cacttaaaca cttaaattat 109320 tttatcgaac gactatcaaa aggtgagctt tacgccgaga gggcttattg caatataacc 109380 gagtagagta catgtagctc atacctacat ggaatagcct agaagtagat agtaacgtat 109440 ttacttaaga tatagtctag tcccctaata atacggga aaccgaggggt ataacggag 109500 tcagagtttt cgtttgcagg taaaaataat atgacagttg atgaagctac tgaaatatttt 109560 aaagtttt attctaataa acctgctatt aagagtcta tagatgaac tcatgagtttt 109620 gttcaaaaac atggatatgt agaaacaatg atggacaca gagatatat acactcagca 109680 caatctagag aaaaagat taaaaatgag ggtcttagac agtcctttta cacgattatt 109740 caagtacag gtggttacct tactacatg gctattactt atattgacga ctttattcaa 109800 aagaata tgaaatcgaa gttagtagct actgttcatg atagtattgt agtagactca 109860 cctcctgaag aagttaat tatggctaaa gttattgtcc atgtaatgga gaaccttcct 109920 tatgatttcc taaaaataa aattaatggt gagttaaggc agtacctat agatgctgat 109980 atagaatag ggctaacata tatgatatg gtagaataca acgagagtt aaaataa 110040 tttattcat aataaggata tattaat aaactagccct tacagcaat taaggactac 110100 tatgaatcag gtaaactac tgagagcag tachaaaaaacgaata tattaaaaat 110160 atattgaca gtttcaaagt tatatagtat agtaacctat atcatataa atagaggat 110220 ggtattatgg agatacattt agatacatta gatttcaatg agttaacctt aaagataac 110280 aatggaaaca cacagacttt tatatccat gatgaacta aacttagtga gtatacaatt 110340 caagacgaaa tgtaccaaca gtcgtctaaa tttgcatgt gggctctcctt aaagaacgt 110400 gtgagtaatt atgccgaagc agagcaacgt aagttagaa aaataggagc tcaacttaat 110460 ctacaaatta gagctcagta cgacaacag ggaagaaac ctacaaaga ccaagtagag 110520 tctgctgtat ttctttctga tgaatca cagcaagcaa aggttgtaga agcatggaat 110580 tatagagaaaaaattaca ttatatcgta aaagctttg aaacacgtac aactagtta 110640 gtacagatta gtgcggaact aagacaaaaaaaatg gtggtgttac taacccattt 110700 acacattagg tattgacaaaaaagaaa catgttatac taattaagta atttttaaaa 110760 taaaaggaga aagatatta tggatttta tcaatttatt atcagcaat cagaaagct 110820 acatcaagt ggttttgaca atgaggtaga gacgtacaa ccaagaatc cggttttgcg 110880 attaggaag atttaggacg tcaata tcaattaat aaagagtctg cacttgtacg 110940 tgtactaccg cctgtagcag gttctaatga gttctttaag gatttagaa cattaggtat 111000 taactatgtt aaaaagacg gggcacaaaa gttctctatg cttacttac ccgaagaagt 111060 taactcatct gttgtagacc cttatgtaaa tacatggtta aagcaggtg tacaatttag 111120 taacttccct aaaacctg cacgacgagc atattcat gttattgaat actttaatca 111180 aaatggtcaa ttagttccta acacagatga acaagtaat gttgttattc aacctatgga 111240 gctatctaac acgggtctgt ctcattgat tgaccgatta aagataaaa tgttatcacc 111300 atcacctact gctacacaca gctttattc agccgat gcattcccta ttaatattgc 111360 taaagctaaaaagtgaaa atcatggaa tgtaactgtt tatcctacag taaaattagg 111420 tgccttacct caggttggg aacagcagtt atcggatttta gataagttag ctacaccac 111480 agaagaaaat aaccctact ttgtaactg gttgattaac atgttaata accagaagt 111540 ttctcatgat aattttaat tcagtagaga aaaacaca ttaggtgag atcatcaac 111600 acaagcaa acacaagctc ctacgcaca aagtgtagag storm ctagtaattt 111660 aggtggacaa ataacacac aaccaactt taataatgta cacacaca caccacaagt 111720 tcccccacaa caaatacac agttttggtca aggaacacct gtgcacaag caccacagca 111780 accacaacaacaaa gtaatccatt tgagaacttt gatgctaata acattgacga 111840 ttctcaatc ccattcaca CAATGAATc aacaccagaa ccacctaac aaaatcacc 111900 tagagtgta gatgatgtat tagcaggtttt agatttata taactttata gagtgctatc 111960 ttagcactct tttatttaaa ttcatataa aaggatgata taatggctag agcaaaaaaa 112020 ggtaagag tagatactac aaatttaaat actattgact taggtaaga attaggttta 112080 actttactat cagatagtaa tagagcagat attagata tcattcctac tatgattcca 112140 chaattgata gattttagg tggaggtatt cctctaggaa gacttacaga agtttacgga 112200 ttacaggta gtggttacct taatagcca caatggctta taatgagtta ttacaaatcc 112260 acgtgaattg ctgggaagcc ttaagactt gttaactaca acgtaactgg aaacggtaag 112320 cgtgaatgtt aaaaataca agtatatgag ttatatgta taacgagtta ttaaactgtt 112380 atattatata gtgtaggtaa tcagcatcca agctcctgta aaatggagaa ggttcaacga 112440 ctatcgaaaa ggtagctaat attgagaagt attagtgagt aactgagtag agtagggaaa 112500 ccgaagtacg tgggaattgc ctacgaaatc tattaaat ggagagtagt attatatggt 112560 aaaacgagta tggtctaatg aaaaaaaca agatatagtg aaatcctttc aagaggtaa 112620 gaatttagt gagatacaaaaagtataa tgcacattac tttacatta aaaagtatt 112680 agatgagtttt atattgaca actagcaa gagagatgg actagtaac aaaaaaaaacaga 112740 tattttaaga atgtacactg aagagtctat gtctattgca gagataaag cagtctatac 112800 aacacatgca agagagataa gtaaaatatt aagagacttt ggtattgata catcttacta 112860 tcacctagg agagttaata gaatattaa taagatttc ttgaagtaa ttgatactga 112920 agagaaagca tatattttag gtttattgat ggctgacggt tgtgttagat atagaagaga 112980 aggtcaatgt tacttacac tagattaat tgataagaa atagtagaaa gagttcaaa 113040 agaattgaat tcagacagta aaatttatga atctcataga aaagagatt ataaaaaaa 113100 tgaaaattct acgtatactt ttagtgttac cgatgaaaaa ctagtaatg atttagctaa 113160 atatggtata atacctatga aaactaaaaaacagattgg ttacacag acatacctta 113220 tgatttaagg aacattact tagaggatt gttgatgt gatggttcta ttggatgtta 113280 fatherfather father gatggtcaat aactttagtt aacaatcatc ctgaattttt 113340 aaagagta ggtagttgga ttgagactt attaggtttt aatgtccta caatactaa 113400 aacttctacc tcttatagaa taggttatac aggtaaaaa gctaaaaaat taatgaaaac 113460 attatatcga gataata ttcatataga ccgaaaaaaaacttgcag accaagcaat 113520 taaagatata gtctaagccc actattaagt tagtgttaaa gtactaggaa actaggggta 113580 gtaactgaaa tcgacctttg cagtacactt atctagagta gcaacaat taggatt 113640 tacagttttgg attgacattg aaggaacagc ggataccaa cgtatggaac attaggtgt 113700 agacgtatct aaattgttct caatacagtc aggtgaaggt agacttaaaa atgttactga 113760 actatcagta gaaccgtag gtaaagagtt agaatactgg attgatacat ttaatgagaa 113820 agcaccaggc gtacctattt tgttcattg ggattcccta ggagctacac gcacacaaga 113880 tgaaattgat gcaggagtag accataaaa acttggaacg aaagcgacaa gtacacaaa 113940 agtagtaat gctatttcac ctaagcttaa tgatacaat acaggattaa ttgttattaa 114000 ccaagcacgt gataatttaa attgagtaa tccttatgat gaccctatta agtctacagg 114060 aggaagagct tttgaacatg gtgctagttt acgtattaaa gtatctaaag gtaaagaatc 114120 agaattaaaa cagaatgatg ctatgacagg taaacctacg tataaaggtc atgttatgcg 114180 tattgaaact aagaagtcta agctatctag acctggtcaa aaagcggaag ttgatttatt 114240 atcaggttat gaagtaggtt ctgatgaaga tactattcaa ttaaacggtg ttgaccctta 114300 tcatactatc tataaagaag ccgttgagcg tggtttaatt actaaaggaa catggcgtaa 114360 ttatgttacg ttaaatggtg aagaaattaa aaaatatgat aaagattggg taccgacatt 114420 aatggacaac catgaattat acttagaatt atttagtaga gtttaccacg agaatttccc 114480 tcataagtat gcacctttaa acaatacaaa agtagacact actcaattag aagagtttaa 114540 agcattacaa gattactacg aagagcttag ctctactaat aaagagacta aggagaatgt 114600 aaatgaataa tctaatagat agaaatatta atagtgttaa agaagcatta ggtagggcta 114660 atacaaatga tgtattgccc ttaccttata ttgaaatagc agaacgtttt aaaaaagcta 114720 gagataataa ggagcctatc attgtagaag agtcgggatt tccttacact gattctacag 114780 tttgtatat tgagcatgta gagtcaagat gggcaggagg ttactcttta gtacgttata 114840 atagttctga agtcaaagta cctaaaacaa tacattattc cgatatctat gtatcaaatg 114900 atgtacacag gattaagatt gtatttgagg gagcacatcc ttatgaagaa agttaataat 114960 gggaatagat atattataga cttagatggt attcctattg actttggtag agacttagac 115020 atgcttttaa agagatataa aaaccttaga tggtcattat ttcataggta ctctagaggt 115080 atgagtcatg actttgagaa acaagagcta cgggaataca tagatgagca gtttattaag 115140 ttagttaagg agtatgatat acaaagtaaa gtagattttc cagggtatat taaaactaaa 115200 ctaacactac gagtacagaa cagttatgtt aagaagaaca ataatataa acgtactgaa 115260 cttgtaggta aaacagatta tacagtagag tccttaacac aggagttaaa tgtgggatta 115320 gaagaaaatg aattacttaa ttatgtcttt gatgatacac aatttactga agtacaaagt 115380 gaactgctaa aagagctcct tattatacg gataagaag acacgcatt tattgtgtct 115440 actgtagcta ataggttaga tgtagaacgt tcagaagtat ctagagagct tacagaactt 115500 aagattatg ttaatttaa aaaatgct tatcacgac aaaacagtag agatacatt 115560 agagacaca aaatagatac acaaatcat gtatgggaat aacacaaca agccttcctt 115620 ttgttatatt attaatgaaa ataatacat agggaggtttt tttctatgtt ataatgtaaa 115680 aaataatgat tggatta tattatggc taagaaaat attaatgag tattaaaca 115740 agataccgct actgtagcag ataagtattt acagttca gtagagcaag atggttatac 115800 acgtacacac cgtggtcagt atactacaa agtagtagat ataagggag aattattctt 115860 atacccgatt gaaacagatg gtagaggaaa tattaaaatt atgaaaaagg ctcctgttgc 115920 ttatacagat ggagaccaaa ttcattttgt agttaatact gttaaagacc cttacaacca 115980 tgctttatt agaactgaaa atattaaagg taaagaaa ggtaaacaat taattcaagc 116040 gtttttagca ttcgttgaag accgtttcag ctttggagta tacaatgtat tccttgctaa 116100 taacaagagg gatgtttttg ctttagttga tgctgaaagt aaagatgcta aaaaagtagt 116160 agatagtaat gagaaacctc atgaagacgt gagcgctgag tttcctgcta gtccactacg 116220 taaagacgtt aaaggagtag actcaggaga aggtcaagga gatacttcag aaccgtcagt 116280 acctaaaaat gtaacagtaa cagctaaaga aacaacagct gatattacag ctgaataatt 116340 atataaagga tgacttagtt tggataaatt aaatttatat aaaggtgacc agctattaaa 116400 aagtgaagag aaacaagcag gtaaaacatc aattacaatt gataacttaa ctgctaacac 116460 agactaccca caaggtacat ataaagtatc tttctctaat gaatcaggag aatcagaaaa 116520 agtagatgtt cctgcgttta agactaagga cattaaagta gtatccgtta ctttagatgt 116580 agaaacacta gatttaaaag taggagaaac acataattta gtagctacga ttgaacctag 116640 taacgcaaca aaagctactt atacatttac ttcagaacat gatgatattg ctagtgtatc 116700 aagtaaggt ttagaag ctaaagcaa agtcagact acaatcactg ttacaactga 116760 tgatggtaat catacagata ctgtaactgt agttgttaa gataagtac ctgaagctcc 116820 tacaaatgta actgtagacc ctaaagaac aacagctgat atcagcat atcggaggt 116880 Aaaaaaat ggaaaaaaaaaagt aaagatgg tgagtagta ggtactaga 116940 ctgctgaaca aacaggtaaa acactattt ctattagtgg ttacacca gatacgt 117000 atcctaaagg aacttataaa gtagcatact ctaatgagtc tggtgaatca gaaaaggtag 117060 atgtacctga atttagaca gcaccacata gtgagctata ataattaaa gtccaactta 117120 attgttgggc tttttttat tgacttatat tatttat gctatagtta aacaagaatt 117180 aaaaggag gtactatatg gatataaaa cagtacactt acttcagat acgaccatt 117240 tgaaagttaaaaattaatg gagatagg aaaagtatat tgcagttgcg tgattaata 117300 aatcagtaag taagtcaat atcattatgg ttattaatgt tattaagac ctagtgcata 117360 tgtataggta taaaattgtt gagtatggat tatctaataa tgataaggaa aatgaaaagg 117420 tagggtattt aatagaaagg attgaggatt gatgttatt attttaaatg aagtagcttc 117480 acacacagaa catttatccg aaggtataga tatgttcgac gttgaaagtg tagtatcttt 117540 tgactcggca ttacatttag ctagtgataa tacgtatgat tctgttattt ttttaggttt 117600 tatatacaat aatgaggatt acttaaagta taaagaatta ttaaaaggata caaaattata 117660 ctttgtttct aatattaact tacccgataa caaagatttt attaccgtag gtgatgattt 117720 aaaataccta tccttattag agcaacttgt ggttctagat gacaaaggtt taaatattaa 117780 tttcagtagt tatacaaaag acattgctca caagtacact gagttgttta gctttaaatc 117840 tacttatgag gaggcaaaag aaaagggtct agtaggttac cctgtagatagtattacc 117900 tattatgact gacaagtttt acaacgtaaa tgatttgtat gtactatatg aagtagcacc 117960 tgagtataaa ttacctttag catatgaatg ccttaaggat aaagaaaaag gtattgttgt 118020 tataggttca caaacaagag gtactagtga tatccttact ttctatgtaa aagggtatga 118080 tgtcagtagt gttgctaaaa cgtttggagc atcctataat gaaaattcta atatatttag 118140 tatctttat gatagtcata ttagtgtatt aggtgagaat atgaacaagt atttaataac 118200 ggaaggatgt atttatgagt aattataaaa caatagaaga gttacaagca attattgtag 118260 gtattttatt taaagatgaa ggtaaggtag ttacatctaa atttaataag attctaacaa 118320 gttttggtat tgatagagta aaccgtaatg agttaaaaga cattgtagaa aatattagaa 118380 gtgatgagta ccttaaccaa ctaaagaata aagctgttaa aggtgaagtg ttattagaag 118440 acttaagaga tgtagagat aaacaagtat ttgagggtaa tgactatcat caagaagtgt 118500 catcttatgt agtagcacat gaaaaagaac tatctagact aagggaatta cgaaagatta 118560 atagacaaac tgcataccct actattttgt ttgatgaatt aaagcgtact atggttaatg 118620 agctaaaagg gaataagtta ctagaccata aagtaagtaa gtatacttct actgaggaag 118680 aagagagct ggttatctta ctgtcggact tccatgtagg tgtgctttt caatttaa 118740 ctaatgagta taacttgag gtactaaaaa gagattaaa tcagctacta caggaacta 118800 ttaggatat tagtaacgt ggtattagta atgttacagt atacttgta ggtgatttaa 118860 tagcatat taatatgaga gatgttaacc aagcttttga tactgagttc actatggcag 118920 agcaggtagc aaaggaact agactattaa tcgactctt aagaatta tctccatatg 118980 tatgggtaa tttacgtttc ggtatgatag caggtaacca cgaccgtgta cagggtaata 119040 agaaccaaaa agtatacaat gatagtgtag cttatattgt attggattct ttactgctgt 119100 taaaagaaaa cggtgttatta gaggtattg agattcga caatagaaa gaggtatata 119160 ctattaaaga cacagtagt aacttaaata ttattaaa ccatggagat ggacttaaag 119220 gtaaaggtaa gcatattcct aaatttattg agaacactca cattgatttg ttattacag 119280 gtcatgtaca ccactctca gtaacacaag aagattacaa tegatgcat attgtagcaa 119340 gtagtcctat gggatataat aattatgcta aagaactaca tctatctga acaaaccat 119400 cacaacact actatttta aaaaaaa aaaagacat tgacattaaa actgtattct 119460 taggattaggg agagataata tggacattct atcaattata gccttaacat tgcttatcat 119520 tattattgtt ataccacaa tgaactttgt aggtagtta cgtggtgagc gtgaattagt 119580 aaaaaaagga ggtaaccctc tacccattg gcagtactat atgtgttat tacctaattt 119640 atgtggtatt atcctcttag gtattgttgt ttattttgga gattcgattt ataaaattac 119700 aaaaggtta gaagttcttt ttgcttat tgcgcttatt gtaatagatg tattgttaac 119760 agcgttagta tgagtttcgt aaaaaaaat aagaatagt aagaagga 119820 gtctggttta tacttgactc tcttgttat ttatgtata ttagatatga ggtgattttt 119880 gttgcaatta aattttggta aatttgaata tgaaattatt aagacaaag tagtgaagg 119940 tgtttactct tttagaggtg ttccttatta ctacatagaa catgtccaag atgaaacttc 120000 tgagtagta ttagtatata acatacatag tgttgatgat gaggtaccac aaagaaata 120060 taaaatagaa acagtaagta aaactattag aggtggtacg atattaagta atacattaa 120120 gtcaatgcta cctaatata agagtataa aaagtatat gaacctccta tctttttagc 120180 taatatta cctttaggta cagatacaac tacaggttct gtaggtaag ggttttttcga 120240 aagaaaaaaaaaaaaaaaaaaggtaa ctattacaca aaaaaggc actaagtta tacatggtga 120300 gtatacagga gtatttatat gtttatctaa tgttaaatgg attaagtctt atacacctttt 120360 agatagtata ttacaatatt atcaacgtat taaggggat agataatg tctgagataa 120420 ctaaattcta tgagcaggat attaagatt taattagaac gagagacac atgtttaag 120480 atgatgagat aacaagtaat atacagata ttagaatatt tatgaaaaa gctatttgtc 120540 aaggtaaatg tagactgac tgtttaattc ttgatagaaa tggtactgtt atgggtatag 120600 accelerate accelerate tctacacaaaaactaaacaactac tattagtc 120660 tagtatgtaa gtatgttat gtgatgtgtc atgataagca tgtacctaaa gtagagcaaa 120720 tactaaaaag gtataaacac catcatgtag gtattatgag ctatattaac tttaaaggca 120780 gtccagtagt aggtaagtat aaggaagcta cgccttcacc actaagaagt ccttatcata 120840 cactaaatat tttatggaag caacatttaa tgactatact taaacagtta agagattata 120900 atacatacct aactggatat aactataggg agcacggtaa aatactaac aatgagggta 120960 gttatacaga gggaacccaa cgtatgagaa tgaaaaagtc agctattatt aaccaagtta 121020 ttcattactt aggtgtagag aactcttata agatatttac tagaggtgtt atctatggtt 121080 acagtaatag atggcagata ttagaagatg atttctttaa agttatacag aacggagtga 121140 gggtattata tggcaaagag gaaacctgat acatttaaac ctaaatctaa cggatataaa 121200 catcaacctg ttaactttgc tcctacgggt aacttatcag gtagaagtac ttcttttttt 121260 aataaaaaaa gaaaagatat atcagatgaa agtattgttg ttaaatacaa acctttgttt 121320 gttaaaaggt ttgataatat tactgctaca gacattaaaa tacaaaagaa gtatgcgtta 121380 gacttaatta gtgaagctgt gaatataaag aagaaatatc ttgtaatgaa gcaaaaaggt 121440 aaattaacac aaactatttt acatacggat agagtttatt atgtttatag aggtaagaaa 121500 ttaataggta aatgtagtat tcgtgaacaa cgtacattta gaggtacaca tttaatctac 121560 atttttagta ctagacatag aatatctata cgcaaaaata gtagattaga taagaaaaga 121620 acaccaaaga aaatgatata taaaggtggt aaataatggt taaatattta agaacaaaag 121680 ctaaaaaac aaatataagt actttattta agaaactaca aagtaaagat attacactat 121740 taggagtgtc ctatgatagt gattatttcc ctagcggtgt aacaataata ccttattag 121800 aggacatatc acaagtagaa gatggtatag aatttacgaa taaagtaata gttactgaga 121860 acttaaaacc tgctattgta ggtatgaata atatgataag tgattcagga ctaggttatg 121920 ttaaaacaga gcagttaaat aaaagattag aaaatactgg attaatgaca gatttattat 121980 ctaaaggaac agaatttact tcaaaga aagtagacat tgtacact tttattgaac 122040 ctactatt gtaccaagat actactatta aagaatt aaacttaga ttatacacta 122100 tcgaagatgt atccccttta atgattaca cacatgttgt attacktacta gtaactgata 122160 agcaatga cggtcaatca ttcataggta cattatgtaa ccaagtaca ttaacaat 122220 tagatactct aaagttctt acatctca agggtaataa ttatcaat agagtgtgt 122280 tttctgttaa gttagatacg aaaataatc attatagtttt ataataca catgagaccg 122340 gtattttctt tttagatgat gataaagact taattattgc tgtggtca tcctatgtaa 122400 agttagata windows gttagatta gttagata agttagata ataacta 122460 aaatgattgt taatcttgtt ggtaatgatg agctaacaat tctcttatag tataatactc 122520 ccttaaatat gtatactaag gtataaatat acgtataata gggattttt atacatattt 122580 ttttcaagta gttagttaat ttctaaaagg tattattctt atttttaaat tatattata 122640 aaacattaaa atacctttta gtatagggt tttagaaaa agatttatat tgcttaaaat 122700 agttacacta tagtgtaaaaattagaata tcctttaga aaaaaata gatgcagaaa 122760 ttgtgatata ttatatagtg taagtata aacagttgat ttgataggt tatgtgaata 122820 cacatactcc ttattgt tcacacatat gtaagacac ttgagacaag aaggaat 122880 ataatggcta gaaaaaagaa tttaagaat aaaaatctg ataatggct agttccagat 122940 aaggaaagta ttctctaa actatataat aaaagta taggtcta agtggataat 123000 gctatagatg aagatgttag ttatgatgat attatagacc tatgtaaga gtatgactta 123060 gagttatcca aatctgccat tacagat aagagtaac gtaagaagc tattgaaat 123120 ggatgggatt tagggact tattgataa agaagaaag tagcgctac tcaatacag 123180 aaaaaagaaa atcctatgaa agattagat agtgagaatt atacacctttt tgaactggct 123240 acacaatg acaat aatxatatc actat tattcaaaaa 123300 gttgctaaag gtttaaactt tgtagaaca ttagaccctg ctttaatgat taagctatg 123360 gaaaaaaag atagaattac gggtaaccaa ctaaaaggta tgtcattcat aggataga 123420 gaacaatga tthaacaca acacaagat actgctatga spagagttat gcttgagtttt 123480 attcctgaag aaacatga agaagttctt aaagaatgg agcactaca agagagttc 123540 tataaaaact agataga tgagaagga agataaact agatacatt agatagagata 123600 ggctatacaa tatagataat gaggtaatac atatgacaga agaattagt ttattccaa 123660 taaaagatgt taaaccactt acagatatag tagatatt aacacaccta tataaaggtg 123720 atgtacttag agttaaca gagaaccaag gagatatatt acttagacta agtactggaa 123780 aacataagtt tactgagtg txagagact tactgaaga aaccatgttc tataaaaggt 123840 attgggtact atacaatgta tctattaatt ctttactaac ttttgatgtt tattagaag 123900 acgattgt agatctaca aaagttaagt tccctaagaa cacaattgta gatatgtaa 123960 gagataatca agaatcagat gtagctaagg ttaaaagatat tttagtagat agtaacggta 124020 attatttcta tgcactttca ggagaaacat ctttatataa tgaagataaa cttaataaaa 124080 ttaaaagtta atgattgaca cactcatatg ggtgtgttat tcttttatta caaacaataa 124140 aaggagcaat tgattatgat tattacatta aatgaagaag agaaagcatt attagaaaat 124200 aaaagcaact atacgccatt aagtaagaat aaagagttca atacaccaaa agaagaatat 124260 attgttacaa gttataataa aggtgtacct gtaactgata ttgccaaaga agctaaagta 124320 agtatgggtt tgatttatac agtgttaaac ttctataaag tacctaagaa acataagaaa 124380 tctagagtag caaaacgtgt aaagcatatt actaatgata agaataaagt acaagcctta 124440 attaaagatt atcaatatat ggacttacaa agtatctata aaaagtataa cattcacaag 124500 aatggtttat actatatttt agattttat aatattgaaa gaaaatcaga tttaaaagag 124560 aaagccttag aagatactat cgaggtagaa taagaggtgt catatgcgca aagaacgaat 124620 tgtagattac tgtataatg windows tgataataat tgtagattac aaggaataga 124680 aaatagttta tttaataag aatctctaca agacttagta cctgattttg atactcttag 124740 taaagatt atgaagta attackacct atgtacata ccagagatt atactccga 124800 ccatgtagaa agtggtcagt atatagtat agatgttggg tatgtatctg aagaccctgc 124860 ttttgaccat ttaataggtc aagttcctag aagtgtatat gagaaagcgc atgttatgca 124920 accactatt agatagaaa atactgatat agattatacc caggctgata tgattaatga 124980 tattaagta ggtacaagta ttagtgt aaagattaaa gataattaa gtttaatgtc 125040 aaataatctt attacacatt tagaattgt tgatagtat tactttgata gtagtataga 125100 agaagcacta ctaaagtatt atgagttaa aaatcctgac tattatta aacattttct 125160 taaactaaaa gaacttgtca gagacaatag atgatatat tgtcctttac tgttaaaatg 125220 tattaaagtt atagactaag tattattatt ataagtagta aaggatggtg cgctatgagt 125280 aaaaaagcaa taattgctta tgtattatc tagcttgt tagctttatc tatctact 125340 tattacgtat cctcatactt attackcatgaa aaaaccaaat cacaagttac agaccaatta 125400 acacaccacg gtaaactaa aaaagataag atgtagagt atgtaggga ctatacactt 125460 aagaaagtaa tagacaa agcatacttt atgaaaaac tacctaccta tttaccagga 125520 agaacaagtg aaaagtat tgaatgaga tattagtaatt tagagaggt 125580 gtaaacttta aacttattcg tgtatacaca gaggataatg acataatcc agtacacaa 125640 tataggtttg aggcagtatt aaaaaaag taaaggtag atagtctatg accgtagtaa 125700 ttatactgt atgtattgct attatatact atttatta caggattga gtcaagttta 125760 tacttgactc ttttttag ctatgttata gtttaaatat aaggagatga taatgatga 125820 aaaaaagtga tttagataat ttgtatattg tggtcgtaag tattagaat ggtgttttac 125880 ctgatgagcg tgtatattcca attggtttag atgtactag taagtatta gagggtaaaa 125940 ctacatggac agttaagaa gaattaaac atacattgg taagatga ttaaaagat 126000 ttaagataa ttacaagttc ttgcacata aaattgtaga ccttgctaca caggatata 126060 ggtaggtggt ataaatggat atagtagata aactcatgtt aggttttatt ttattgtttt 126120 atgtaggtgt atttattgg tacttatggg aagtctctga attacktct ttatatctg 126180 atatagttat taagtatt gttcgtagg gatgggttaa aggtttatta ccttatttga 126240 ttcatcaagt attattacg tagtttgggg ctactctagt attagtact ttatactta 126300 gttatataat gataaataat ttgataggag gttactaaat ggtagta tatgagaatg 126360 aatgtagagg atattatt tgtgtcatag atatgaagg tagtatgaa gtatcatctt 126420 ttaaaaaatc agtaaaaaa tataccccctg aaattatagg gtatactaca gaaagttac 126480 tcttggaatt aaaaatacca tgtacatatg taaatgctag tgagtagaa agttttatgc 126540 aagaatttaa agtagcacgt attgcgcttg acagtttac windowattta tataaag 126600 gcataacaaa tattatattc taaagggtgg ttagtatgta tacagaaaaa tatagaaatt 126660 taatccatat tacacatagt atcttggtta gtattcaaga attagcaagt aatttattaa 126720 ataaggaagt aaaactagtt acaaaagaaa ataagtactt atgtgttgta gatggtatta 126780 ttatgttaat tgttgaagaa gggttagtat acacctattt tgataaggta ggtttaaaag 126840 tgcctgaacg tattgcactt ggtcatttag caaaaagttt acagtttaca atatcagaat 126900 caaataaaga tttagaaaat caaaaataag tgttgacacc tttaacatgt tgctttatac 126960 taagagtaac aaaacgttag aggtgattttt ttatgtgtaa agaaaaagtt catagacagc 127020 tatctaatgc tatagaaata ttagcaactt acaaagagtg gtggtctttt ccaaaagaat 127080 taagtaccac agaaacattt aagattatta actggaaaga agatacatta gtatttgaag 127140 ttagagataa cggtaattat ataggtaggt ttagtgtagc aactcctatt attgactttc 127200 attatgatag attaaaaaa acgacagcac aatacatgat aaattatttt gctaaactag 127260 tatgtaaaga tatgtatacg tattataaat tacagagagg acagtaaaaa tgaaaaattt 127320 aaataaaacag aaacgcttga cgttggaatt gattagtgat aatctaaata cacaacataa 127380 cttaaataca tcggttagtc ttggatatta tagtataaaa gactttacaa atagaaaagt 127440 gtatgtaaga actaaaaaag gtttagaact tactaatatg aaaagtttaa aaagtactga 127500 gtcattagat ttattattta agtatctaga attaatttta aaaggagatg tataacatgc 127560 taacaccaga acaaagaaca caattaaaag aatatcaaaa taaaatgaca aaaaagaaaa 127620 aataaatgtt gacttactaa ataacaagtt gtataattaa cttaacaaag aaaaaggaga 127680 ttgataaata tgaaaaactt atataaatt ttaacaggag tattctttag cactacacta 127740 ttattaggag gttgtgctta ctactcacaa gaagatacac cgacgcacaa ttataaggaa 127800 gacaagaaag aaaataagaa agatgaaact tcctcattag aagaacaaga gaataaacaa 127860 attaaagaag acaacactgt tcaaataac caacaagata accaaacaca aggacaagat 127920 aagactcaag ctcacaaaa tgacaaatg cavaagcaa gtagaagtga acataatggt 127980 ttatctaatg ctgagtatgc agacaagtat atcaata gggaagctca acgagcacaa 128040 gcagaattag agaatagaac tgaggcggat aaagctagcg gtggtggagg cggaggagcc 128100 tcatggaact atgcaggagc tatgaagt tttgacaat ggttacaacg ttcacaaca 128160 gaaggagggagg aggcaggatt acaataat taaaaaga tacaggaga tagtaga 128220 aaaataaca caggagaac taaataaat tctagtagaa cataagctag cgtagtaga 128280 tacaaggattg atttaatatg aacattgtag aaacgaaa acctataaa agtaagcata 128340 tttacctaac taacacgcg tatgaacgtt attackacctag agttagtaac gatagtaag 128400 aacgtgcttg tcagtggttt gctagtgctt taatgcaagc tactttgaa catacacaa 128460 aaggcggtaa tgagtatat gtatttaaaa attatagaat tattattgat aagcatctaa 128520 ctattattac cgttatagat actgagatg atattggga agcataag gagcaagg 128580 aacaaataga tacgtatatt aaaggtaagc taaaaagaac tgttacacct ctatttacta 128640 agttagatag aatagatatt agtatccatg aagcacatat cagcatgatt aaaacaagaa 128700 accctaagac aaaagatata attaacaaaa atattgttga acttgaaaga aataaatctt 128760 tactattaaa tagtataagaa ggtgtaaaga aaacagcaca taagtattat gtagaattaa 128820 aagacattca taaaagatta aagactgat aataatgtgt ttaaaagatt taattgaaga 128880 ttatataaat caagataaag aaataattat aacagttaca agtactaaag taattattga 128940 ggcagactat gatgttatt gtttaacctaa aagtaaaatt gatattgacg atttaaaagc 129000 ttatgtatat ggatttaata gatttaatat agagcaaatt gtattaaagg acgtggaata 129060 atgcaagact taaaaaggat aacacaacct gaattagatt tattgataga aaagcatgaa 129120 caatggctag ctacaaatga aaaggaagga gaaaagcttt tttacagtg tgtagattta 129180 agaaatcttg actttcattc cgctgacctt caatattcaa ctattgtaat gtctagttta 129240 agtgatgcta acctaagtta ttgtgattta agttattctg atttaagtta cagtgagtgt 129300 atatctacga gatttacaaa tgctcgaatg aaagatattg agttgcatca tactaactta 129360 gagtgggcta atttagtaaa agcaaactta gaaaatgcct gcttagctga agctaatgta 129420 agtgaggcag acgcaaggtg ggctaacatg aaaaatgcta acttaagtat ggctaattta 129480 aaaggtgcag atttggtgg tacaaaccta actaatacaa cattatatta tgctaacatg 129540 cttgacgtgt ttgggataag tatctatact ataagtaatg tacttgattt tgacgagcat 129600 gtaacttatt tacctgatta tgatagaatt attagtaatt ataatgaata tacccttgaa 129660 gagtttggta aactagaacc tacacttgag tacgaagaag atagaataaa agaagtctca 129720 aagaaaatta aattagctta cgatttcttt aaaggagtga aagaacttga taaaatttaa 129780 ttcagacgaa cataaacata tacttaatgt tatggataga ttaccatata tttgttggtt 129840 agatactgta gatggtgagt caggtgctga ctttttatgc gtatcgcata gaacacacta 129900 tgaacttact gaactaggta taatgattta tagttatggt agttggtata tgatacctta 129960 tgacaaagaa gatttaattg aatatgcaat aaaaagagat atagaggagg aaggggaatg 130020 gtaggtatgg tgattacatt tttaattgtt ttaggtatta tattgctaag tgtactaatt 130080 attgtatac cagatttaag caaagcaaaa aaacgtaaag aagactcaga tattaactat 130140 aatcaatata ctaaagacat ggcttctgag tactatgaaa agtatataac acctaccgaa 130200 cacattattc aaactaaagt agaagaggta attgaaaata taaagaaaga atataatgtc 130260 tctactgtaa ttattgactc ttctagtaat gaagacaaaa ttatcttaca tgttaacgat 130320 aagtacttaa aaaagtagt gtataaagat acgtatgaat acatctacga ttctaataca 130380 aaataccaat acattattaa taatgtaaca tatgagtcga gtatcttatt aaaacaagat 130440 gaagtaaata attaaaaga tatacttaat aaagtacctg tcacagctaa gcatacattt 130500 aaaaatgagt tgcttaatcg taggaatgaa tatgtgttag gttatattac aatatatatt 130560 tatggtgact taactgctaa aattacaaag aatggttatg tacagactt tagtacacta 130620 gaagatttt gtgataagta tgaagcttac tgtagatttg ttagaattga ttatatgac 130680 tgggtaaag aagtaagaac tattaatgggg tataaatta aggtagat taaaccttat 130740 tttaaaatta ctgctactaa aacaagtaaa tacgaatttg tagtagtga tgatgtatct 130800 aatgttaagg tatatagaga tgatatacta ctacaaca ggtagtgca aaagcaatt 130860 gatatacagg aatagtaga ggaaacattg ataata ctgtggtatt ttaaaaaag 130920 ggtatgaata atgaaaaatt taggtaaat tataaatatt attgaagg atgggaat 130980 taacatagat agagaatatt tggcagatat tattatat gaagttgaac aaggtagaaa 131040 wireless agtacgcta aacgtact agagagat aaagttat aagtact 131100 tttgacact tttctagagg cattaaaaaa gagagacatt aaagagttg tatcttattt 131160 taaaaattt ttaaggtg ggagaataat ttaattca aagacatata cttgtaaga 131220 attatagaa aaatacttta atggttattt aaagaaggt acttacacag gtacatccga 131280 tggcttagat acttattacc ttctgttaga aaataaccgt atgactattg gatatcaagt 131340 acctttggac gctagtttta tagtagaga agaattact atgacacaa actagaaaa 131400 ctgctgggta ttattaaata gtcatgcaaa agaactattc atggataca caggtaatgt 131460 gagtattaat gattgtatag aaatacgg agatgatta ttactgtca gtatcttaat 131520 cgatggtacc tttaatg tatggagaa tgatgatt tttatagag gaggagata 131580 atgaaaaaaaaaaga agaatttaat aaagttctag aagagcaata atttagta 131640 gaagcaatg aggaagg taaaagagca gattaagtt ttacagactt acgtgaccta 131700 gatttaaagg atgttgattt aagagaagct accttaatag gtgctgattt aagttatgta 131760 gatttacag gaggcagattt aagatatgct gattagcgt gtgctaact atagagtt 131820 aattacag aagctatctt agcatatgca gatttaagtt ctgttgattt ataaggtct 131880 aatttaaaaa atacccattt aacagaagct aacttaaaag gtgctaattt agtagatagt 131940 gatttaacaa atgctacttt atagaggct gattaaagc atgcctcctt atcaggtatt 132000 aatttataa gtgcatattt acaaaatgct gatttagat ttctttatt aagaatact 132060 gtttaatag gtgctaactt atctcaagca tctactcaag gtattagagg tttagaatg 132120 tattctatag attattgg tagttttaa aaaagtaa cgtacctacc taatataat 132180 aaagtattg taggattg ggaggaat taggagaat ttctaaaaaa aggattag 132240 atgaatgag gagataata agagcgtacc aacattgtac tagcttaca gttctttaaa 132300 aaccagctat aaatttaa gtatgagtat ttcttagtaa gtaataagta gtaaaata 132360 tcctacttat ttcatatata agtgttgaca tgaatagtg taaggtttat atagtata 132420 tagttaat attattagag gagacattaa tcatgaaaaattattagt tagttttat 132480 ccgtattaat tgtactaca ataatcaatg tgttgaaaaa ccaagagcaa gtagaacaa 132540 gtaaccaag acctacaac gtaaccaaag taaccaaag tctcaaata 132600 atgatgcaga tgaccatact tcatacgtac ctgagaataa cggagcat aaagacgtta 132660 gtgagaacg taaagatta tggggtacag agtatcaga aggtgaaca cataaccaa 132720 atgctaagt gtttaatca gatcaggag aacaggttca atagagta agaggaggcac 132780 ttattatgga gtactggaaa gacagaca ttattattc aaaaaaaaaaaggtgtta 132840 taagctatat agacttatct tccttaccta aaagaagtc tcgtattgat tgggtaaatg 132900 taaaccatta tatacccttt gagtatcata gcacgaaagg taagctat attaattacc 132960 ttacaccac taaaaaagaa tctagagtag aaatactta ccaaaaa atccaagcta 133020 cccaagtagc taatgtctat aaggttaat tcaacttat tacccaggt cagaagtctt 133080 atactgttca tataaaaa caggagata ttgcgaagta ctaaaagtag 133140 tagacactca tttaggtaca caactttatg tatatacat aaggaaa gtctatggta 133200 aagtagtaa aaatttac taaaata aactgataac tatataccat atggtact 133260 tcctcaatct aagatgttat accataagaa actattcat agtagcta atattaaga 133320 cttatttaa tataagtata caactaagaa aagatagaa acgatttgcc ctattgtaa 133380 aagaaaaaaa gatttagaa ttacagattt aattaagat aactatagct gtcaatgctc 133440 windows tctagcttcg gagaagatt aacacaagt tattagata ttgcaacat 133500 agagtatatt agagaatatta aatttaaga attaggtaa aaagatttg attttttctt 133560 acctaagtat ataccgtta taagtaca cggtgttcaa cattaccaag aagtcagtgg 133620 atacatgaac caccagaaaaaattatc agacataga aagagagaat attgtaaga 133680 aaatagtata catatatag agatgatgc tagaaatct acctttaaac atatattag 133740 taacctaca agacattta atactcta tatagagt aagagta ttaaagata 133800 tagtagtag tgtagtag tagtagtaaaaaaaaaaaaaggta 133860 taggattga tgtaggtaga agttatataa gtaagtaata ggtaaaaga agcaatatat 133920 attaataagt attaataag attaatag window agaacact attattaag 133980 gtacctatat atcaggaaaaaataag aaaaaaac aattgat agcacataga 134040 tagcagtag gtagtagta gtgtatagt atagctaa tagtagta aaaattact 134100 gtataacagt ttgaagatat gatataag aaagaat tattaagta cttaagtatt 134160 aaaatatt ctaatagta gtaatagata tagtaata ggtaagtaac taaaagaag 134220 taactaaag aaagtagcta ccactacac ttaggttagg tagacagt tacctagta 134280 tttctttaca tcttctagat agataata gtagataagct agtaagct agtaagtaat 134340 taaaagaaaa caggtacatg gtatacctat attackagta gcaagtatca agtatcagt 134400 multiplication tagtagtag tagtagtagtagtagta 134460 agtagtagt agtagtagtc agtagtag tgtagtag gtagtag 134520 tcaagtagta agtatcaagt atcaagtagt aagtaagaac agttacctag gaatttcttt 134580 gcttcccacc ttcatagtgt ataaatagtt aggtatctaa ctgttagata cctaactatt 134640 tatttttata tagttttaac tactgtgaac tatgcttatg tagtattaaa ctatgctgat 134700 tatatgctaa actattctaa tgtatagtta aactaagctg aagtagtatt tactgtgtat 134760 aaaggtatat ttagtattag atattgtgta tatggtatac tataattctg aacattactt 134820 atttaatata tatatatagt ttgtttctat ggtagtattg acttaatttt ccctagagta 134880 aaagtttaat atatttagta atttccgaac aataaagaaa ttttaactat tttacacata 134940 tgtgttgaca gtatattact tatggtttat actaagtata taaagttaaa ggagatgatt 135000 tatcatgaag attaaaagag aagtttcgtt tatagaatta atgtatatgt attataaagg 135060 tgatgtaggt aaaggtcagt actattctac taatagtcag tttattgttg ttataactgt 135120 tgatgatata tcgttttata atgcattgta ccctaataaa tctattacta ttactatacc 135180 taatgacact aagtttattg tagagcggt tatagatgct tctactgagt tagtagt 135240 agtagttact tataagcaag gtaacagtgt attackca gtatggtata ggattagtat 135300 taatgaagtt attgactact atgtcgagg taaaaataca tggttactat ctgttagtac 135360 tgttgtagat aatgagttag ttactatatg gaagatggt aacgtattgt gatttgtat 135420 atagtatat tcagtatact tatatatgta catcacttgt attattatgt gtagtactag 135480 tatatagagg ggttaaataa ccgcttcaat aaagacttag taacgaggag ttgtattatg 135540 agttttacag atatttgt acatttaat cagttaggat aaaataga agttttagggg 135600 concatenated contgactc concatcgaaa concatenated concatenated tggt 135660 tttaggtta caggtaa tgtattttta tctgtatatt atggtgaaga cgtagtaaga 135720 ttctttaaac aaggttatt aaatagtat tttgttagt tatacttgag aattatta 135780 aaggagggat tagtttag gtatatttat aagtatagtt tctatatttt tagctactat 135840 tagtattgta ctaagtataa ggttttggtaa gaagtattat aagcatgtac ttgatatta 135900 tgagtgtt agtgatttag atcagctag tgtatttggt tattatta tgagtatttg 135960 tattggtact atttctattg ttttgagtttt aggttacata gtaagtagag tattttatta 136020 taggagggg ttgtagatga tgagttcaac tttaatgtat attgcggtta gtattttagg 136080 tattagtatt atagttgta tgcttagtgc tttattact gatatagtta aatctattaa 136140 gcagaaagaa gtgtttttta gtatatatctct ttgttttct ctgttttagt 136200 ttttgcttct ataatactac atatgttagg tatgtaatag aaagagggta ttagtatagg 136260 ttactttgta gtaagtttat cattaatgta tttagttata gatatagata tatgttatag 136320 atatatagt aaagaggta atagtaag atttaagtta gcagtgtttt taactatact 136380 tatattgatt atgtttatat atggagtagg tgttttatta acacaataga aagaggctta 136440 tttaggaga attagatata ctagatagag tgttacataa taatcaggt atagtgagt 136500 ttacgtatac aaattgtata agaacaagtg atgataagta tatttatagg ttctttctgg 136560 aagatactta ttttgttgt gctattatgg tatgatga tatgagtgag tatgagtag 136620 tagtacagg tacaggtag gtgtagttt ccttattgaa agatgtagtt agtaatgt 136680 attagatact agtagag tatgataact atttaaaag tagtgcatat caaaaata 136740 tgtataatat atttgagaa caagtagaac agtataacta aagttttttct ctagggaaaa 136800 gcagtcaaag gtaaaaatag ggcttgaacc cgcattctat ggttgacatt taggtaaaat 136860 tagataggtt ttccctagaa gaaagtttta aaagtaaaaaggagttgg ttactatgtc 136920 aaaattagct aagttttgta ggaagtatgg agagttact ggcataatgg agagtattac 136980 agattatgag gtgtacttag gtaggggtta taaagtagg tgtagagtag gtaatagcct 137040 tattatatt cttgtatata aagacaatca tatcattgct aggtttgagg aagcggataa 137100 tatagtattt cctttgagtg atacgcttga ggtgggaaca attaagact tagaggact 137160 agaaggtttg tatactata tctatatatt actagggtat ttatatacag aatgaaaa 137220 taaagttatg tatgaatatg ggaggttaga attaatgata tattagtag tgaattattt 137280 gagtatatat taggtcataa cactcacatt ctgggaatt ggcatactta ttacttagat 137340 aaaggttact gtattaagt tatgatgat aacattata atacatgaa gtttatcaa 137400 aatggtagag tagtaaaga ggttattaac agtgacacct tactaccta aggattcagt 137460 agtatctata gtcttattga ttactgag gaagctttag atgaaagtg cagaaaagaa 137520 aaagagcgtc tgaaagaat tcgtacgttc ctaggtaagt aagtattata tataaccgct 137580 tctatatgaa actttatacc tatagctatt ataactatag gtatttttt atatttctta 137640 cataaatgtg ttgatttt gtgtgttaag gtttatactt atatataat taaaggagtg 137700 Daddadat ggatatgac aggtagt agatagtttta ggtggtagt 137760 tagacagc agtacacat agttatgaat ctttaattta atacaatt actcaaggta 137820 ttagattt atgttcaata agtatattat tatctataac agctatctta tgggtggctt 137880 tgtataagtc agataaaaag tctaatgaag gtcatagtac cctattattt gagtttgttt 137940 ataagaatga aaaagagctt tctgctgcag gatgcacagt aattatatttt gctgttactc 138000 tgtctattat ttcttttta gtgctattaa taggcttgcc tattgctatt caagagattt 138060 ttaatccaga aggatatttg attaagagta cgatagataa tttaaaataa ttgtaaaaat 138120 aaggaggaaa atataatgtt agaacaagct aaaggcataa ctacagatta tattatggaa 138180 tttattgatg aacatgagca ttattctat gaagacttac acaagttagc aggggagtta 138240 gtgttgaaag atacacatga cacaaaccct attgttatta atgatggtga tggttactca 138300 ggtactatta tatctaaatt taaatcaaag gtagagggtg ttccagatat cactgttagt 138360 gatttttacg gttcatgttc tttctgtgat actttagcta atatctatga aggtagtgat 138420 gaacttgaga taattagaga tttagctact atggtactac atacaattca atctatggaa 138480 gagaagtag aaatgtat aagggagtgttgt agtagagaa aagaattta 138540 agagtataag aaaaaggtt actctgttga ttatatgggt gttttttag gattatttgg 138600 tcttggcgat gttttatact atgtagaac taatagaaa tacttaagt cattagcgt 138660 aggtaagat gawaccaat atgtatatga ctttaatggt tatgaatact tatcagaca 138720 tagttaat atcaagaag aagaactaat gtctaaagct attgctcagt tagtatca 138780 aggtttaaag aattttaatg gagttaagca tattttgggat gtaggttct taggcaatc 138840 ttttaata catcgtaag atattgac ggttaactt aaactaagtt ttgatgaaga 138900 gggtaccta tattatgaat taggattagg ttggattaat atttataag agtatacagg 138960 tgtaaaagac tttcttaata cagtagataa ctatctcaac ttctctata aagatatagt 139020 cactagtggt cttgagttaa aacaagtact atataatact tttaggg gagatttaga 139080 gtttgtagta tctccatata atgttgtagt atataggaa gttgagttaa ttgattaaa 139140 gaaattttac tctgatactt atggaattta ttcctatggt tatggcacta atgtacataa 139200 acctttacaa acattaagt attatctgga atacctag aatgaagtat aaccactca 139260 atattatat aaaggagtg cttaatatga gtaacggaaa agtagcgtta attggtagta 139320 agtattaga nationalattatacha tcattagtga gaacatata tacttag 139380 atagtgttga tgtgactttt aatgatggga aggtattacc tatatacatt gatagtgtat 139440 taaaaacatt aagtaagat gataaaaatc tatattttc tgaagagat atagata...

Claims

1. An isolated, purified phage comprising the polynucleotide sequence of SEQ ID NO:

1.

2. An isolated, purified phage comprising the polynucleotide sequence of SEQ ID NO:

2.

3. The phage according to claim 1 or 2, wherein the phage is resistant to blood complement inactivation.

4. A phage composition comprising one or more phages, said phage being selected from the polynucleotide sequences of phages including SEQ ID NO: 1 and SEQ ID NO:

2.

5. The phage composition of claim 4, comprising two or more phages selected from the polynucleotide sequences of phages including SEQ ID NO: 1 and SEQ ID NO: 2; and wherein the target bacterial range of the composition is more effective than the sum of the potency of the individual phages in the composition.

6. The phage composition according to claim 4, wherein the phage infects and kills Staphylococcus aureus. 。 7. The phage composition according to claim 4, further comprising a storage medium stored at 8°C or lower.

8. The phage composition according to claim 4, wherein the phage is resistant to blood complement inactivation.

9. The phage composition according to claim 4, wherein one or more phages belong to the genus Sylviavirus.

10. The composition of claim 4, wherein the composition comprises a bacteriophage containing the polynucleotide sequence of SEQ ID NO:

1.

11. The composition of claim 4, wherein the composition comprises a bacteriophage containing the polynucleotide sequence of SEQ ID NO:

2.

12. The composition of claim 4, wherein the composition comprises a bacteriophage containing the polynucleotide sequence of SEQ ID NO: 1 and a bacteriophage having a genome containing the polynucleotide sequence of SEQ ID NO:

2.

13. The phage composition according to claim 4, wherein the composition has less than 0.1% contaminant.

14. The composition of claim 13, wherein the contaminant comprises bacterial host proteins.

15. The composition of claim 4, wherein the composition further comprises a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.

16. The composition according to claim 4, wherein the composition is a liquid, semi-liquid, solid, freeze-dried or lyophilized formulation.

17. The composition of claim 4, wherein the bacteriophage of the composition targets one or more of vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and methicillin-resistant Staphylococcus aureus (MRSA).

18. The composition of claim 17, wherein the bacteriophage infects and kills one or more of vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and methicillin-resistant Staphylococcus aureus (MRSA).

19. The composition of claim 4, wherein the composition comprises 1×10 8 and 1×10 11 Each phage between PFU / mL.

20. The composition of claim 4, wherein the composition is at least 1 × 10⁻⁶ per milliliter. 9 The dosage of total phages from PFU was administered.

21. The composition according to claim 4, wherein the composition is stored at 2-8°C.

22. The composition according to claim 4, wherein at least one phage is obligately lytic.

23. The composition according to claim 4, wherein the sequence of at least one bacteriophage is genetically modified.

24. Use of the bacteriophage according to any one of claims 1-3 in the preparation of a medicament for treating Staphylococcus aureus bacterial infections.

25. Use of the composition according to any one of claims 4-23 in the preparation of a medicament for treating Staphylococcus aureus infection in a subject, the treatment comprising administering the composition to a subject suffering from Staphylococcus aureus infection.

26. Use of a composition comprising one or more unique phages targeting Staphylococcus aureus in the preparation of a medicament for treating a subject suffering from a Staphylococcus aureus bacterial infection, wherein the treatment comprises administering the composition to the subject; wherein at least one of the one or more phages is selected from phages comprising the polynucleotide sequences of SEQ ID NO: 1 and SEQ ID NO:

2.

27. The use according to claim 26, wherein the bacteriophage is resistant to blood complement inactivation.

28. A bacterial manufacturing strain comprising a bacteriophage, wherein the bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO:

2.

29. Use of a phage that infects and kills Staphylococcus aureus and is selected based on resistance to blood complement inactivation in the preparation of a medicament for treating Staphylococcus aureus bacterial infection in a subject, wherein the phage comprises a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO:

2.

30. The use according to claim 29, wherein the treatment comprises a phage selected for resistance based on complement C3 protein-mediated inactivation.

31. Use of one or more unique phages in the preparation of a medicament for treating Staphylococcus aureus bacterial infections, said phage being selected from the following: a polynucleotide sequence selected from SEQ ID NO: 1 and SEQ ID NO:

2.

32. The use according to claim 31, wherein the bacterial infection is at least partially caused by Staphylococcus aureus.

33. The use according to claim 32, wherein the one or more unique bacteriophages infect and kill Staphylococcus aureus.

34. The use according to claim 31, wherein the one or more phages are selected based on resistance to complement C3 protein-mediated inactivation.

35. The use according to claim 29, wherein the bacteriophage belongs to the genus Silviavirus.

36. The use according to claim 29, wherein the phage comprises the polynucleotide sequence of SEQ ID NO:

1.

37. The use according to claim 29, wherein the phage comprises the polynucleotide sequence of SEQ ID NO:

2.

38. The use according to claim 29, wherein the use comprises administering a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1 and a bacteriophage comprising the polynucleotide sequence of SEQ ID NO:

2.

39. The use according to claim 29, wherein at least 80% of the phages retain lytic activity after exposure to human plasma for a period of time between 10 minutes and 120 minutes.

40. The use according to claim 39, wherein the time period is between 10 minutes and 90 minutes.

41. The use according to claim 29, wherein the bacterial infection includes lung infection, sinusitis, urinary tract infection, intra-abdominal infection, skin infection, skin structure infection, bacteremia, sepsis, endocarditis, or implant infection.

42. The use according to claim 41, wherein the implant infection includes cardiac implant infection, prosthetic joint infection, or prosthetic valve endocarditis.

43. The use according to claim 29, wherein the bacterial infection is bacteremia.

44. The use according to claim 29, wherein the bacterial infection is resistant to antibiotics.

45. The use according to claim 29, wherein the bacteriophage is in a concentration of 1 × 10⁻⁶. 8 Up to 1×10 11 Total phages were administered at plaque-forming units (PFU / mL).

46. ​​The use according to claim 29, wherein the bacteriophage is in a concentration of 1 × 10⁻⁶. 8 and 1×10 11 For each phage administration, the PFU / mL range is specified.

47. The use according to claim 29, wherein the bacteriophage comprises at least 1 × 10⁻⁶ per milliliter. 9 The dosage of total phages from PFU was administered.

48. The use according to claim 29, wherein the use further comprises administering antibiotics.

49. The use according to claim 48, wherein the antibiotic is selected from the following classes of antibiotics: fluoroquinolones, carbapenems, aminoglycosides, ansarmycin, cephalosporins, penicillins, β-lactams, β-lactamase inhibitors, folic acid pathway inhibitors, fusobionic acid, glycopeptides, glycylcycline, lincosamide, lipopeptides, macrolides, oxazolidinones, florfenicol, streptozotocin, and tetracyclines.

50. The use according to claim 29, wherein the phage is administered intravenously.

51. The use according to claim 29, wherein the phage is administered via intra-articular injection.

52. The use according to claim 29, wherein the bacteriophage is administered by inhalation.

53. The use according to claim 29, wherein the bacteriophage is administered via atomization.

54. The use according to claim 29, wherein the subject is a human.

55. The use according to claim 42, wherein the cardiac implantation infection includes ventricular assist device infection or pacemaker infection.

56. The use according to claim 24, wherein the bacterial infection includes lung infection, sinusitis, urinary tract infection, intra-abdominal infection, skin infection, skin structure infection, bacteremia, sepsis, endocarditis, or implant infection.

57. The use according to claim 56, wherein the bacterial infection is bacteremia.

58. The use according to claim 29, wherein the phage is administered subcutaneously.

59. The composition of claim 13, wherein the contaminant comprises host bacterial proteins or endotoxins.

Images